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1. Summary 
1.1 English language summary 
Adjuvant endocrine therapy leads to substantial gains in breast cancer survival outcomes. 
The real-world use, effectiveness, tolerability and adherence to recent innovations in the field of 
adjuvant endocrine therapy for breast cancer is not well characterized. To tackle these concerns 
and hence help patient-physician decision making and future clinical research we developed a 
series of projects aiming to: 1) describe the implementation in real-world practice of recent 
innovations in the field of adjuvant endocrine therapy for breast cancer and summarize its 
effectiveness, 2) quantify adjuvant endocrine therapy impact on patients’ quality of life and 3) 
quantify  patients adherence and persistence to adjuvant endocrine therapy. To do this, we used 
different cohort studies and applied standard and novel statistical methods. 
Using two retrospective cohorts from Southern Portugal Cancer Registry, one of ~1300 
postmenopausal women and the other of ~1700 premenopausal women, we identified that both 
aromatase inhibitors (AI) and ovarian function suppression (OFS) were successfully introduced in 
clinical practice after landmark publication in 2005 and 2014, respectively. In the postmenopausal 
cohort, 41% of patients received an AI (16% as monotherapy, 25% as sequential therapy) and 59% 
tamoxifen with differences by center. After a median follow-up of 6.3 years, AI use was associated 
with a better overall survival (OS) when compared with tamoxifen (adjusted-HR 0.55, 95% CI 0.37-
0.81). Using a complementary retrospective US cohort of ~800 postmenopausal women with 
lobular tumors, similar findings were registered and no heterogeneity in efficacy was recorded by 
histology, in specific comparing pure lobular carcinomas to mixed ductal and lobular 
carcinomas. In the premenopausal cohort, 17% of patients were treated with OFS with a 
substantial increase of its use from 2014 onward (16% vs. 25% after 2014), particularly for the 
combination with AI (0.4% vs. 8% after 2014). After a median follow-up of ~3 years, patients treated 
with OFS had a better OS than those not treated with OFS (adjusted-HR 0.44, 95% CI 0.19-0.96). 
Using a sub-cohort of ~4300 breast cancer patients with available patient reported outcomes from 
CANTO, a nationwide French prospective cohort, we described a substantial impact of treatment 
on QoL 2 years after diagnosis. Using the EORTC C30 summary score, a composite score of several 
functions and symptoms, endocrine therapy but not chemotherapy had a persistent impact on QoL 
2 years after diagnosis with differences by specific domains. In addition, we uncovered a differential 
effect of treatment by menopausal status: in premenopausal patients CT seems to be the 
predominant driver of QoL domains deterioration, whereas in postmenopausal patients it was ET 
the predominant driver of QoL deterioration. Finally, using a second sub-cohort of ~1200 patients 
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from CANTO that were taking adjuvant tamoxifen and with serum assessment of tamoxifen, we 
identified that 1 in every 6 women (16%) were non-adherent, i.e. had serum tamoxifen levels were 
below the adherence threshold. This proportion was higher than the self-reported rate of non-
adherence (12.3%). After a median follow-up time of 2 years from tamoxifen serum assessment, 
biochemically defined non-adherent patients had a shorter DDFS (adjusted-HR of 2.31, 95% CI 1.05-
5.06). 
This work detailed the kinetics of introduction in clinical practice of recent adjuvant 
endocrine treatment innovations. In addition, it provides real-world evidence of the effectiveness 
of adjuvant AIs and OFS. Nevertheless, it suggests that for a substantial number of patients 
endocrine therapy leads to a persistent negative impact on QoL, especially in postmenopausal 
women, and to an alarming proportion of non-adherence to treatment, to a certain extent related 
to tolerability issues. 
Keywords: early breast cancer; adjuvant treatments; endocrine therapy; treatment effectiveness; 
quality of life; treatment adherence. 
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1.2 Portuguese language summary 
O tratamento hormonal adjuvante de doentes com carcinoma da mama melhora a 
sobrevivência global. O uso em contexto de mundo real, efetividade, tolerabilidade e adesão a 
inovações recentes da terapia hormonal adjuvante de cancro da mama não está bem caracterizado. 
Para abordar estes pontos e assim apoiar a tomada de decisão de doentes-médicos e a investigação 
clínica futura desenvolvemos uma série de projetos com o propósito de: 1) descrever a 
implementação na prática clínica de mundo real de inovações recentes no campo da terapia 
hormonal adjuvante de cancro da mama e sumarizar a sua efetividade, 2) quantificar o impacto da 
terapia hormonal adjuvante na qualidade de vida das doentes e 3) quantificar a adesão e 
persistência das doentes à terapia hormonal adjuvante. Para concluir estas tarefas utilizámos 
diferentes estudos de coorte e aplicámos métodos padrão e inovadores de análise de dados. 
Fazendo recurso de duas coortes retrospetivas derivadas do Registo Oncológico Regional 
do Sul, a primeira com ~1300 mulheres pós-menopáusicas e a segunda com ~1700 mulheres pré-
menopáusicas, identificámos que quer os inibidores da aromatase (IA) quer a supressão da função 
ovárica (SFO) foram introduzidos com sucesso na prática clínica após publicações científicas de 
referência em 2005 e 2014, respetivamente. Na coorte pós-menopáusica, 41% das doentes 
receberam um IA (16% em monoterapia e 25% em sequência) e 59% tamoxifeno com diferenças 
por centro. Após um acompanhamento mediano de 6.3 anos, os IA associaram-se a melhor 
sobrevivência global (SG) quando comparados com tamoxifeno (HR-ajustado 0.5, IC 95% 0.37-0.81). 
Fazendo recurso complementar de uma coorte retrospetiva estado-unidense de ~800 mulheres 
pós-menopáusicas com tumores lobulares, registámos resultados semelhantes e não foi 
identificada heterogeneidade de eficácia por tipo histológico, em específico quando comparando 
carcinomas lobulares puros a carcinomas ductais e lobulares mistos. Na coorte pré-menopáusica, 
17% das doentes foram tratadas com SFO com um crescimento substancial do uso de 2014 em 
diante (16% vs. 25% após 2014), particularmente para a combinação com IA (0.4% vs. 8% após 
2014). Após um acompanhamento mediano de ~3 anos, doentes tratadas com SFO tiveram melhor 
SG que doentes não tratadas com SFO (HR-ajustado 0.44, IC 95% 0.19-0.96). Fazendo recurso de 
uma sub-coorte de ~4300 doentes com cancro da mama com resultados reportados por doente 
(patient reported outcomes) disponíveis do estudo CANTO, uma coorte prospetiva francesa, 
descrevemos um impacto substancial do tratamento na qualidade de vida (QdV) 2 anos após o 
diagnóstico. Usando o C30 summary score da EORTC, um resultado compósito de várias funções e 
sintomas, a terapia hormonal, mas não a quimioterapia, teve um impacto persistente na QdV 2 
anos após o diagnóstico com diferenças nos domínios impactados. Adicionalmente, expusemos um 
efeito diferencial do tratamento por estado menopausico: em doentes pré-menopáusicas a 
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quimioterapia parece ser o promotor principal da deterioração de domínios de QdV, enquanto que 
em doentes pós-menopáusicas foi a terapia hormonal o promotor principal da deterioração da 
QdV. Finalmente, fazendo recurso de uma segunda sub-coorte de ~1200 derivada do estudo CANTO 
e de doentes que estavam a tomar tamoxifeno e com avaliação sérica do tamoxifeno, identificámos 
que 1 em cada 6 mulheres (16%) eram não-aderentes ao tratamento, i.e. tinham os valores séricos 
de tamoxifeno abaixo da linha de corte de adesão. Esta proporção foi maior que aquela auto-
reportada (12.3%). Após um acompanhamento mediano de 2 anos após a avaliação do tamoxifeno 
sérico, doentes não aderentes quando avaliadas por via bioquímica tiveram uma sobrevivência livre 
de recidiva à distância mais curta (HR-ajustado de 2.31, IC 95% 1.05-5.06). 
Este trabalho detalhou a cinética de introdução na prática clínica de inovações recentes na 
terapia hormonal adjuvante. Adicionalmente, revelou evidência de mundo real da efetividade de 
IA e SFO adjuvantes. Estes dados sugeriram porém que para uma proporção substancial de doentes 
a terapia hormonal leva a um impacto persistente e negativo na QdV, especialmente em mulheres 
pós-menopáusicas, tal como a uma proporção alarmante de não-adesão ao tratamento, até certo 
ponto relacionada com questões de tolerabilidade. 
Palavras-chave: cancro de mama precoce; tratamentos adjuvantes; hormonoterapia; efetividade 
terapêutica; qualidade de vida; adesão ao tratamento.  
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2. Introduction 
2.1 Epidemiology of breast cancer 
Female breast cancer is the most frequently diagnosed cancer in women in the world with 
approximately 2.1 million diagnosis in 2018.1 Globally approximately every 1 in 8 women from those 
reaching the age of 85 are affected by breast cancer.1 In the European Union (EU), breast cancer is 
also the main cause of female cancer and cancer related death with an estimated absolute number 
of diagnosis, incidence and mortality of 364 450 cases, 108.8 cases per 100 000 women/year (age-
standardized rate, ASR) and 22.4 cases per 100 000 women/year (ASR), respectively.2 In Portugal, 
slightly lower rates are recorded with an estimated absolute number of diagnosis, incidence and 
mortality of 6 900 cases, 85.6 cases per 100 000 women/year (ASR) and 18.4 cases per 100 000 
women/year (ASR), respectively.2 In addition, of the estimated 90 580 deaths due to breast cancer 
recorded annually in the EU, 1 570 occur in Portugal.2 
Of all cases of breast cancer, between 90 and 95% are diagnosed in stage I-III and are thus 
eligible for curative treatments.3 The wide implementation of screening contributed to the 
identification of tumors in earlier stages.4 In addition, the adoption of cumulatively better adjuvant 
treatments contributed to the improvement of cancer outcomes in patients with early breast 
cancer.4,5 Currently, the estimated 5-years overall survival for female BC in Europe is of 
approximately 81%, while it is 83.4% (95% CI 82.5 - 84.3) in Portugal.6,7  
2.2 Subtypes of breast cancer and implications to treatment 
Breast cancer is a heterogeneous disease for which a group of biomarkers are routinely 
assessed as tools to inform about disease prognosis and sensitivity to treatment.8 As a matter of 
fact, breast cancer was the first type of cancer in which routine biological markers started to be 
used in routine clinical practice to define therapy. Cancer biomarkers are molecules that can either 
be produced by the tumor cells or other cells of the body as a response to the tumor and can be 
genes, gene products, molecules, enzymes, hormones or specific cells. These markers can be 
detected in blood, secretions (urine, sputum, sweat or others) or tissues and can be used for cancer 
screening, as prognostic factors for outcomes but also as predictive factors of response to 
therapies.9 Two of such biomarkers are the estrogen and progesterone receptors (collectively 
referred to as the hormone receptors [HRe]). More recently, the human epidermal growth factor 
receptor 2 (HER2) was also described as a useful molecular marker in breast cancer. The prognostic 
and predictive power of these biomarkers to identify patients responding to endocrine therapy 
(those with HRe-positive tumors) and HER2-directed therapy (those with HER2-positive tumors) led 
to the systematic characterization of the estrogen, progesterone and the HER2 receptors in routine 
Page 13 of 175 
 
clinical practice.8,10,11 The combination of such receptors defines four immunohistochemistry (IHC)-
defined subtypes of breast cancer with clinical implications: HRe+/HER2-, HR+/HER2+, HRe-/HER2+ 
and HRe-/HER2- (triple negative). Subsequent studies dissecting the underpinnings of the breast 
cancer biology identified genomically-defined intrinsic subtypes of breast cancer that include the 
luminal types A and B, the HER2 amplified/overexpressing and the basal-like subtypes.12 These 
genomically-defined subgroups are derived from the evaluation of the gene expression profile of 
tumors and partially overlap with the IHC-defined subgroups of breast cancer, especially when also 
assessing the cell proliferation marker ki-67 and histologic grade: luminal A tumors tend to overlap 
with HRe+ (high ER and PR)/HER2- with low ki-67 (and low grade) tumors, luminal B tumors tend to 
overlap with HRe+ (lower ER and/or PR)/HER2- with high ki-67 (and high grade) tumors or 
HRe+/HER2+ tumors, HER2 amplified/overexpressing with HRe-/HER2+ tumors and the basal-like 
with HRe-/HER2- tumors.13,14 While the intrinsic subtypes of breast cancer add to our biological 
understanding of breast cancer, such classification defined by gene expression profile does not 
encapsulate all the complexity of the biology of breast cancer. To that end, other classifications 
were also developed, remarkably the integrative clusters looking to the genome and transcriptome 
in the overall landscape of breast tumors, and the Lehman and Burstein classifications in the 
subgroup of HRe-/HER2- (triple negative) breast tumors.15–17 Both the pan-breast cancer 
classifications of the intrinsic subtypes of breast cancer and the integrative clusters of breast cancer 
have clear prognostic implications15,18, but the predictive value to define the most appropriate 
therapy in the clinics is still mostly defined by the tissue evaluation of the HRe and the HER2 
receptor.19  
Up to 80% of all breast carcinomas present ≥ 1% of cells positive for the estrogen and/or 
progesterone receptors thus being considered HRe-positive.20–22 For these, especially those with 
HRe present ≥ 10% of cells, it is well established the clinical utility of the use of hormone-related 
therapies/endocrine therapies.10,21 
2.3 The evolving field of adjuvant endocrine therapy 
Endocrine therapy was the first targeted therapy used for the treatment of breast cancer. 
The landscape of hormone-related therapies evolved substantially over time, from pioneer 
approaches more than 1 century ago by Beatson and colleagues of surgical ovarian ablation 
(oophorectomy)23 to more contemporaneous medical approaches using ovarian suppression (e.g. 
goserelin), selective estrogen receptor modulators (SERMs; e.g. tamoxifen), aromatase inhibitors 
(AI; e.g. letrozole) and selective estrogen receptor degraders (SERDs; e.g. fulvestrant). Dr. Beatson 
was a surgeon studying breast milk formation. During his research he observed that the removal of 
ovaries would halt breast milk production in rabbits. This fact pointed towards the possibility of the 
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ovaries having control over the secretion of a complete separate organ. Beatson ended up 
transporting this principle to breast cancer treatment without even knowing about the substance 
who caused it: estrogen.24 From those days until now, knowledge on endocrine therapy for breast 
cancer multiplied and currently the clinical use and sequence of different classes of endocrine 
treatments differs by menopausal status, underlying intention of care (curative or palliative) and in 
patients with early breast cancer it even differs by the perceived risk of recurrence.25  
Tamoxifen is a selective estrogen receptor modulator that acts mainly as an estrogen 
receptor antagonist at the tumor levels inducing growth arrest and apoptosis.26 Nevertheless, in 
other tissues tamoxifen acts as an ER receptor agonist and in postmenopausal women it can 
prevent postmenopausal osteoporosis and have an impact in blood cholesterol.27 Tamoxifen was 
the mainstay of adjuvant endocrine therapy in breast cancer for several decades and is nowadays 
the treatment of choice for premenopausal women with low or average risk tumors and for some 
postmenopausal women with low risk tumors, intolerant or with formal contra-indication to AI.28–
30 The AIs are a class of drugs that inhibit the aromatase, an enzyme responsible for the conversion 
of androgens into estrogens (mostly at peripheral sites as the fatty tissue).31 While in 
premenopausal women the ovaries are the primary source of estrogens, in postmenopausal 
women, peripheral conversion of androgens is the main mechanism of estrogen production; hence, 
the use of AI effectively reduces estrogen levels in postmenopausal women or pre/perimenopausal 
women with concomitant treatment with ovarian function suppression. At present, AIs are a 
standard treatment for postmenopausal women or premenopausal women at high risk of 
recurrence, in this later case if provided in combination with ovarian suppression/ablation.29,30  
In the postmenopausal setting, the establishment of AIs as a standard treatment was a long 
and winding road. While the two largest and most mature trials showed consistent results in terms 
of DFS, the overall survival results were inconsistent between trials and over time.32,33 In the breast 
international group (BIG) 1-98 trial, 8010 patients were randomized in a 1:1:1:1 fashion to 5 years 
of letrozole or tamoxifen alone or their sequence. While at a median follow-up of 8.1 years there 
was an improvement both in terms of DFS (inverse probability treatment weighting [IPTW] HR 0.82, 
95% CI 0.74 – 0.92) and OS (IPTW HR 0.79, 95% CI 0.69 – 0.90) favoring letrozole, in the most recent 
analysis after a median follow-up of 12.6 years only a non-significant trend was registered in favor 
of letrozole both for DFS (HR 0.91, 95% CI 0.81 – 1.01) and OS (HR 0.89, 95% CI 0.77 – 1.02).34,35 In 
the arimidex, tamoxifen, alone or in combination (ATAC) trial 6241 women were randomized in a 
1:1 fashion to 5 years of letrozole or tamoxifen. In both the 8.3 years follow-up analysis and the 10 
years follow-up analysis, letrozole showed an improved DFS (10 years, HR 0.91, 95% CI 0.83 – 0.99) 
but not an improved OS (10 years, HR 0.87, 9% CI 0.74 – 1.02).36,37 These observations led some 
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clinicians to challenge the clinical superiority of adjuvant AIs when compared to tamoxifen.38 An 
EBCTCG patient-level meta-analysis summarized results of BIG 1-98, ATAC and other studies 
showing for the comparison 5 years of letrozole vs. 5 years of tamoxifen an improved DFS favoring 
letrozole in years 0-1 (RR 0.64, 95% CI 0.52 – 0.78) and 2-4 (RR 0.80, 95% CI 0.68 – 0.93) but not 
afterwards.39 A modest but measurable OS improvement at 10 years was also recorded (RR 0.89, 
95% CI 0.8 – 0.97; death from any cause of 24.0% vs. 21.3% for tamoxifen and AIs, respectively - 
absolute difference of 2.7%, 95% CI 0.1 – 4.7). The same EBCTCG metanalysis also summarized the 
impact on clinical outcomes of switch strategies (2-3 years of tamoxifen followed by an AI for a total 
duration of therapy of 5 years) when compared to both tamoxifen and an AI when given for 5 years. 
In both cases, i.e. for the comparison of a switch strategy vs. tamoxifen or an AI, DFS is improved in 
favor of the arm providing an AI while treatments differ, but not thereafter. As for OS, the switch 
strategy also seems to improve survival when compared to 5 years of tamoxifen (RR 0.82, 95% CI 
0.73 – 0.91), but does not differ when compared to 5 years of letrozol (RR 0.96, 95% CI 0.86 – 1.07). 
Clinical practice guidelines reconcile these observations by identifying groups of patients at higher 
risk of recurrence or with perceived higher sensitivity to AIs for preferred treatment with AIs, as 
patients with stage II/III disease, with tumors with histologic grade 3, high ki67, lobular histology 
and with HRe+/HER2+ receptors.14 The real-world effectiveness of these treatments is however 
poorly understood.  
Over the last years we have observed an escalation of adjuvant endocrine treatment 
options in the early disease setting, either by the extension of treatment duration or by its 
intensification. Seminal studies of adjuvant tamoxifen used somehow arbitrary treatment periods 
of 1 or 2 years. Backed by basic research findings40 and the clinical observation that more than half 
of the recurrences of hormone receptor-positive tumors occur after 5 years of diagnosis41, 
subsequent research steps aimed at testing the role of longer treatment durations and consistently 
showed that incrementally higher duration of treatment from 1 to 2, to 5 and more recently to 10 
years was of additional benefit both in terms of disease-free survival and overall survival. Current 
clinical practice guidelines recommend the use of extended tamoxifen (or AI in postmenopausal 
women) for patients with baseline increased risk of disease relapse, as defined by node positive 
disease (stage III disease or node positive stage II disease).14,29 It is however important to keep in 
mind that the added benefit of treatment beyond 7 to 8 years might be very modest. The absolute 
and relative merits of extending the duration of the treatment with tamoxifen were summarized 
by an EBCTCG meta-analysis and the recent “Adjuvant Tamoxifen: Longer Against Shorter” (ATLAS) 
and “Adjuvant Tamoxifen–To Offer More?” (ATTOM) trials.10,42–44 In summary, compared to no 
tamoxifen, 5 years of adjuvant tamoxifen, reduced by half the risk of recurrence in the years 0-4 
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and by a third from years 5-9 with a very small effect thereafter; regarding overall survival, 5 years 
of tamoxifen decreased the risk of death in the first 15 years by 30% which translated into an 
absolute reduction in the risk of death from 33.1% to 23.9% (absolute difference of 9.2%).10 As for 
continuing treatment beyond year 5, the contemporaneous read of the available evidence favors 
its use.29,45 While a meta-analysis of non-individual patient data concluded that in an unselected 
population of hormone receptor positive tumors there is not a disease-free or overall survival 
benefit, the group of node-positive patients emerged as deriving a DFS benefit from extended 
tamoxifen (HR 0.76, 95% CI 0.63 – 0.92)46. In addition, a hint emerged from the observation that 
while in years 5 to 9 no DFS difference is seen, at longer follow-up in years 10 and beyond, a DFS 
difference emerges (HR 0.80, 95 CI 0.73 – 0.88). Although this meta-analysis included 5 trials and 
more than 21 500 patients, the results were challenged by the fact that it included trials with 
considerably different follow-up times (most trials had less than 10 years of follow-up), by the fact 
that the estrogen receptor status was unavailable in some patients and by the fact that it 
constituted a non-individual patient data meta-analysis. With these points in mind, the two largest 
trials included in the aforementioned meta-analysis (the ATLAS trial with close to 13 000 patients 
and the ATTOM trial with about 7000 patients) showed both an early DFS advantage and a deferred 
breast cancer specific and overall survival advantage (after 10 years of treatment): in the ATLAS 
trial, the HR for breast cancer specific survival was 0.97 (SE 0.10) in years 5 to 9, 0.70 (SE 0.10) in 
years 10 to 14 and 0.79 (SE 0.27) after 15 or more years after, all favoring 10 years of adjuvant 
tamoxifen; consistent results were found for overall survival.43,47 
Similarly to tamoxifen, recent clinical research efforts are pushing for a similar path of 
validating the role of extended treatment with AI in postmenopausal women. Several combinations 
of treatment extension were tested, some of which including a starting period of tamoxifen ranging 
from 3 to 5 years. Despite the fact that no study found an overall survival improvement with 
extended AI in postmenopausal women, current clinical practice guidelines recommend the use of 
extended AI (or tamoxifen) for postmenopausal patients at higher risk of recurrence, as defined by 
node positive disease (stage III disease or node positive stage II disease).14,29 As in other 
problematics of adjuvant endocrine therapy, the EBCTCG also performed an individual patient data 
meta-analysis of 12 clinical trials (including close to 25 000 patients) aiming at dissecting the role of 
extended adjuvant AIs.48 In patients that received  5 years of adjuvant tamoxifen (n=7500), an extra 
5 years of an AI improved any recurrence (RR 0.67, 95% CI 0.57 – 0.79) and distant recurrence (RR 
0.77, 95% CI 0.63 – 0.93), but not breast cancer mortality (RR 0.77, 95% CI 0.59 – 1.00). As for 
patients receiving in the first 5 years of hormone treatment an adjuvant AI, an extra 5 years of an 
AI (n=4 800) also improved any recurrence (RR 0.76, 95% CI 0.61 – 0.95) and distant recurrence (RR 
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0.78, 95% CI 0.59 – 1.04), but not breast cancer mortality (RR 0.99, 95% CI 0.68 – 1.44). Similar 
findings were recorded for patients receiving 5 to 10 years of adjuvant tamoxifen followed by an AI 
(n=12 600). The absolute difference seems to be more clinically relevant as the nodal burden 
increases: the 5-years absolute recurrence improvements vary from 1.1% (95% CI 0.1 – 2.0) in 
patients with no nodal involvement, to 3.8% (95% CI 2.2 – 5.4) in patients with 1 to 3 involved nodes 
and to 7.7% (95% CI 3.9 – 11.6) in patients with 4 or more affected nodes. In addition, the types of 
recurrence were not affected similarly, with contralateral tumors being the most reduced (RR 0.61, 
95% CI 0.47 – 0.78), followed by isolated local recurrences (RR 0.74, 95% CI 0.57 – 0.96) and distant 
recurrences (RR 0.84, 95% CI 0.72 – 0.97). 
In premenopausal women, the intensification of treatment with the use of ovarian function 
suppression/ablation has also emerged as a competing strategy to escalate adjuvant endocrine 
therapy. Such strategy comes from the observation that premenopausal women with hormone 
receptor positive tumors that have permanent chemotherapy-induce amenorrhea/premature 
ovarian failure after adjuvant chemotherapy seem to have a better prognosis compared to those 
with menstrual resumption after adjuvant chemotherapy.49,50 Contemporaneous clinical practice 
guidelines recommend the use of OFS in premenopausal women with intermediate/high risk ER-
positive breast cancer.14,29 A 2007 meta-analysis by Cuzick and colleagues showed that, in patients 
with HRe-positive breast cancer, despite the small number of patients included (n=338) and the 
direction of effect favoring OFS, use of OFS in monotherapy compared to no systemic treatment 
did not improve relapse risk (HR 0.72, 95% CI 0.49 – 1.04) nor death after recurrence (HR 0.82, 95% 
CI 0.47 – 1.43). Conversely, the addition of OFS to chemotherapy (with or without tamoxifen, 
n=2741) improved both recurrence (HR 0.88, 95% CI 0.77 – 0.99) and death after recurrence (HR 
0.85, 95% CI 0.73 – 0.99). Furthermore, a significant interaction with age (using the 40 years cut-
off; p=0.046) was shown: in women aged 40 or younger, OFS reduced both recurrence and death 
after recurrence but not after 40. This is in line with the hypothesis that ovarian function is a 
relevant driver of the risk of recurrence in patients with HRe-positive tumors as the risk of 
chemotherapy-induced amenorrhea rises considerably after the age of 40. Recent studies further 
added evidence to the filed. In the suppression of ovarian function trial (SOFT), 3066 
premenopausal women were randomized to 5 years of tamoxifen, tamoxifen plus OFS or 
exemestane plus OFS.51,52 The randomization was stratified by receipt of chemotherapy and the 
primary analysis compared tamoxifen to tamoxifen plus OFS. At a median follow-up of 8 years, 
tamoxifen plus OFS compared to tamoxifen monotherapy showed an improved DFS (HR 0.76, 95% 
CI 0.62 – 0.93) and OS (HR 0.67, 95% CI 0.48 – 0.92). On the other hand, exemestane plus OFS when 
compared to tamoxifen monotherapy showed improved DFS (HR 0.65, 95% CI 0.53 – 0.81) but not 
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OS (non-significant trend; HR 0.85, 95% CI 0.62 – 1.15). A consistent effect but with larger absolute 
magnitude was recorded for these comparisons in the subgroup of patients receiving adjuvant 
chemotherapy. In the SOFT trial patients could be enrolled up to 8 months after completion of 
(neo)adjuvant chemotherapy to allow for proper menopausal status definition. In a similar study, 
the ASTRRA trial, that randomized 1282 premenopausal women to 5 years of tamoxifen or 5 years 
of tamoxifen plus 2 years of OFS, patients could be enrolled up to 2 years after completion of 
(neo)adjuvant chemotherapy.53 Of the 1483 women screened, 1282 had menses/ovarian function 
resumption, and after a median follow-up of 63 months, patients receiving tamoxifen plus OFS 
when compared to tamoxifen monotherapy had an improved DFS (HR 0.69, 95% CI 0.48 – 0.97) and 
OS (HR 0.31, 95% CI 0.10 – 0.94). Taken together both SOFT and ASTRRA studies favor the use of 
OFS in premenopausal women that remained premenopausal after receipt of adjuvant 
chemotherapy. Of note, the use of OFS renders premenopausal women functionally 
postmenopausal thus allowing for the use of AIs. As in two of the arms of the SOFT study, the 
“tamoxifen and exemestane trial” (TEXT) randomized premenopausal women to OFS plus 
tamoxifen or OFS plus exemestane. The resemblances between the SOFT and TEXT trials allowed 
for a combined analysis that further refined our understanding about the most appropriate 
combination endocrine therapy to OFS, i.e. tamoxifen or AI.52,54 In this analysis, 4690 patients were 
randomized in a 1:1 fashion to OFS plus tamoxifen or OFS plus exemestane. After a median follow-
up of 9 years, OFS plus exemestane improved both DFS (HR 0.77, 95% CI 0.67 – 0.90) and distant 
DFS (DDFS; HR 0.80, 95% CI 0.66 – 0.96), but not OS (HR 0.98, 95% CI 0.79 – 1.22). Based on these 
results and at this point in time, the preferred combination therapy of OFS is still unclear. 
Extending or intensifying endocrine therapy improves cancer outcomes, but it also comes 
at a cost of added toxicity. This toxicity might further have downstream effects as decreasing the 
real-world adherence to treatment and in the process compromise treatment effectiveness. The 
real-world use, effectiveness, tolerability and adherence to these treatments is poorly 
characterized. 
2.4 Cancer survivorship in the intersection with safety, tolerability and quality of life 
impact of endocrine therapy 
Major improvements in early diagnosis, treatment and supportive care lead to a growing 
community of cancer survivors.55 While relevant during all the continuum of treatment, for this 
group of patients, tolerability issues and how the treatment trajectory impacts QoL is an issue of 
utmost importance. In the US, more than 3.5 million women live with an history of diagnosis of 
invasive breast cancer.56 In Europe, such number is estimated to be in the range of 2 million women. 
The field of survivorships deals with a large scope of topics, namely the surveillance for recurrence 
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and screening for second cancers, long-term and late side effects of cancer treatment, health 
behaviors (e.g. diet, weight management, physical exercise, as well as smoking and alcohol 
consumption) and promotion of psychosocial wellbeing (depression, anxiety, return-to-work and 
other financial issues).55 Other topics pertaining to special populations include fertility issues and 
premature ageing in younger patients and a comprehensive geriatric assessment in the elderly. In 
the specific case of long-term or late side effects, these refer to adverse events persisting from 
treatment introduction to a date beyond treatment discontinuation or starting after treatment 
discontinuation, respectively. Some of the late side effects can have a long-lasting effect too. 
Examples of long-term effects include fatigue, chronic pain, sexual dysfunction, cognitive 
dysfunction, chemotherapy induced neuropathy or ovarian dysfunction. Examples of late side 
effects include osteoporosis (with corresponding risk of fractures), but also hematological 
malignancies and myelodysplastic syndromes. 
While it is unquestionable that endocrine treatments present a favorable risk-benefit that 
support their regulatory approval and extensive clinical use, specific agents are known for specific 
side effects. Tamoxifen is associated with gynecological symptoms, thromboembolic events, 
cerebrovascular events and, in postmenopausal women, endometrial cancer.57,58 Conversely, AI are 
associated with more vaginal dryness, joint symptoms, bone fractures and cardiovascular 
events.57,58 The intensification of treatment with OFS also increases the risk for osteoporosis, 
musculoskeletal symptoms, vaginal dryness, hypertension and glucose problems.52 Likewise, 
extending treatment duration further increases the risk of known deleterious adverse events, but 
without new safety signals.59  
Beyond health professional reported outcomes, endocrine therapy seems also to impact 
health related quality of life (HRQOL) as measured by patient reported outcomes (PRO). The 
European Medicines Agency (EMA) defines PROs as “any outcome evaluated directly by the patient 
himself or herself.”60 EMA further details that “it can be measured by self-report, generally in the 
form of a questionnaire, or by interview, provided that the interviewer records only the patient’s 
response.” PROs are measured using various tools available both for routine clinical practice and 
for clinical research. These person-centered instruments measure symptoms, functional status, 
treatment adherence or satisfaction with care, but the two most common uses in cancer research 
include the assessment of patients’ symptoms and HRQOL. The available instruments used to assess 
PROs in patients with breast cancer were critically reviewed elsewhere.61 Some of the most used 
instruments include the European Organisation for Research and Treatment of Cancer (EORTC) 
instruments Quality of Life Questionnaire (QLQ)-C30 (designed for all types of cancer) with or 
without the complementing QLQ Breast Module 23 (QLQ BR23; currently being updated to the QLQ 
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BR4562) and the Functional Assessment of Chronic Illness Therapy (FACIT) Functional Assessment of 
Cancer Therapy (FACT)-B and FACT-Endocrine symptoms (FACT-ES). An emerging instrument for 
symptoms assessment is the US National Institutes of Health (NCI) PRO-CTCAE (Patient Reported 
Outcomes – Common Terminology Criteria for Adverse Events) inspired in the CTCAE instruments 
used for graduation of adverse event in clinical trials.63 
In early breast cancer, the mind-body study was a prospective observational cohort study 
of 186 women that were receiving or not adjuvant endocrine therapy and for whom PROs are 
available.64 Compared to patients not receiving endocrine therapy, the group receiving AI had more 
severe musculoskeletal issues, hot flashes and cognitive problems, while those receiving tamoxifen 
(also compared to no endocrine therapy) had more hot flashes, cognitive problems and bladder 
issues. In this setting, in the previously discussed ATAC trial of adjuvant tamoxifen, anastrazol or 
their sequence in postmenopausal women, 1021 patients were enrolled for the QoL substudy and 
thus had QoL metrics available as assessed by the Functional Assessment of Cancer Therapy – 
Breast Trial Outcome Index (FACT-B TOI) and FACT-ES (Functional Assessment of Cancer Therapy – 
Endocrine Subscale) scales. Despite the identification of small differences in the side effect profile, 
no overall significant differences in QoL were recorded between treatment arms.65 Likewise, 
treatment intensification with OFS seems to impact side effects profile but QoL. In the previously 
discussed SOFT trial of 2045 premenopausal women randomized to tamoxifen with or without OFS, 
QoL PRO data as assessed by the International Breast Cancer Study Group QoL Core Form and a 
trial-specific module was available for 1722 patients.66 Patients receiving combination endocrine 
therapy had more hot flashes at 6 and 24 months, loss of sexual interest and sleep issues at 6 
months and vaginal dryness up to 60 months. However, changes in global QoL metrics were not 
substantial and did not differ between treatments. As adjuvant OFS is reserved for high risk 
patients, especially if younger than 35 and treated with adjuvant chemotherapy, the SOFT and TEXT 
trial investigators also looked at the QoL in the subgroup of women 35 years or younger. Vasomotor 
symptoms were the most prominent symptom, however, loss of sexual interest and difficulties in 
becoming aroused were also recorded and considered to be clinically meaningful. Even so, the 
symptomatic impact was similar to that identified in older premenopausal women and similar rates 
of early endocrine therapy discontinuation were documented (approaching to 1 in every 5 
patients). 
Despite the different impact in terms of side effects profile, QoL seems to be scarcely 
impacted in clinical trials of different strategies of adjuvant endocrine therapy. However, how 
different types of endocrine therapy and other systemic treatments modulate breast cancer 
survivors QoL in the real-world setting is still poorly characterized. The effect of different 
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treatments in QoL has several downstream implications namely by modulating the adherence to 
long-term adjuvant treatments which can impact cancer relapse and survival.  
2.5 Adherence to oral adjuvant endocrine therapy 
Oral adjuvant endocrine therapies were designed to be administered for periods of time 
spanning years. Moreover, such periods are being extended with most guidelines recommending 
between 5 to 10 years of treatment and considering 10 years in growing groups of patients.45,67 In 
cardiovascular medicine, non-adherence to oral therapies for primary or secondary prevention of 
undesired health outcomes is in the range of 30 to 50%.68 Likewise, non-adherence to breast cancer 
adjuvant endocrine therapies ranges from 20% at up to 2 years and to around 50% at 5 years.69,70 
These observations merit substantial clinical attention, given the impact of non-adherence on 
deleterious cancer outcomes (as recurrence and death), health care resources 
consumption/spending, the perception of drug activity/dose adjustments and patient-physician 
relationship.71 Despite these objective estimates, it is important to consider that the setting in 
which adherence is measured (as e.g. in clinical trials or real-world practice) as well as the 
instruments used to measure adherence (as e.g. self-report, pills count, electronic monitoring 
systems or serum/urine assessment) might further add variability to the quantification of 
adherence.72 
The identification of patients at higher risk for non-adherence, i.e. the identification of 
sociodemographic, behavioral and clinical features predicting for non-adherence, is an active field 
of research. Classic predictors of non-adherence include patient (as social support and family 
stability, health beliefs, previous adherence history and mental health problems), treatment (as 
regimen complexity, tolerability, duration and cost) and disease characteristics, but more complex 
models aiming to capture behavioral dimensions have also been developed.72 These later models 
include e.g. the patients’ perception of the risks posed by the disease and the efficacy/tolerability 
of treatment, as well as the individual set of beliefs concerning how her/his future is impacted by 
her/his own behaviors vs. by chance, but also the relationship between the patients and her/his 
health care providers.72 
The real-world incidence of non-adherence to adjuvant endocrine therapy is scarcely 
characterized. In addition, it is unclear if more objective methods of assessment, e.g. serum 
assessment, will reveal consistent estimates of non-adherence when compared with more common 
methods of assessment as questionnaires. 
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2.6 Outcomes research as a tool to summarize real-world evidence 
While well conducted clinical trials are the most robust tool to ensure precision and 
establish causality (thus overcoming bias and confounding) in studies comparing the efficacy of 
clinical interventions, a growing body of evidence reveals that the group of patients recruited for 
clinical trials might not represent the overall group of patients observed in routine clinical practice, 
both due to stringent selection criteria, small number of recruited patients (less than 5% of patients 
participate in clinical trials) and due to overconcentration of clinical trials in specific academic 
centers.73 Overall, underrepresented groups in cancer clinical trials include e.g. elderly patients, 
patients with relevant comorbidities, ethnical minorities, pregnant women, patients living in 
remote areas and those with specific disease presentations, as brain metastases. 
Underrepresenting certain groups of patients harms the external validity of the study findings and 
thus the generalizability of the conclusions. Derived from this perception, some have proposed that 
outcomes as measured in clinical trials are at most a surrogate of the actual outcome captured in 
real-world practice/true outcome.74 Another challenge applicable to randomized clinical trials 
comes from the increasing regulation applicable to interventional research and the limited 
resources available to fund large clinical studies with human participants, reasons that further limit 
the number of clinical questions that can be addressed using randomized clinical trials.75 
To increase the number of patients included in clinical studies and with it the external 
validity of clinical research, but also to extend the scope of questions that can be addressed in a 
timely manner, a growing number of researchers are complementing clinical trials research with 
observational studies using real-world data.73 Real-world data, i.e. observational data collected 
from routine clinical practice (e.g. through electronic medical records, registries and billing data) or 
directly from patients (e.g. through wearables and health applications) and not from clinical trials, 
when properly curated, allows the generation of real-world evidence.76 As the overall group of 
patients seen in routine clinical practice compose the real-world data, real-world evidence 
maximizes the external validity of study findings. Conversely, while external validity is maximized, 
other methodological issues ensue namely the risk for confounding and bias. To deal with the 
methodological challenges of such research the field of real-world research matured to apply the 
methodological tools of epidemiology and in the process reach sound conclusions. This dynamic 
field of clinical research is commonly referred to as outcomes research. Outcomes research deals 
with the study of the end results, i.e. the outcomes, of different clinical interventions. In the United 
States national library of medicine medical subject heading (MeSH), outcomes research is 
considered a synonym of “outcome assessment (health care)” and defined as “research aimed at 
assessing the quality and effectiveness of health care as measured by the attainment of a specified 
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end result or outcome. Measures include parameters such as improved health, lowered morbidity 
or mortality, and improvement of abnormal states (such as elevated blood pressure).”77 The 
outcomes that are measured can be collected both through the lens of health-professionals (e.g. 
breast cancer distant recurrence or common terminology criteria for adverse events [CTCAE]-
defined diarrhea) or through the lens of patients (patient reported outcomes [PRO]). While health-
professional and patient reported outcomes should report a similar perception of a clinical 
phenomenon, it is becoming clearer that these two lens to characterize clinical phenomena tell 
complementary stories thus making the case for the systematic collection of PROs in clinical 
research studies.78 
One of the aims of epidemiology is to estimate unbiased causal associations. To attain that, 
several methodological optimizations were implemented to prevent, reduce and quantify bias and 
confounding.79 While bias derives from inadequate study design and/or conduct, confounding 
reflects the rich interrelationships between factors and outcomes. Several design and analytic 
techniques are available to handle bias and confounding. The most effective tools to reduce or 
eliminate bias come from appropriate selection of patients, randomization and from several types 
of blinding of the research stakeholders (e.g. participants, researchers and statisticians). These 
strategies are widely implemented in interventional research/randomized clinical trials. Given the 
non-interventional nature of outcomes research, strategies to overcome bias come from thoughtful 
study design and careful patient selection. While impossible to exclude, bias needs to be proactively 
handled and be taken into consideration when interpreting results. Design strategies to reduce 
confounding include individual or group matching, while analytic strategies include stratification 
and adjustment. In the body of work presented here we took advantage of thoughtful study design 
and patient selection, we further adjusted analyses using standard statistical methods, including 
multivariable modelling. In cases where expected unmeasured patients’ characteristics could affect 
both the decision to treat and the outcome we used propensity score risk adjustment (matching or 
inverse probability treatment weighting). 
Throughout the present body of work, we made use of real-world evidence derived from 
national and international data sources to answer several clinical questions around treatment 
effectiveness, tolerability of interventions, among others. As outcomes, we used both health-
professional reported outcomes and patient-reported outcomes, the former to measure efficacy 
and the later to assess tolerability and quality of life. While not a substitute for randomized clinical 
trials, our body of work using real-world data reveals relevant pieces of information that 
complement interventional research in the field of early breast cancer.  
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3. Objectives and thesis overview 
The real-world use, efficacy, tolerability and adherence to adjuvant endocrine therapy is 
scarcely characterized. In this thesis we aimed to quantify such dimensions using quantitative 
research methods. Bellow we detail the specific objectives of this work. 
Specific objective 1 – Patterns of care of adjuvant endocrine therapy 
a) To detail patterns of use of endocrine therapy in the adjuvant treatment of pre and post-
menopausal women with breast cancer. 
• Using data from ROS-Sul this specific objective contributed to generate manuscripts 1 (Ferreira et al, 
Breast 2018) and 3 (Ferreira et al, Clin Breast Cancer 2019). 
Specific objective 2 – Effectiveness of adjuvant endocrine therapy 
a) In post-menopausal women with HRe+ breast cancer, to assess the relative effectiveness 
of adjuvant AI vs. tamoxifen using a multi-institutional cohort; 
– To assess how histology and histologic differentiation modulates response to AI 
and tamoxifen; 
• Using data from ROR-Sul and DFCI through NCCN this specific objective contributed to 
generate manuscripts 1 (Ferreira et al, Breast 2018) and 2 (Metzger and Ferreira et al, 
Oncologist 2019). 
b) In pre-menopausal women with HRe+ breast cancer, to assess the effectiveness of ovarian 
function suppression using a multi-institutional cohort; 
– Quantify OFS effectiveness in the pts <35 years of age and/or treated with adjuvant 
CT; 
• Using data from ROR-Sul this specific objective contributed to generate manuscript 3 
(Ferreira et al, Clin Breast Cancer 2019). 
Specific objective 3 – Tolerability of adjuvant ET 
a) In women with HR+ BC receiving adjuvant ET, to describe safety and tolerability and its 
impact in QoL using a prospective multi-institutional cohort (CANTO). 
• Using data from CANTO this specific objective contributed to generate manuscript 4 (Ferreira et al, 
Annals of Oncology 2019). 
Specific objective 4 – Adherence to adjuvant ET 
a) In women with HR+ BC receiving adjuvant ET, to describe safety and tolerability and its 
impact in QoL using a prospective multi-institutional cohort (CANTO). 
• Using data from CANTO this specific objective contributed to generate manuscript 5 (Pistilli et al, JCO 
2020).  
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4. Methods 
Here we briefly detail the data sources used to complete the set of projects developed in 
this thesis. Specific methods are further detailed under each project.  
To complete the set of projects in this thesis we used data from 3 independent data 
sources: 
• Registo Oncológico Regional do Sul (Cancer Registry of Southern Portugal [ROR-Sul], 
currently included in Registo Oncológico Nacional [National Cancer Registry]). ROR-Sul was 
a population-based cancer registry collecting data from patients diagnosed and/or treated 
for invasive carcinomas in southern Portugal or Madeira island; 
• Dana-Farber Cancer Institute institutional data obtained through the US national 
comprehensive cancer network (NCCN) database (currently breast cancer outcomes 
research database [BC-CORD]); 
• CANTO cohort (NCT01993498), a nation-wide, multicenter, French, prospective, 
longitudinal study of breast cancer survivors [reviewed by Vaz-Luis et al in reference80].  
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5. Results 
This current body of work generated 5 publications. These publications will be presented in 
the sub-sections ahead. In all studies Arlindo R. Ferreira participated in all steps of the project, from 
study design, data analysis, results interpretation and manuscript writing. 
5.1 Treatment adoption and relative effectiveness of aromatase inhibitors compared 
to tamoxifen in early breast cancer: a multi-institutional observational study. 
5.1.1 Introductory notes 
This project details the introduction in clinical practice of adjuvant aromatase inhibitors for 
the adjuvant treatment of postmenopausal women with hormone receptor positive breast cancer 
and summarizes the real-world effectiveness of such intervention compared to tamoxifen. This 
project was published in The Breast. Arlindo R. Ferreira led the study design, data analysis, results 
interpretation and manuscript writing. 
5.1.2 Authors 
Arlindo. R. Ferreiraa,b, Ana Palhaa, Lurdes Correiaa, Pedro Filipea, Vasco Rodriguesa, Ana 
Mirandac, Rosário Andréc, João Fernandesd, Joaquim Gouveiad, José L. Passos-Coelhoe, António 
Moreiraf, Margarida Britof, Joana Ribeirog, Otto Metzger-Filhoh, Nancy U. Linh, Luís Costaa,b, and Inês 
Vaz-Luísi,h§. 
Authors Affiliations: a Hospital de Santa Maria, Centro Hospitalar de Lisboa Norte, Av. Prof. 
Egas Moniz, 1649-035 - Lisbon, Portugal; b Instituto de Medicina Molecular, Faculdade de Medicina, 
Universidade de Lisboa, Av. Prof. Egas Moniz, 1649-035 - Lisbon, Portugal; c Registo Oncológico 
Regional do Sul, Instituto Português de Oncologia F. G. de Lisboa, R. Prof. Lima Basto, 1099-023 
Lisbon, Portugal; d Hospitais CUF Lisboa, R. Mário Botas, 1998-018 Lisbon, Portugal; e Hospital da 
Luz, Avenida Lusíada, 100, 1500-650 Lisbon, Portugal; f Instituto Português de Oncologia F. G. de 
Lisboa, R. Prof. Lima Basto, 1099-023 Lisbon, Portugal; g Fundação Champalimaud, Av. Brasília, 
1400-038 Lisbon, Portugal; h Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, 
USA; Institut Gustave Roussy, Unit INSERM 981, 114 Rue Edouard Vaillant, 94800 Villejuif, France; 
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5.1.3 Abstract 
Background: Since 2005, aromatase inhibitors (AIs) have been the adjuvant treatment of 
choice for postmenopausal women with early breast cancer (BC). In this study we characterize the 
adoption of AIs in Portugal, variables associated with treatment administration, and compare its 
effectiveness (either in monotherapy or sequential therapy) to tamoxifen monotherapy (TAM). 
Patients and methods: This was a retrospective cohort study that included postmenopausal 
women with stage I-III hormone receptor (HR) positive BC diagnosed from 2006-2008 and treated 
with adjuvant endocrine therapy in four participating institutions. 
Results:  Of the 1283 eligible patients, 527 (41%) received an AI (16% as monotherapy, 25% 
as sequential therapy) and 756 (59%) TAM. Patients treated with AI had less differentiated tumors, 
with higher TNM stage, and were more frequently HER2-positive. Use of AI also differed by center 
(use range from 33%-75%, p<0.001). With a median follow-up of 6.3 years and controlling for 
clinicopathological and treatment characteristics, treatment with AI had a better overall survival 
(OS) when compared with TAM (adjusted-HR 0.55, 95% CI 0.37-0.81). 
Conclusion: AIs were successfully introduced as adjuvant treatment for HR-positive BC in 
Portuguese hospitals. Its use was influenced by tumor and patient characteristics, but also center 
of care. In this large cohort, AI use was associated with an OS benefit. 
Keywords: early breast cancer, aromatase inhibitors, tamoxifen, treatment effectiveness. 
5.1.4 Introduction 
In developed countries, the majority of breast cancers (>80%) are diagnosed in early stages, 
and can be treated with curative intent.81 Of these, more than 2/3 are hormone receptor-positive82, 
for whom the prognosis is substantially improved by adjuvant endocrine therapy (ET). As compared 
to no endocrine therapy, adjuvant ET is associated with a reduction in the rates of disease 
recurrence of approximately 50%, and this translates into a reduction in breast cancer mortality of 
more than 1/3 in the first 15 years after diagnosis.10 Since 2005, international guidelines have 
supported several adjuvant ET regimens for postmenopausal patients, including  tamoxifen (TAM), 
aromatase inhibitors (AI) or a sequence of these agents.83–85 Nevertheless, several clinical trials 
showed an advantage of regimens including an AI, an effect recently summarized in a large meta-
analysis of the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) that estimated a lower 
10-year breast cancer mortality in the AI vs. TAM group (RR = 0.85, 95% CI 0.75–0.96).39 Therefore, 
given the absolute benefit of strategies with AIs, there is an overall consensus that the treatment 
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of high risk patients, such as those with nodal involvement, high grade or high Ki-67, should include 
an AI.84  
Even so, the choice between different ETs also entails the choice of different safety, 
tolerability/adherence and cost profiles. While TAM is associated with an increased risk of 
thromboembolic events and endometrial cancer, AIs are associated with an increase in the risk of 
osteoporosis and bone fractures, as well as arthralgias and other musculoskeletal complaints.58 
Out-of-pocket and health system cost differences also exist (for example, in the United States, 
patients receiving AIs were more likely to experience financial hardship than those taking TAM 
only86). 
Recently, a multi-institutional group of Portuguese centers, both public and private, started 
to collect granular information on clinicopathological features, patterns of care and clinical 
outcomes of their patients with breast cancer using a regional cancer registry platform.87 In this 
study we characterize how real world providers introduced different ET strategies after 2005 (date 
of first consensus advocating the use of AI-based strategies for postmenopausal women85) and 
explore the comparative effectiveness of these interventions.  
5.1.5 Patients and Methods 
Study design and data source 
This is a retrospective cohort study. Data from four hospitals in the Lisbon area, Portugal, 
were retrieved from Registo Oncológico Regional do Sul (ROR-S; Southern Regional Oncology 
Registry). ROR-S is a population-based cancer registry. Data audits focused on 10% of cases were 
performed and variables had a higher than 95% concordance rate. Due to the observational nature 
of the study, treatments and follow-up were performed at patient-physician description. ROR-S 
institutional review board approved study protocol. Description of data collection and procedures 
were previously reported.87 We followed the STROBE statement in reports of cohort studies. 
Cohort definition 
We selected all consecutive postmenopausal primary breast cancer patients with stage I-III 
disease, tumors expressing estrogen/progesterone receptor (≥1%) and diagnosed and treated 
systemically (i.e., treatments beyond local therapy as surgery or radiotherapy) at Centro Hospitalar 
de Lisboa Norte, Hospitais CUF Lisboa, Hospital da Luz or Instituto Português de Oncologia Francisco 
Gentil de Lisboa between 2006 and 2008. Follow-up details (treatment, new tumors and vital status) 
were available up to December 2013. We excluded patients who did not have surgery and patients 
with other concurrent primary tumors. A cohort of 1283 patients was identified (M1 Figure 1). Two 
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groups were further defined as a function of type of ET received: Group A) 756 (58.9%) patients 
treated with TAM monotherapy and Group B) 527 (41.1%) patients treated either with AI 
monotherapy or sequential TAM-AI/AI-TAM. In addition to this cohort of 1283 patients (overall 
cohort), a landmark cohort and propensity score matching cohorts were built specifically for the 
effectiveness analyses as a strategy to address confounding, and the details about their set-up are 
elaborated in the statistical analysis section. 























Primary outcome was overall survival (OS).  OS was defined as time from diagnosis to death 
of any cause. Follow-up was available until up to December 2013.  
Menopausal status 
 Post-menopausal was defined as older than 52 at date of diagnosis. Previous studies of 
unselected Portuguese women showed that the median age of menopause  for the Portuguese 
population is 48 years (interquartile range [IQR] 44 - 52) 88. Given the treatment with (neo)adjuvant 















Postmenopausal patients, stage I-III, treated systemically in 
the contributing centers between 2006 and 2008 
(N= 1567) 
Unknown hormone receptor status (N= 27) 
Negative hormone receptors (N= 225) 
No histology information (N=0) 
Hormone receptor positive patients with known histology 
(N= 1315) 
Unknown hormone therapy (N=32) 
Unknown survival status (N= 0) 
1283 eligible patients for overall cohort 
1223 eligible patients 
for landmark cohort 
Death during first 2 years of therapy (N= 60) 
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median age for menopause, thus selecting the upper IQR estimate for the definition of the cut-off 
for the age of menopause.  
Covariates 
Covariates included age, clinicopathological characteristics (UICC/AJCC TNM staging, 
histology, grade, and human epidermal growth factor receptor 2 [HER2] status); treatment 
characteristics (systemic therapy), center of care and year of diagnosis.  
Statistical analysis 
Baseline clinicopathological characteristics and treatment received were tabulated, and 
differences between groups tested using chi-square test or t-test, as appropriate. To examine 
treatment characteristics (type of ET used and the duration of therapy) we used descriptive 
statistics. Multivariate logistic regression was used to examine associations with AI prescription. 
Survival plots were built using Kaplan–Meier method. Effectiveness analysis between groups was 
completed using multivariate Cox proportional hazards models. To overcome 
immortal/guaranteed-time bias89 in patients receiving ET switch, the effectiveness analysis was 
performed as a landmark analysis at 2 years, so that patients dying before that period were 
removed (close to median time to treatment switch in case of sequential therapy). The landmark 
analysis was used as primary analysis because the planed ET strategy was not available at baseline, 
and treatment group assignment was based on the actual prescription. Therefore, patients planning 
for a switch from tamoxifen to an aromatase inhibitor, but dying before the planned time for switch, 
would invariably be assigned to tamoxifen only cohort, thus disproportionally enriching one of 
those cohorts of patients with worse survival outcomes (immortal/guaranteed-time bias). As a 
sensitivity analysis, we repeated the analyses in the full cohort, which included all the patients 
removed from the landmark, to avoid the opposite bias. Since absolute benefit of AI is higher among 
high-risk patients, we also tested the interaction between type of ET and TNM stage. Finally, given 
the differences in demographic and clinicopathological features of the groups, and to further 
address confounding we performed a propensity score matching (with a 1:1 matching) to assess 
the effectiveness of tamoxifen when compared to AI exposure (n= 1019), AI monotherapy (n= 762) 
or AI sequencing (n=878). All patients with missing data in relevant variables were excluded from 
multivariate analysis. All analyses met proportional hazards assumption as assessed by the 
Schoenfeld residuals. Missing information was considered missing completely at random. The 
analyses were performed using Stata 12.3 (StataCorp LP). For propensity score matching, Stata ado-
file psmatch2 was used.90 
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5.1.6 Results 
Study sample and baseline characteristics 
The overall study sample was composed of 1283 postmenopausal women with hormone 
receptor positive early breast cancer. Of those, 756 (58.9%) were treated with TAM monotherapy, 
while 527 (41.1%) were treated with an AI at some point in time (205 as monotherapy and 322 as 
sequential therapy). Baseline demographic and clinicopathological characteristics are shown in M1 
Table 1. 
M1 Table 1 – Baseline demographic, clinicopathologic and treatment characteristics 
 Tamoxifen 







Number of patients (%) 756 (58.92) 322 (25.10) 205 (15.98) 527 (41.08) 
OS follow-up (months) 
Median 
P25 – P75 
 
75.62 
(65.39 – 85.25) 
 
78.48 
(70.85 – 87.61) 
 
72.46 
(62.16 – 84.23) 
 
75.77 
(67.15 – 86.98) 
Age at diagnosis (mo.)           
      Median 
      P25 – P75   
 
66.11 
(58.30 – 75.66) 
 
63.28 
(56.46 – 71.53) 
 
65.74 
(58.69 – 74.58) 
 
64.31 
(57.29 – 72.29) 






































































Hormone receptors, % 






















































Page 32 of 175 
 
Patterns of endocrine therapy use 
Patients receiving TAM were older (median 66 years, IQR 58 – 76 vs. 64 years, IQR 57 – 72 
for AI treated), had lower stage disease (e.g., 57.1% had stage I disease vs. 24.3% for AI treated), 
had more differentiated tumors (e.g., 25.3% had histologic grade I disease vs. 13.9% for AI treated) 
and were less frequently HER2 positive (8.7% vs. 16.0% for AI treated) when compared with those 
treated with AI (all p<0.01). Furthermore, patients treated with TAM were less frequently treated 
with (neo)adjuvant chemotherapy (29.4% vs. 71.1% for AI treated; p<0.001).  
In the overall cohort, more patients were treated with TAM (M1 Figure 2 – A). Use of TAM 
varied according to disease stage and center of care (M1 Table 1 and M1 Figure 2 – B). For example, 
77.8% of patients with stage I disease received TAM monotherapy, while only 36.6% of patients 
with stage III did. Remarkably, treatment pattern differed markedly between centers, with some 
centers providing TAM to the majority of patients (67% in center B), while others providing TAM to 
a smaller proportion of patients (25% in center A; p<0.001).  
 
M1 Figure 2 – Relative use of tamoxifen, aromatase inhibitors or their sequence per year of 












In the multivariable model, variables independently associated with prescription of AI-based 
strategies included younger age at diagnosis, higher TNM stage, less differentiated tumors, HER2 






















































A – Year of diagnosis B – Center of care 
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M1 Supplementary Table A.1 – Multivariate model of features associated with the prescription of 
aromatase inhibitors based strategies. OR – Odds ratio. 




Age of diagnosis (years) 
Between 50 and <60 



















2.72 – 5.04 













0.97 – 2.08 
1.14 – 3.19 
  
0.013  












 (reference)  
0.09 – 0.21 
0.10 – 0.39 
0.05 – 0.82 
  
 <0.001 










0.59 – 1.23 




Among those exposed to AIs, the proportion of patients treated with monotherapy or 
sequential therapy differed between centers and year of diagnosis (M1 Supplementary Figure A.1). 
For example, the proportion of sequential therapy in center A decreased from 2006 to 2008 
(sequential therapy of 49% in 2006, 24.5% in 2007 and 21.4% in 2008), while in center B sequential 
strategies were always preferred across the study period (sequential therapy of 68.1% in 2006, 
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M1 Supplementary Figure A.1 – Relative use of tamoxifen, aromatase inhibitors or their sequence 

























A detailed characterization of ET strategies and duration is shown in M1 Table 2. When 
analyzing the group of patients with available date of initiation and completion of ET as a 
monotherapy (33% for patients treated with TAM and 38% for those treated with an AI), the median 
time on either agent was close to 5 years, despite the IQR extending from as low as 38 months to 
as high as 61 months.  Among patients treated with sequential therapy the majority were started 
with upfront TAM (95%). Median time on first agent TAM was 32 months (IQR from 20 to 44 
months), while median time on second agent AI was 25 months (IQR from 13 to 33 months) 
completing close to 5 years of adjuvant ET. The reverse sequence (AI → TAM) was infrequent and, 
in this case, up-front AI was given for a shorter period than TAM (16 months; IQR 2 to 16 months) 
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Diagnosis in 2008 
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Time on treatment 
Median, months 
P25 – P75 
Date of completion available, n (%) 
 
55.61 

















Option as first agent, n (%) 290 (95.39) 14 (4.61) 
Time on first agent 
Median, months 
P25 – P75 
Date of completion available, n (%) 
 
32.26 




(2.00 – 16.33) 
7 (50) 
Time on second agent 
Median, months 
P25 – P75 
Date of completion available, n (%) 
 
24.56 








Median follow-up for the entire population (overall cohort, n= 1283) was 6.3 years (IQR 5.5 
– 7.2). Date of study enrollment and follow-up time was equal for both patients treated with TAM 
and exposed to an AI (p=0.705 and p=0.282, respectively). 
In the overall cohort, from the 527 patients treated with TAM, 171 (22.6%) died, while from 
the 474 patients exposed to AI, 101 (19.2%) died. OS was very favorable for both groups: for those 
treated with TAM, the 5 and 7 years OS proportion was of 83.8% (95% CI 81.0 – 86.3) and 76.2% 
(95% CI 72.5 – 79.4), respectively; while for those exposed to AI, 89.2% (95% CI 86.2 – 91.5) and 
80.1% (95% CI 76.0 – 83.6), respectively. 
In the landmark cohort (n=1223), when controlling for age, TNM stage, histologic grade, 
HER2 status, treatment with (neo)adjuvant chemotherapy and treatment center, exposure to an AI 
was associated with an improved OS (M1 Figure 3; HR 0.55, 95% CI 0.37 – 0.81). Of note, there is a 
consistent curve separation between groups until year 5. Other variables associated with survival 
included age at diagnosis and TNM stage (p<0.001), but not center of care (p=0.358). The same 
analysis performed in the overall cohort (n=1283) is consistent with the landmark cohort (M1 
Supplementary Figure A.2). 
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M1 Figure 3 – Overall survival in the landmark cohort (n=1223) and according to treatment with 















M1 Supplementary figure A.2 – Overall survival in the overall cohort (n=1283) and according to 















Tamoxifen AI exposure 
Events (n, %) 171 (22.62)  101 (19.17)  
Univariate-HR 0.79, 95% CI 0.60 – 1.04; p=0.098 
Adjusted-HR 0.55, 95% CI 0.37 – 0.81; p=0.002 
 
Tamoxifen AI exposure 
Events (n, %) 171 (22.62)  101 (19.17)  
Univariate-HR 0.81, 95% CI 0.63 – 1.03; p=0.086 
Adjusted-HR 0.57, 95% CI 0.40 – 0.82; p=0.003 
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Stratifying the relative effectiveness according to TNM stage, an incremental and consistent 
benefit was observed for stage II and III (stage II: HR 0.57, 95% CI 0.34 – 0.95; stage III: HR 0.32, 95% 
CI 0.17 – 0.60; M1 Figure 4). Interaction between ET and TNM was significant (p for interaction = 
0.002). 
M1 Figure 4 – Overall survival according to the treatment with tamoxifen or with exposure to 
aromatase inhibitors and disease stage/nodal status in the landmark cohort (n=1223): A) stage I, 
















































243 240 237 226 168 87 20Aromatase Inhibitor
226 212 200 188 132 51 9Tamoxifen
No. at risk


























194 192 185 177 127 62 9Aromatase Inhibitor
536 525 515 503 361 176 33Tamoxifen
No. at risk


























117 116 112 108 78 38 7Aromatase Inhibitor
399 394 389 383 277 136 26Tamoxifen
No. at risk
2 3 4 5 6 7 8
Follow-up Time (years)
A – TNM Stage I B - TNM Stage II 
C – TNM Stage III 
E – Node positive (pathological) 

























243 240 237 226 168 87 20Aromatase Inhibitor
226 212 200 188 132 51 9Tamoxifen
No. at risk



























116 112 108 104 78 39 7Aromatase Inhibitor
65 54 49 40 33 16 3Tamoxifen
No. at risk


























287 281 277 265 201 104 25Aromatase Inhibitor
158 139 127 112 84 31 5Tamoxifen
No. at risk
2 3 4 5 6 7 8
Follow-up Time (years)
Page 38 of 175 
 
Finally, we further conducted an exploratory comparison using a propensity score matching 
analysis of patients receiving 1) tamoxifen or aromatase inhibitors exposure, 2) tamoxifen or 
aromatase inhibitors as monotherapy, and 3) tamoxifen or aromatase inhibitors as sequencing 
therapy, all favoring the use of aromatase inhibitors (M1 Supplementary Table A.2). 
M1 Supplementary Table A.2 – Propensity score matching comparison of tamoxifen and different 
aromatase inhibitor-based strategies. A 1:1 matching was performed. Sample size varies according 




Hazard ratio (95% 
Confidence Interval) 
5 years survival 
estimates 




























Over the last 40 years breast cancer detection and treatment has evolved significantly, and 
this has translated into measurable improvements in OS, especially for hormone receptor 
positive/HER2-negative and HER2-positive breast cancers.7 One typical example of treatments that 
are now widespread and which have had a major impact on clinical outcomes is ET, first with TAM 
and more recently with AIs. In postmenopausal women, multiple randomized trials have 
demonstrated that AIs decrease the risk of disease recurrence, which led international guidelines 
to support its use in early 2005.85 However, implementation of such treatments guidelines is not 
optimal.91 
In our study, which focused on the care delivered from 2006-2008 in four Portuguese 
institutions, we found a substantial adoption of the randomized trial data, with almost half of the 
patients being treated with AI by 2008.  As expected, providers selected patients at higher risk of 
recurrence to receive AIs, and were more likely to prescribe TAM to those at lower risk of 
recurrence. Although the EBCTCG meta-analysis showed no substantial heterogeneity in the benefit 
of AI according to age, body-mass index, stage, grade, PR status, or HER2 status, the selection of an 
AI-based strategy for those at higher risk is reasonable, as these are the patients most likely to 
derive a larger absolute benefit of AI over TAM.  In an era where the choices of extending therapy, 
or, in the case of premenopausal women, of treatment intensification with ovarian suppression in 
association with an AI or TAM are taking place92, it is likely that these same risk-based decisions will 
be happening: more effective cancer therapies will have substantial adoption among those at 
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higher risk and, and less so for those at smaller risk, who may do well regardless of the treatment 
choice (e.g., 5 and 7 years survival for stage I patients were 93.7% and 87.8% for those taking 
tamoxifen, respectively, and 92.4% and 87.4% for those taking an AI, respectively). Patients and 
physicians will have the flexibility to more easily personalize choices according to treatment side-
effects, patients’ preferences and cost.  
Nevertheless, in parallel with the higher level of prescription of AI therapy in high risk 
patients, it is also remarkable that introduction of AI was asymmetrical between centers, and center 
of care was a strong independent predictor for the receipt of AI. While some of the variation may 
be appropriate, the very wide absolute differences in uptake rates between centers point to 
reasons beyond tumor characteristics or patient preference as driving factors. Factors that might 
have contributed to these differences include: local challenges in access to treatment innovation, 
cultural differences in the weighting of the risk/benefit of interventions, or even cultural differences 
in application of treatment innovation. Therefore, obstacles in the access to innovations in cancer 
care should be studied to reduce disparities in cancer outcomes in Europe, both at the regional 
level, but also at the center level.93 Empowered by evidence-based guidelines produced with great 
effort from international associations83,84,92, locally, we need to be vigilant and make efforts to 
translate these recommendations into clinical practice thus contributing to overcome disparities in 
cancer care. 
In this cohort, median time on ET was approximately 5 years, suggesting an adequate 
treatment duration (at time of treatment decision). However, some treatment duration disparities 
were noted, which highlights that there may have been patients that struggle with adherence. For 
example, in the monotherapy group 25% of patients received ET for less than 38 months, and in 
the sequencing group starting with an AI, median time on AI was only 16 months, suggesting an 
eventual premature switch due to reasons other than initial treatment decision (as tolerability). 
Finally, our study also showed an OS advantage for patients taking AI vs. TAM alone. This is 
concordant with the EBCTCG meta-analysis that showed that, when compared to 5 years of 
adjuvant TAM alone, 5 years of AIs improved 10-year breast cancer mortality (12.1% vs. 14.2% for 
TAM).39 Relatively similar results were obtained for sequential strategies. When accommodating all 
possible strategies, all-cause mortality also significantly favored AIs (RR 0.88, 95% CI 0.82–0.94). 
Our data are consistent with these findings, however a more pronounced benefit in terms of OS 
was noted (adjusted-HR 0.55, 95% CI 0.37 – 0.81; proportion alive at year 7 of 76.2% and 80.1% for 
TAM and AI, respectively). Our data provides real-world confirmation of the benefits of AI therapy, 
whether given as monotherapy or as part of a sequential approach, as compared to TAM alone, 
outside of a controlled clinical trial setting.   
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Although this study provides interesting insights, it also has several limitations. It is a 
retrospective observational study, thus despite statistical rigor we cannot exclude residual 
confounding. To this end, we did not have access to patients’ co-morbidities, educational level nor 
Ki67; their distribution between arms is unknown, which might contribute to residual confounding. 
This cohort includes data from four large centers from a single region in Portugal, which might not 
reflect practices in smaller centers and/or other regions. Treatment effectiveness was measured as 
OS, not cancer specific survival (due to cancer registry specifications), a limitation in a cohort of 
postmenopausal women with other competing causes of death. No data on actual reasons for 
treatment discontinuation or drug non-adherence was available (actual drug intake), and patients 
receiving consecutive prescription were considered to be active takers of the respective drug. 
Studies on patients’ preferences are needed. Of note, a high proportion of cases did not have 
information regarding definitive treatment stop date. Lastly, our study did not examine quality of 
life nor pharmacoeconomic metrics.  
5.1.8 Conclusion 
AIs were effectively introduced as adjuvant treatment of early breast cancer in a group of 
Portuguese centers, particularly among patients with high stage disease. However, its use relative 
to TAM was not only influenced by tumor and patient characteristics, but also center of care. In 
accordance to guidelines at the time of diagnosis (2006 to 2008), treatment was provided for 
approximately 5 years. Finally, exposure to an AI was associated with a strong OS benefit. 
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5.2 Mixed Invasive Ductal and Lobular Carcinoma of the Breast: Prognosis and the 
Importance of Histologic Grade 
5.2.1 Introductory notes 
This project details the relative effectiveness of aromatase inhibitors and tamoxifen for the 
adjuvant treatment of postmenopausal women with hormone receptor positive breast cancer 
within the lobular family of tumors, in specific in pure invasive lobular carcinoma and mixed ductal 
and lobular carcinoma. It further dissects its prognostic implications and summarizes the prognostic 
role of histologic grade according to histology. This project was published in The Oncologist. Arlindo 
R. Ferreira led the study design, data analysis, results interpretation and manuscript writing. 
5.2.2 Authors 
Otto Metzger Filhoa,*,§, Arlindo R. Ferreiraa,b,*, Rinath Jeselsohna, William T. Barrya, Deborah 
A. Dillona, Jane E. Brocka, Ines Vaz-Luisa, Melissa E. Hughesa, Eric P. Winera, Nancy U. Lina 
* co-first authors (equal contribution) 
Authors Affiliations: aDana-Farber Cancer Institute, Brigham and Women’s Hospital, 450 
Brookline Ave, Boston, MA 02215, USA; bHospital de Santa Maria and Instituto de Medicina 
Molecular, Faculdade de Medicina, Universidade de Lisboa, Av. Prof. Egas Moniz, 1649-035 
Lisbon, Portugal; §Corresponding author. 
5.2.3 Abstract 
Background: The diagnosis of mixed invasive ductal and lobular carcinoma (IDC-L) in clinical 
practice is often associated with uncertainty related to its prognosis and response to systemic 
therapies. With the increasing recognition of invasive lobular carcinoma (ILC) as a distinct disease 
subtype, questions surrounding IDC-L become even more relevant. In this study, we took advantage 
of a detailed clinical database to compare IDC-L and ILC regarding clinicopathologic and treatment 
characteristics, prognostic power of histologic grade and survival outcomes.  
Methods: In this retrospective cohort study, we identified 811 patients diagnosed with 
early-stage breast cancer with IDC-L or ILC. Descriptive statistics were performed to compare 
baseline clinicopathologic characteristics and treatments. Survival rates were subsequently 
analyzed using the Kaplan-Meier method and compared using the Cox proportional hazards model.  
Results: Patients with ILC had more commonly multifocal disease, low to intermediate 
histologic grade and HER2-negative disease. Histologic grade was prognostic for patients with IDC-
L, but had no significant discriminatory power in patients with ILC. Among postmenopausal women, 
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those with IDC-L had significantly better outcomes when compared to those with ILC: disease-free 
survival (DFS) and overall survival (OS; adjusted-HR 0.54, 95% CI 0.31 – 0.95). Finally, 
postmenopausal women treated with an AI had more favorable DFS and OS than those treated with 
tamoxifen-only (OS adjusted-HR 0.50, 95% CI 0.29 – 0.87), which was similar for both histologic 
types (p=0.212). 
Conclusions: IDC-L tumors have a better prognosis than ILC tumors, particularly among 
postmenopausal women. Histologic grade is an important prognostic factor in IDC-L, but not in ILC. 
Keywords: breast cancer, early; carcinoma, lobular; invasive ductal carcinoma, breast; 
tumor grading; outcomes research. 
5.2.4 Introduction 
Breast cancer is morphologically classified as either invasive breast carcinoma of no special 
type (NST), also known as invasive ductal carcinoma (IDC), or as a “special subtype” of breast 
cancer.94 Special subtypes account for an array of different histological features, with invasive 
lobular carcinoma (ILC) being the most common subtype.95 In addition, certain breast carcinomas 
present with varying proportions of NST and other types of breast cancers and are classified as 
carcinomas of mixed type. This category is defined as tumors in which at least 50% of the tumor has 
a specialized pattern and a non-specialized pattern in 10% to 49% of the tumor.94 Mixed invasive 
ductal and lobular carcinomas (IDC-L) account for approximately 5% of all breast cancers and, side 
with ILC, present a growing incidence.95–97 
ILC has long been distinguished from other types of breast cancer for its unique 
clinicopathologic features and more recently genomic landscape.98–100 When compared to IDC, ILC 
tend to lack the cell adhesion molecule e-cadherin, is more frequently multifocal, hormone 
receptor-positive/HER2-negative, lower grade (I or II), presents reduced response rates to 
preoperative chemotherapy and may benefit differently from adjuvant endocrine therapies.101–104 
In contrast, studies characterizing IDC-L are currently scarce and limited by cohort size, lack of 
granular clinicopathological/treatment data or short follow-up.95,105–109 It is thus unclear how 
patients with these tumors perform in terms of survival outcomes and whether known classic 
prognostic features of IDC, as histologic grade, apply to IDC-L. 
In this retrospective analysis, we took advantage of a large, detailed and curated single 
center database to compare clinicopathologic features and outcomes between ILC and IDC-L. We 
further focused on the prognostic implications of histological grade taking into consideration 
differences in systemic therapies. 
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5.2.5 Patients and Methods 
Study design and data source 
This is a retrospective cohort study using prospectively collected data from the Dana-Farber 
Cancer Institute (DFCI) and stored in the National Comprehensive Cancer Network (NCCN) Oncology 
Outcomes Database. The current study was approved by the DFCI Institutional Review Board and 
complies with all national regulations. We applied the STROBE statement in reports of cohort 
studies (http://www.strobe-statement.org/).  
Patient selection and extracted information 
We identified all patients who were older than 18 years of age, and were diagnosed and 
treated at DFCI for stage I-III breast cancer of ILC or IDC-L histology from 1997 to 2007. IDC-L was 
defined as tumors in which at least 50% of the tumor is of lobular pattern and 10% to 49% of non-
specialized pattern. Follow-up details (disease recurrence, new primaries and death) were available 
up to January 2012 and analyzed as per registry specifications. Dates of study entry were balanced 
between groups. We excluded patients with metastatic disease at presentation, patients who 
received neoadjuvant therapy, patients who did not have surgery and patients with other 
concurrent primary tumors. A cohort of 811 patients was identified for the analysis (M2 Figure 1).  









Overall survival (OS), disease-free survival (DFS), and time to specific relapse were defined 
as time from diagnosis to death, time from diagnosis to any relapse or death, and time from 
diagnosis to local, regional or distant relapse, respectively.   
 
Statistical analysis 
Descriptive statistics of baseline demographic, clinicopathologic and treatment 
characteristics were performed. Differences between groups were tested using chi-squared test or 
t-test where applicable. Time-to-event data was analyzed using the Kaplan–Meier method and 
compared using Cox proportional hazards models. All patients with missing data in relevant 
variables were excluded from the multivariate analysis. All the presented analyses successfully met 
Patients with primary invasive lobular carcinoma or mixed 
invasive ductal and lobular carcinoma diagnosed and 
treated at the DFCI from 1997 to 2012: n=849 
Metastatic disease at presentation: n=35 
Surgery not performed: n=3 
Patients eligible for primary analysis: n=811 
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proportional hazards assumption as assessed by the Schoenfeld residuals. Missing information was 
considered as missing at random, as per study design. The analyses were completed using Stata 
12.3 (StataCorp LP). 
5.2.6 Results 
Study population and baseline characteristics 
The study population included 811 patients, 337 (41.6%) with ILC and 474 (58.4%) with IDC-
L (M2 Table 1).  When compared to patients with IDC-L, patients with ILC were slightly older, had 
larger tumors (11.0% had tumors > 5 cm vs. 3.0% for IDC-L; p<0.001), more positive nodes (16.9% 
had ≥4 nodes vs. 9.7% for IDC-L; p=0.002) and less frequently poorly differentiated tumors (8.3% 
vs. 19.8% for IDC-L; p<0.001). In addition, ILC was less likely to be HER2-positive (3.9% vs. 8.6%; 
p=0.02). Finally, multifocal disease was also more common in patients with ILC (36.2% vs. 26.6%; 
p=0.004). 
M2 Table 1 – Patient demographics, clinicopathologic characteristics and treatments overall and by 
histologic type.  
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ER – estrogen receptor; HER2 – human epidermal growth factor receptor 2; IDC-L – mixed invasive 
ductal and lobular carcinoma; ILC – invasive lobular carcinoma; IQR – interquartile range; PR – 
progesterone receptor. 
Treatment  
Patients with ILC underwent mastectomy more frequently than those with IDC-L (57.0% vs. 
46.8%; p=0.004; M2 Table 1). Yet, no significant differences were found in the frequency of 
radiotherapy (69.1% vs. 72.6% for IDC-L; p=0.287). Nevertheless, despite the higher tumor burden 
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Outcomes 
The median follow-up for the entire cohort was 7.9 years, and was similar for both 
histologic types (p=0.190). Among 337 patients with ILC, 73 (21.7%) developed a DFS event and 62 
(18.4%) developed an OS event; while among 474 patients with IDC-L, 70 (14.8%) developed a DFS 
event and 59 (12.5%) developed an OS event. For patients with ILC, the 5- and 10-year proportion 
of patients free of a DFS event was 89.3% (95% confidence interval [CI] 85.3 – 92.2) and 74.2% (95% 
CI 67.8 – 79.6), respectively; while for IDC-L, the 5- and 10-year rates were 90.4% (95% CI 87.3 – 
92.8) and 81.0% (95% CI 75.7 – 85.3), respectively. 
In a multivariate model, variables associated with DFS included year of diagnosis, TNM 
stage and histologic grade; whereas variables associated with OS included age at diagnosis, TNM 
staging and histologic grade (M2 Table 2). Overall, the differences in DFS and OS outcomes by 
histologic type were not statistically significant, despite a trend towards an improved outcome for 
IDC-L when compared to ILC. Specifically, the hazard ratio for DFS was 0.72 (95% CI 0.49 – 1.08; 
p=0.114) (M2 table 2 and M2 figure 2) and the hazard ratio for OS was 0.77 (95% CI 0.50 – 1.20; 
p=0.244) (M2 table 2 and M2 figure A-1). 
M2 Table 2 – Multivariate Cox proportional hazards model for overall survival and disease-free 
survival.  
Variable list  Disease-Free Survival 
(No. patients: 681/811; Events 110/143) 
Overall Survival 
(No. patients: 681/811; Events 93/121) 
HR 95% CI p-value HR 95% CI p-value 
Main multivariate model (estimates without interaction terms) 
ILC (vs. IDC-L)  0.72 0.49 – 1.08 0.114 0.77 0.50 – 1.20 0.244 
Age at diagnosis 
(per year increase)  
1.01 0,99 – 1.04 0.091 1.03 1.00 – 1.06 0.034 
Menopausal status 1.08 0.60 – 1.96 0.791 1.14 0.59 – 2.21 0.703 
TNM staging  
Stage I 
Stage II 







1.37 – 4.31 






















1.06 0.67 – 2.11 0.815 1.18 0.72 – 1.93 0.519 
Histologic grade  
Grade I 
Grade II 







0.73 – 2.12 



















ER positive  0.70 0.22 – 2.22 0.543 0.46 0.13 – 1.59 0.222 




0.76 0.39 – 1.46 0.406 0.96 0.49 – 1.88 0.906 
Adjuvant 
chemotherapy use  
0.66 0.37 – 1.17 0.159 0.87 0.46 – 1.65 0.673 
Adjuvant hormone 
therapy use 
0.58 0.18 - 1.84 0.360 0.72 0.20 - 2.57 0.613 
Year of diagnosis 0.91 0.83 – 0.99 0.034 1.04 0.93 – 1.16 0.489 
Interaction term 1 in the main multivariate model (see accompanying figure 3) 
Histologic type x 
menopausal status 




































































Interaction term 2 in the main multivariate model (see accompanying figure 4) 
Histologic type x 
grade  















0.57 – 1.97 











0.58 – 2.35 




















0.70 – 7.80 



















CI – confidence interval; ER – estrogen receptor; HER2 – human epidermal growth factor receptor 
2; HR – hazard ratio; IDC-L – mixed invasive ductal and lobular carcinoma; ILC – invasive lobular 
carcinoma; x – interaction between terms. 
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M2 Figure 2 – Disease-free survival in ILC and IDC-L.  
CI – confidence interval; IDC-L – mixed invasive ducal and lobular carcinoma; ILC – invasive lobular 
carcinoma; HR – hazard ratio. 
 
M2 Figure A-1 – Overall survival in ILC and IDC-L. 
CI – confidence interval; IDC-L – mixed invasive ducal and lobular carcinoma; ILC – invasive lobular 
carcinoma; HR – hazard ratio. 
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Given the hormone dependent nature of lobular carcinomas, we tested whether 
menopausal status modified outcomes according to histologic type. The interaction between 
histology and menopausal status was statistically significant for OS and a trend in the same direction 
was noted for DFS (M2 Table 2). When stratifying the analysis by menopausal status, no difference 
in DFS or OS was seen in premenopausal patients (adjusted hazard ratio [HR] for DFS 1.06, 95% CI 
0.52 – 2.17; p=0.875), but superior outcome is evident for postmenopausal patients with IDC-L, 
compared to ILC (adjusted HR for DFS 0.58, 95% CI 0.34 – 0.97; p=0.039) (M2 Figure 3 and M2 Figure 
A-2).  






CI – confidence interval; IDC-L – mixed invasive ducal and lobular carcinoma; ILC – invasive lobular 
carcinoma; HR – hazard ratio. 
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CI – confidence interval; IDC-L – mixed invasive ducal and lobular carcinoma; ILC – invasive lobular carcinoma; 
HR – hazard ratio. 
To explore the prognostic role of histologic grade, we performed an interaction analysis 
between histology and grade, which was statistically significant (M2 Table 2). While histologic grade 
was unable to discriminate the prognosis of patients with ILC, it was an effective tool to discriminate 
the prognosis of those with IDC-L (M2 Figure 4 and M2 Figure A-3). 
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94 91 87 81 67 62 46 37 26 16 10 6 2Grade 3
309 308 302 293 262 230 199 166 141 104 68 37 18Grade 2
69 69 69 67 63 57 54 42 34 27 22 14 5Grade 1
No. at risk
0 1 2 3 4 5 6 7 8 9 10 11 12
Follow-up time (years)
Grade 1 Grade 2 Grade 3
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We further explored the relative effectiveness of tamoxifen versus AI among 
postmenopausal patients with hormone receptor-positive tumors. Patients treated with an AI (as 
monotherapy or sequentially with tamoxifen) had more favorable outcomes than those treated 
with tamoxifen-only, both in terms of DFS (HR 0.36, 95% CI 0.21 – 0.61; p<0.001) and OS (HR 0.50, 
95% CI 0.29 – 0.87; p=0.015) (M2 Table A-1). The magnitude of benefit was similar for both 
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188 188 187 180 164 139 115 99 85 66 50 35 19Grade 2
113 111 111 111 101 94 86 74 59 49 39 26 15Grade 1
No. at risk
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Follow-up time (years)
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309 308 306 302 274 242 208 174 146 110 74 39 19Grade 2
69 69 69 68 64 58 55 43 35 28 22 14 5Grade 1
No. at risk
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Follow-up time (years)
Grade 1 Grade 2 Grade 3
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a landmark analysis including only patients free of recurrence at 24 months (which would be a 
reasonable date of endocrine therapy switch from tamoxifen to an AI in clinical practice).  
M2 Table A-1 – Efficacy of therapy in postmenopausal hormone receptor-positive patients. 
Adjusted-HR controlling for age, stage, tumor grade, LVI and HER2 expression.  
Type of therapy 
DFS model 
(No. patients: 358/441; Events 65/86) 
OS model 
(No. patients: 358/441; Events 60/77) 
HR 95% CI P-value HR 95% CI P-value 
Type of hormone therapy 
Tamoxifen  









































AI – aromatase inhibitor; CI – confidence interval; DFS – disease-free survival; HR – hazard ratio; OS – overall 
survival. 
Disease recurrence 
A total of 91 patients had a disease recurrence: 44 (48.35%) patients with ILC and 47 
(51.65%) patients with IDC-L (p=0.163) (M2 Table A-2). When considering the specific site of disease 
recurrence, bone was the most frequent site in both histologic types (14 [37.84%] vs. 17 cases 
[53.12%], for ILC and IDC-L, respectively). Nevertheless, intra-abdominal recurrences (excluding 
liver) were only identified in ILC (7 [18.9%]). 
M2 Table A-2 – Recurrence and second primary tumor characterization. 
Disease relapse Total sample ILC IDC-L P-value 










Type of first relapse, n (%) 
Local relapse  
















Type of first relapse, n (%) 















































CNS – central nervous system; IDC-L – mixed invasive ducal and lobular carcinoma; ILC – invasive lobular 
carcinoma; NOS – not otherwise specified. 
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Finally, using a multivariate analysis model (controlling for the same variables detailed in 
M2 Table 2) we found no significant differences according to histologic type for other outcomes, 
namely locoregional recurrence (HR 0.97, 95% CI 0.36 – 2.60; p=0.944), distant recurrence (HR 0.69, 
95% CI 0.41 – 1.18; p=0.174), bone recurrence (HR 0.80, 95% CI 0.35 – 1.80; p=0.584) and second 
breast cancers (HR 1.81, 95% CI 0.65 – 5.05; p=0.258).  
5.2.7 Discussion 
In this retrospective analysis, we took advantage of a clinical database including 811 
patients to compare clinicopathologic features, management, and survival outcomes between IDC-
L and ILC. Patients with ILC were older, had more multifocal disease, larger tumors, more positive 
nodes, HER2-negative tumors, and received less frequently adjuvant chemotherapy than patients 
with IDC-L. When compared to ILC, IDC-L had superior survival outcomes, particularly for women in 
the postmenopausal setting. Histologic grade was an important prognostic factor for IDC-L, but not 
for ILC. These observations resemble differences between hormone receptor-positive IDC and 
ILC.105,110–112  
Previous retrospective studies have failed to identify meaningful differences in survival 
outcomes in patients with ILC compared to patients with IDC-L.106–109,113,114 By contrast, in a 
retrospective series including 140 patients with IDC-L, Rakha et al reported worse outcomes for 
patients with IDC-L than those with ILC (n=380).105 The interpretation of previous results is impaired 
by cohort size, limited multivariate adjustment or short follow-up. In this study, the overall results 
suggested similar survival outcomes between patients with ILC and IDC-L, but when stratifying by 
menopausal status, we noticed superior survival outcomes for patients with IDC-L. These 
observations were corroborated by a large analysis of SEER database including a total of 209,109 
patients.115 In the SEER analysis, Xiao et al compared survival outcomes based on histology including 
172,379 IDC, 17,503 ILC and 19,227 IDC-L patients. The survival analysis performed pointed to 
better breast cancer-specific survival (BCSS) for patients with IDC-L than IDC and ILC. The evaluation 
of HR over time using Scaled Schoenfeld residual plots revealed interesting findings: the HR of IDC-
L versus IDC increased over time indicating a continuous long-term risk of relapse, which could be 
attributed to the lobular component of mixed tumors. By contrast, the HR for the comparison of 
IDC-L versus ILC decreased over time indicating better long-term prognosis for IDC-L versus ILC. 
When evaluating the differences in outcomes between IDC-L and ILC, patients > 50 years diagnosed 
with IDC-L had superior outcomes.115 While the larger sample size from the SEER analysis provided 
robust prognostic information, the lack of detailed clinicopathologic information (e.g. HER2 status) 
and treatment information is an important limitation.  
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Our results complement the findings from the SEER analysis, given that we were able to 
interpret survival outcomes correcting for important clinicopathologic variables (e.g. adjuvant 
systemic therapy). Taken together, available data suggests that patients diagnosed with IDC-L have 
a better survival outcome when compared to patients with ILC, which is probably explained by the 
continuous long-term risk of relapse associated with ILC. Furthermore, patients with IDC-L generally 
did not develop intra-abdominal relapses that characterize ILC. The TCGA research network recently 
published results of genomic characterization of 490 IDC, 127 ILC, 88 IDC-L, and 112 other breast 
cancer cases.116 As expected, ILC-like tumors were enriched for luminal A subtype, CDH1 mutations 
and loss of e-cadherin by mRNA expression. Among the 88 cases of IDC-L, there did not appear to 
be a distinct genomic profile; rather, the IDC-L cases segregated into IDC-like (n=64) or ILC-like 
(n=24) tumors. The overrepresentation of molecular IDC-like tumors in the clinical IDC-L cases in 
the TCGA is consistent with our findings – IDC-L (as assessed by pathological evaluation) diverged 
from ILC in histologic grade, frequency of HER2 status, and survival outcomes, among other 
differences, which would be expected if most clinical IDC-L are molecular IDC-like. Further research 
is needed to investigate whether there is any clinical utility of molecularly classifying IDC-L for the 
purpose of prognostic evaluation and/or treatment planning.   
In our cohort, histologic grade was prognostic for IDC-L, but not for ILC. In a previous 
retrospective series pooling outcomes from 707 classic ILC, 102 special subtypes of ILC and 44 mixed 
tumors, Talman et al. found a significant difference in OS and DFS between grade II and III tumors, 
but not between grade I and II tumors.117 In addition, a subsequent study including 517 ILC 
patients118 reported a significant prognostic value for histologic grade. However, approximately one 
third of cases in the series were special subtypes of ILC often characterized by tubule formation, 
and when tubule formation was removed from the analysis, the remaining histologic grade 
variables (i.e., mitotic count and nuclear pleomorphism) were no longer associated with outcome. 
Collectively, our findings and those of others suggest that the current grading system may be limited 
for ILC, but useful for IDC-L.  
In an exploratory analysis from our cohort, postmenopausal patients receiving adjuvant AI, 
either as monotherapy or sequentially after tamoxifen, had better outcomes when compared to 
patients treated with tamoxifen monotherapy independently of the histologic subtype. These 
results are in agreement with the updated aromatase inhibitor (AI) overview meta-analysis.39 Of 
interest, two retrospective studies have compared the effectiveness of AI versus tamoxifen among 
patients diagnosed with ILC or IDC: the BIG1-98 study and the ABCSG-8 study.103,104 In the BIG1-98 
study, patients with ILC derived a greater benefit to letrozole when compared to tamoxifen103 and 
in the ABCSG-8 study, patients diagnosed with ILC had better survival outcomes when treated with 
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a sequential regimen (tam-AI) than tamoxifen monotherapy.104 Our current study is limited in its 
ability to determine a difference between AI and tamoxifen for patients diagnosed with ILC and 
IDC-L and further investigation into this topic is needed.  
We acknowledge a number of limitations to our study. Despite the methodological rigor, as 
a retrospective observational study, it is amenable to residual confounding. While pathologic 
review was, in most cases, performed by an academic pathologist at Brigham & Women’s Hospital, 
central pathology review and additional immunohistochemical studies, such as E-cadherin/p120119 
to further characterize these tumors, were not performed. Tumor classifications were taken from 
the diagnostic pathology reports and likely reflect both individual pathologist preferences as well 
as changing tumor classification practices over the period of this study. Finally, the relative 
effectiveness of tamoxifen versus AIs results are based on observational data, and not a randomized 
trial.  
Despite these limitations, we report several important findings: 1) patients diagnosed with 
IDC-L have a better prognosis than patients with ILC, particularly for postmenopausal women; 2) 
histologic grade is an imperfect tool for patients with ILC, but provides relevant information for 
patients with IDC-L; 3) consistent with data from phase III studies, where AIs have shown a DFS 
advantage over tamoxifen that appeared greatest in the ILC subset, these improvements also held 
true for patients with IDC-L. Taken together, our work adds to the literature pointing to significant 
differences in survival outcomes for patients with IDC-L when compared to patients with ILC. 
Patients with IDC-L have more favorable outcomes, particularly for those in the postmenopausal 
setting; the unfavorable outcomes associated with ILC are likely to be explained by its continuous 
pattern of relapse beyond year 5.  
5.2.8 Implications for Practice 
We compared mixed invasive ductal and lobular carcinoma (IDC-L) to invasive lobular 
carcinomas (ILC) to assess the overall prognosis, the prognostic role of histologic grade, and 
response to systemic therapy. We found that patients with IDC-L tumors have a better prognosis 
than ILC, particularly among postmenopausal women, which may impact follow-up strategies. 
Moreover, while histologic grade failed to stratify the risk of ILC, it showed an important prognostic 
power in IDC-L, thus highlighting its clinical utility to guide treatment decisions of IDC-L. Finally, the 
DFS advantage of adjuvant aromatase inhibitors over tamoxifen in ILC was consistent in IDC-L. 
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5.3 Effectiveness of adjuvant ovarian function suppression in premenopausal 
women with early breast cancer: a multicenter cohort study 
5.3.1 Introductory notes 
This project details the introduction in clinical practice of adjuvant ovarian function 
suppression for the adjuvant treatment of premenopausal women with hormone receptor positive 
breast cancer and summarizes the real-world effectiveness of such intervention compared to no 
OFS. This project was published in Clinical Breast Cancer. Arlindo R. Ferreira led the study design, 
data analysis, results interpretation and manuscript writing. 
5.3.2 Authors 
Arlindo. R. Ferreiraa,b,§, Joana Ribeiroc, Ana Mirandad, Alexandra Mayerd, José Luís Passos-
Coelhoe, Margarida Britod, João Fernandesf, Joaquim Gouveiaf, Luís Costaa,b, and Inês Vaz-Luisg. 
Authors affiliations: aHospital de Santa Maria, Centro Hospitalar de Lisboa Norte; 
bInstituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa; 
cChampalimaud Clinical Center, Fundação Champalimaud; dInstituto Português de Oncologia F. G. 
de Lisboa; eHospital da Luz; fInstituto CUF de Oncologia; gInstitut Gustave Roussy, Unit INSERM 
981; §Corresponding author. 
5.3.3 Abstract 
Background: Ovarian function suppression (OFS) with tamoxifen or aromatase inhibitors 
(AI) improves disease-free survival in premenopausal women with breast cancer (BC), mostly in 
those at higher risk of recurrence. However, its real-world use and impact remain poorly 
understood. 
Methods: This is a multicenter retrospective cohort study of premenopausal women with 
stage I-III hormone receptor-positive BC diagnosed from 2006-2015 aimed to look at the uptake 
and effectiveness of the addition of OFS to backbone endocrine therapy (tamoxifen or AI). To deal 
with confounding, we used both multivariate modelling and propensity score matching.  
Results: Of 1717 eligible patients, 17.1% were treated with OFS. There was a substantial 
increase of use of OFS over time, especially from 2014 onward (16% vs 25% after 2014), particularly 
for the combination with AI (0.4% vs 8% after 2014). In a multivariate model, only younger age and 
year of diagnosis ≥2014 were associated with OFS utilization (both p<0.001). 
With a median follow-up of 38 months (P25-P75 19.6-66.4) patients receiving OFS had a better OS 
than those not receiving OFS (adjusted-HR 0.44, 95% confidence interval 0.19-0.96, absolute 
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benefit at 5 years: 2.1% (95.3% vs. 93.2% in those not receiving OFS). A similar benefit was identified 
using propensity score matching. 
Conclusions: In the real-world setting, there was an increase in the use of OFS after 2014. 
After 2014 a quarter of premenopausal women received adjuvant OFS, of which more than 30% in 
combination with an AI. In this study, use of adjuvant OFS was associated with an OS benefit.  
Keywords: Gonadotropin-releasing hormone agonist, tamoxifen, aromatase inhibitor, treatment 
effectiveness, breast cancer. 
5.3.4 Introduction 
Breast cancer (BC) is the most frequently diagnosed and the most common cause of women 
cancer related death in the European Union (EU), with an estimated incidence and death rate of 
approximately 108.8 and 22.4 cases per 100 000 women/year, respectively.2 The generalization of 
screening and the introduction of incrementally more efficacious adjuvant treatments contributed 
substantially to improve outcomes of patients diagnosed with BC at early stages. For the two thirds 
of patients with BC expressing the estrogen and/or progesterone receptors, collectively referred as 
hormone receptor (HR)-positive, it is well established the clinical utility of the use of hormone-
related therapies.10  
In the subset of premenopausal women, tamoxifen has been the mainstay of adjuvant 
endocrine therapy for more than 30 years.25,120 However, recent studies showed that intensifying 
treatment with the combined use of ovarian function suppression (OFS) to either tamoxifen or 
aromatase inhibitors (AI) further improves cancer outcomes.51,52,54 Particularly, results of the SOFT 
trial suggested that, after a median follow-up of 8 years and compared to tamoxifen alone, the 
addition of OFS to tamoxifen (OFS-T) improved overall survival (OS; a similar strong trend was also 
recorded for the association between OFS and an AI [OFS-AI]), especially in those patients judged 
to have a risk of recurrence justifying the use of adjuvant chemotherapy and among the very young 
patients (less than 35 years old).52 In the group of women who were treated with chemotherapy, 
the 8-year OS estimates were 89.4% vs. 87.2% vs. 85.1% for the OFS-T, OFS-AI and the tamoxifen-
only arm, respectively (hazard ratio [HR] 0.59, 95% confidence interval [CI] 0.42-0.84 for OFS-T vs. 
tamoxifen and HR 0.79, 95% CI 0.57-1.09 for OFS-AI vs. tamoxifen). In addition, for the group of 
women younger than 35, the 8-year DFS estimates (OS data not reported) were 80.0 vs. 74.6% vs. 
64.9% for the OFS-AI, OFS-T and tamoxifen only arm, respectively. Furthermore, a consistent DFS 
advantage was also found for the combinations OFS-AI and OFS-T when compared to tamoxifen in 
the overall cohort.    
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Since 2006, the Registo Oncológico Regional do Sul (Portuguese southern cancer registry; 
ROR-S) collects detailed tumor and treatment data on a large cohort of women with newly 
diagnosed breast cancer.  In this study of premenopausal women treated with adjuvant endocrine 
therapy we aim to 1) characterize real-world prescription of OFS and particularly to describe how 
recent data from clinical trials modified routine endocrine therapy practice, and 2) examine the 
short-term OS impact of OFS.  
5.3.5 Patients and Methods 
Study design and data source 
This is an observational retrospective cohort study. Clinical data concerning five large 
centers located in Lisbon, Portugal was retrieved from ROR-S. ROR-S is a population-based cancer 
registry that serves as the unifying framework for variables definition, data registry and quality 
assurance. Due to the observational nature of the study, treatments and follow-up were performed 
at patient-physician description. ROR-S institutional review board (IRB) approved study protocol 
and ROR-S performed the oversight of study conduct. Description of data collection and procedures 
were previously reported.87 We followed the STROBE statement in reports of cohort studies. 
Patient selection 
All consecutive premenopausal women diagnosed with hormone receptor (HR)-positive, 
non-metastatic breast cancer between January 2006 and December 2015, and treated at 
participating institutions (Centro Hospitalar de Lisboa Norte, Instituto CUF de Oncologia, Hospital 
da Luz, Hospital de Beatriz Ângelo and Instituto Português de Oncologia de Lisboa) were included. 
Patients with no information about surgery and with incomplete or missing information on adjuvant 
therapy were excluded. For this study, two cohorts of patients were defined: those patients treated 
with adjuvant OFS and those not treated with adjuvant OFS. 
Menopausal status and hormone receptor status 
ROR-S does not collect menopausal status. For this study, pre-menopausal status was 
defined as age at date of diagnosis younger than 50, a reference age adjusted to the Portuguese 
population.88 Hormone receptor positivity was defined as either estrogen receptor positive and/or 
progesterone receptor positive with positivity defined as ≥1% of tumor cell nuclei immunoreactivity 
or tumor classified as “HRe-positive” in the patient medical records. 
Study outcomes and variables 
Outcomes 
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 The primary study outcome was OS, defined as time from tumor diagnosis to death from 
any cause. Vital status, as register on ROR-S, is obtained from a centralized and electronic platform 
of national death certificates (Sistema de Informação dos Certificados de Óbito [SICO] managed by 
Direção Geral de Saúde). Follow-up was available up to December 2016. Given the nature of the 
data source, recurrences were not available. 
 As secondary outcomes we examined use of OFS and duration of OFS treatment. 
Administration of OFS was defined as the prescription of any OFS agent started after surgery and 
for at least two consecutive prescriptions. Duration of therapy was defined as the time from first to 
last treatment prescription plus 1 month (to account for treatment action). Four patients had 
oophorectomy shortly after introduction of adjuvant OFS and here considered as continuing OFS. 
No patient had upfront oophorectomy. 
Other covariates 
Study covariates included age at diagnosis, tumor characteristics (American Joint 
Committee on Cancer [AJCC] TNM staging, histology, grade and human epidermal growth factor 
receptor 2 [HER2] status); treatment characteristics (local and systemic) and year of diagnosis. 
Statistical analysis 
Descriptive statistics of patient, disease and treatment characteristics were performed. 
Differences of these features by use of OFS were tested using chi-squared test or Wilcoxon rank-
sum test, as appropriate and univariate and multivariate logistic regression models. Variables 
included in the multivariate logistic model included year of diagnosis, age at diagnosis, histologic 
type, grade, HER2 status, type of surgery, radiotherapy, and (neo)adjuvant chemotherapy. Time-
to-event outcomes were estimated and plotted using the Kaplan-Meier method. Survival rates were 
compared using Cox proportional hazards models. To deal with confounding, both multivariate Cox 
proportional hazards models and propensity score (PS) matching with a 1:1 matching were 
performed. Variables included both in the multivariate model and PS matching included: age at 
diagnosis, stage, histologic grade, HER2 status, use of (neo)adjuvant chemotherapy, type of surgery 
and year of diagnosis. The patient characteristics of the matched samples are shown in M3 
Supplementary Table A.1. Two sensitivity analysis were performed: 1) to deal with eventual 
immortal-time bias, we performed a sensitivity analysis including only patients alive 1 year after 
surgery and 2) to test the robustness of findings in patients with longer follow-up, we completed a 
sensitivity analysis including only patients with a minimum follow-up of 3 and 5 years. All time-to-
event analyses met proportional hazards assumption as assessed by the Schoenfeld residuals. We 
performed a complete full data analysis. The dataset had 100% completion data for survival 
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outcomes and for other variable, missing values did not exceed 8%. Missing information was 
considered missing at random. All tests were 2-sided and p-values of ≤ 0.05 were considered 
statistically significant. The analyses were performed using Stata 13.1 (StataCorp LP). For propensity 
score matching, Stata ado-file psmatch2 was used.90  
M3 Supplementary table A.1 – Patients demographics, tumor characteristics and type of 
concomitant treatment by type of adjuvant endocrine therapy in the matching samples 
Variable list 
















14.6 – 63.7 
 
36.5 
16.1 – 62.6 
 
0.419 
Demographic and clinicopathological characteristics  
Age (years) 
≤35 
>35 to ≤40 











Year of diagnosis 
2006 – 2009 
2010 – 2012 














































Simplified TNM staging, n (%) 
Stage I 
Stage II 











Histology, n (%) 
Invasive ductal carcinoma 


























Hormone receptor status, n (%) 
ER and PR positive 
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Positive 43 (17.2) 49 (19.6) 
Treatment characteristics  







































Study sample and baseline characteristics 
A total of 1717 consecutive eligible patients were included in the study analysis (M3 
Supplementary Figure A.1), of which 294 (17.1%) received adjuvant OFS (goserelin in almost all 
cases) and 1423 (82.9%) did not.  
M3 Supplementary figure A.1 – Patients flowchart 
 
Baseline demographic and clinicopathological characteristics, as well as treatments 
received are summarized in M3 Table 1. Patients treated with OFS were younger (34.7% vs. 6.5% 
≤35 years) and had less differentiated tumors (grade 3 in 24.8% vs. 16.4%), but similar TNM stage. 
Treatments also differed, with patients treated with OFS receiving more frequently mastectomy 
(56.6% vs. 48.4%) and (neo)adjuvant chemotherapy (78.9% vs. 72.7%). OFS was more commonly 
administered in combination with tamoxifen than with an AI (detailed bellow), and patients 
receiving tamoxifen (compared to those treated with an AI) tended to have more often node 
negative tumors (62.0% vs. 48.5%), less frequently histological grade 3 tumors (24.1% vs. 30.3%) 
and received less frequently adjuvant chemotherapy (administered in 77.8% vs. 87.9%). 
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M3 Table 1 – Patients demographics, tumor characteristics and type of concomitant treatment by 










Ovarian function suppression 
P-value 




OFS + AI 
Number of patients (%) 1423 (82.9) 294 (17.1) 261 (15.2) 33 (1.9) - 
Demographic and clinicopathologic characteristics  
Age (years) 
≤35 
>35 to ≤40 
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Simplified TNM staging, n (%) 
Stage I 
Stage II 
























Histology, n (%) 
Invasive carcinoma of NST 















































Hormone receptor status, n (%) 
ER and PR positive 
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Missing  64 (4.5) 15 (5.1) 14 (5.4) 1 (3.0) 








































Yes, neoadjuvant 276 (19.4) 83 (28.2) 68 (26.1) 15 (45.5) 
 
Patterns of endocrine therapy use 
In this cohort of premenopausal women, only a minority of patients received OFS as part of 
the adjuvant endocrine therapy strategy (294 patients, 17.1%). Median time to introduction of OFS 
was 5.1 months (IQR 1.4 – 8.6; max. 14.0). Of those receiving OFS, 261 (15.2%) received it in 
combination with tamoxifen, while 33 (1.9%) in combination with an AI. There was evidence of OFS 
use since the beginning of the cohort in 2006, but in 2014 there was a significant increase in the 
use of OFS: 15.5% received OFS before 2014, while approximately 25% received OFS in or after 2014 
(M3 Figure 1).  
M3 Figure 1 – Patterns of prescription of adjuvant endocrine therapy over time 
 
A similar trend was noted for the combination with AI, with 0.4% receiving OFS in 
combination with an AI before 2014, and 8% from 2014 onwards; in contrast, the combination with 
tamoxifen was relatively stable (15.1% before 2014 and 16.9% from 2014 onwards). Prescription of 
OFS over time and according to age and disease stage is depicted in M3 Figure 2. A consistent trend 
Page 66 of 175 
 
for OFS use in younger patients was clear, reaching 87.5% of patients in those with ≤35 years old in 
2015 in contrast with 13.2% in those >40 years old in the same year. 
M3 Figure 2 – Patterns of prescription of adjuvant endocrine therapy over time and according to 
age at diagnosis and UICC/AJCC TNM staging 
 
In the univariate analysis, features associated with the use of OFS included age at diagnosis, 
year of diagnosis, histologic type, grade, type of surgery, and treatment with radiotherapy and 
(neo)adjuvant chemotherapy. However, in the multivariate model, only age at diagnosis (reference 
> 40 and ≤50 years; OR 14.7, 95% CI 9.7 – 22.1 for ≤35 and OR 6.1, 95% CI 4.3 – 8.7 for > 35 and ≤40 
years) and year of diagnosis after 2014 (OR 1.9, 95% CI 1.3-2.7) were associated with the use of OFS 
(M3 Table 2). Despite the predominant use of combination with tamoxifen, 32% of patients 
received an AI in the interval from 2014 to 2015. 
M3 Table 2 – Patient and tumor features associated with OFS prescription 
Variable list  Predictors of OFS prescription 
OR 95% CI p-value 
Univariate analysis 
Age at diagnosis 
<35 
35 to <40 






10.1 – 20.8 





Year of diagnosis (for each added year 
since 2006) 
1.08 1.03 – 1.13 0.002 
Year of diagnosis 
Before 2014 























0.69 – 1.20 
0.71 – 1.52 
Histology 
Invasive carcinoma of NST 








0.26 – 0.84 













0.84 – 1.73 











1.99 – 1.94 
 
0.059 
Type of surgery 





























1.04 – 1.90 
 
0.029 
Multivariate model (full model shown) 
Age at diagnosis 
Less or equal to 35 
More than 35 to less than 40 






9.74 – 22.1 




Year of diagnosis 
Before 2014 











Invasive carcinoma of NST 








0.39 – 1.43 













0.68 – 1.59 











0.66 – 1.48 
 
0.969 






























0.53 – 1.18 
 
0.243 
CI – Confidence interval; HG – Histologic grade; HER2 – Human epidermal growth factor receptor 2; OR – 
Odds ratio. 
Among patients treated with OFS and with available date of treatment status, 
approximately 6% were still receiving OFS at the time of analysis. In those with available date of 
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treatment completion (35.2%), median duration of OFS was of approximately 25 months (IQR 20 – 
27; M3 Table 3). 
M3 Table 3 – Adjuvant endocrine treatment description 
 Overall Before 2014 In or after 2014 
P-value 
(<2014 vs. ≥2014) 
Receiving OFS, n (%) 294 (17.1) 210 (15.2) 84 (24.9) < 0.001 














Time on OFS† 
Median, months 
P25 – P75 
Min. – Max. 
Date of completion available, n (%) 
Ongoing treatment, n (%) 
 
24.7 
20.4 – 26.9 





21.5 – 26.9 







†Time on OFS excludes patients with ongoing treatment with goserelin at time of data cut-off and those with 
prescription in of after 2013. NR–not reported; OFS–ovarian function suppression. 
Effectiveness of ovarian function suppression 
After a median follow-up of 38.3 months (interquartile range [IQR] 19.6 – 66.4; minimum – 
maximum 1.8 - 125), 88 deaths were registered, 11 (3.6%) in the OFS cohort and 77 (5.3%) in the 
no OFS cohort. The median follow-up is balanced between treatment cohorts, with 38.9 (IQR 20.5 
- 67.7) months in the no OFS cohort and 36.5 (15.9 - 62.6) months in the OFS cohort (p=0.231). The 
proportion of patients alive at 5 years was 95.3% (95% CI 89.7 – 97.9) in the OFS cohort and 93.2% 
(95% CI 90.8 – 94.9%) in the no OFS cohort (M3 Figure 3-A). Overall survival by treatment arm and 
according to age at diagnosis and staging is shown in M3 Supplementary figure A.2. In a multivariate 
model controlling for age at diagnosis, stage, histologic grade, HER2 status, use of (neo)adjuvant 
chemotherapy, type of surgery and year of diagnosis, patients receiving adjuvant OFS had a 56% 
decrease in the risk of death (HR 0.44, 95% CI 0.19-0.96; p=0.04). Similar results were observed 
when performing a sensitivity analysis including only patients alive at 1 year (adjusted-HR 0.44, 95% 
CI 0.20 – 0.97) and with a minimum follow-up of 3 years (adjusted-HR 0.43, 95% CI 0.18 – 1.01) and 
5 years (adjusted-HR 0.39, 95% CI 0.12 – 1.23). With a 2.1% absolute difference in survival at five 
years, the number needed to treat to avoid one death was of 48. 
The propensity score matching cohort results were consistent with those of Cox 
proportional hazards multivariate analysis (M3 Figure 3-B). While 8 patients died in the OFS cohort 
(3.2%), 22 died in the no OFS cohort (8.8%). Proportion of patients alive at 5 years was 95.4% (95% 
CI 89.0 – 98.2) in the OFS cohort and 86.7% (95% CI 78.1 – 92.1%) in the no OFS cohort. Patients 
receiving adjuvant OFS had a 62% decrease in the risk of death (HR 0.38, 95% CI 0.17-0.86; p=0.021). 
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M3 Figure 3 – Overall survival in the overall cohort (A) and propensity score matching (1:1 
matching) cohort (B). Variables included both in the multivariate CM and PS matching included: age at diagnosis, 
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M3 Supplementary Figure A.2 – Overall survival by treatment arm in subgroups defined by age at 
diagnosis and UICC/AJCC TNM staging. 
 
5.3.7 Discussion 
In this large real-world cohort of premenopausal women with breast cancer receiving 
adjuvant endocrine therapy we observed an increment in the use of OFS in recent years. Moreover, 
young age at diagnosis (≤ 35 years old) was strongly associated with the use of adjuvant OFS. Albeit 
the short follow-up time, treatment with OFS combined with either tamoxifen or AI improved short-
term OS. 
Over the last decades, several randomized trials and meta-analyses examined the impact 
of adding OFS to backbone endocrine therapy (ET) (M3 Supplementary Table A.2). Overall, it 
emerged from these trials that specific populations, such as premenopausal women with enough 
risk of recurrence to be eligible for adjuvant chemotherapy, as well as younger women, may derive 
benefit from adding OS to ET.51–53,121–124. In addition, the most recent SOFT trial results further 
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M3 Supplementary Table A.2 – Summary of adjuvant trials and meta-analyses comparing 
tamoxifen with or without OFS and OFS with either tamoxifen or an AI† 
Study (year of last 
results update) 




Disease-free survival Overall survival 
Clinical trials: tamoxifen vs. tamoxifen + OFS 
SOFT (2018)51,52 Tamoxifen alone vs. 
tamoxifen + OFS (vs. 
exemestane + OFS) 
2033 8.0 
 
HR 0.76, 95% CI 0.62 – 
0.93; p=0.009 
HR 0.67, 95% CI 0.48 – 
0.92; p=0.01 
ASTRRA (2018)53 Tamoxifen alone vs. 
tamoxifen + OFS 
1282 5.3 HR 0.686, 95% CI 0.48 - 
0.97; p=0.033 




Tamoxifen alone vs. 
tamoxifen + OFS 
345 9.9 HR 1.16, 95% CI 0.64 - 
2.08; p=0.62 
HR 1.19, 95% CI 0.52 - 
2.70; 0.67 
ABC/OAS (2007)126 Tamoxifen alone vs. 
tamoxifen + 
OFS/ablation 
2144 5.9 HR 0.95, 95% CI 0.81 - 
1.12; p=0.56 
HR 0.94, 95% CI 0.78 - 
1.13; p = 0.44 
ZIPP (2005)127 Tamoxifen alone vs. 
tamoxifen + OFS 
2710 5.5 HR 0.80, 95% CI 0.69 - 
0.92; p=0.002 
HR 0.81, 95% CI 0.67 - 
0.99; p = 0.038 
INT 0101/E5188 
(2005)128 
CAF vs. CAF + OFS vs. 
CAF + OFS + tamoxifen 
1503  9.6 HR 0.93, 95% CI 0.76 - 
1.12; p=0.22 
HR 0.88, 95% CI 0.70 - 
1.11; p=0.14 
Meta-analyses: tamoxifen vs. tamoxifen + OFS 
Zhang (2017)122 OFS + tamoxifen vs. 
tamoxifen 
7331 NR HR 0.94, 95% CI 0.88 – 
1.01; p=0.09 
HR 0.92, 95% CI 0.82 – 
1.03; p=0.13 
Qiu (2016)123 OFS + tamoxifen vs. 
tamoxifen‡ 
12292 NR RR 0.86, 95% CI 0.75 –
0.96; p=NR 
RR 0.79, 95% CI 0.70 –
0.89; p=NR 
Yan (2015)124 OFS + tamoxifen vs. 
tamoxifen 
6279 NR RR 0.87, 95% CI 0.71 –
1.06; p=0.16 
RR 0.84, 95% CI 0.66 –
1.07; p=0.16 
Cuzick (2007)121 OFS + tamoxifen vs. 
tamoxifen 
1013 NR HR 0.85, 95% CI 0.67 –
1.09; p=0.20 
HR 0.84, 95% CI 0.59 –
1.19; p=0.33 
Clinical trials: OFS + tamoxifen vs. OFS + AI 
SOFT/TEXT 
(2018)52,54 
OFS + tamoxifen vs. 
OFS + exemestane (vs. 
tamoxifen alone) 
4690 9.0 HR 0.77, 95% CI 0.67 – 
0.90; p<0.001 




OFS + tamoxifen vs. 
OFS + anastrazol 
1803  7.9 HR 1.13, 95% CI 0.88 – 
1.45; p=0.335 
HR 1.63, 95% CI 1.05 – 
1.45; p=0.030 
HOBOE-2 (2018)130 OFS + tamoxifen vs. 
OFS + letrozole (vs. 
OFS + letrozole + ZA) 
710ꬷ 5.4 HR 0.72, 95% CI 0.48 – 
1.07; p=0.06 
NR 
†NSABP-30 and ABCSG 13-93 studies further showed that patients achieving chemotherapy-induced amenorrhea had 
improved survival. The 2005 EBCTCG meta-analysis compared adjuvant OFS/ablation to no further ET showing a significant 
effect of OFS on both DFS and OS. ‡Tamoxifen or other ET beyond OFS was not provided in all trials included in this meta-
analysis. ꬷ1065 patients if including the OFS + letrozole + ZA arm. AI–aromatase inhibitor; CI–confidence interval; ET–
endocrine therapy; HR–hazard ratio; NR–not reported; OFS–ovarian function suppression; RR–relative risk; Vs–versus; ZA – 
zoledronic acid. 
The first results of the combined analysis of SOFT and TEXT trials in 2014, suggesting the 
benefit of OFS in some populations, led to the incorporation of this recommendation in several 
breast cancer treatment guidelines.25,120 In fact, in the present study, although there is evidence of 
utilization of OFS since 2006, there was a substantial increment of its use after 2014. As expected, 
in this study of patients with HR-positive tumors diagnosed between 2006 and 2015, of whom more 
than 70% treated with (neo)adjuvant chemotherapy, we observed that patients at a higher risk of 
relapse receive OFS more frequently. We further observed that adjuvant OFS added to tamoxifen 
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or AI led to a statistically significant reduction in the risk of death, with an absolute magnitude in 
line with previous achievements in adjuvant ET and to the updated results of SOFT trial. Although 
these results might be influenced by unmeasured confounders, short median follow-up and time 
bias (given the increase in use of OFS overtime), the treatment effect was consistently present when 
using different methods to deal with confounding. Thus, this study adds real-world evidence to 
clinical trials data, supporting the decision of patients and physicians to incorporate OFS in the ET 
of premenopausal women at higher risk of recurrence. 
These results must be put in context of the tolerability implications of OFS. In the SOFT trial, 
patients randomized to tamoxifen plus OFS had more frequently hot flashes, loss of sexual interest 
and sleep disturbance, as well as vaginal dryness, with early discontinuation of oral ET close to 
20%.66 Interestingly, after 6 months of therapy, symptom-specific treatment differences were less 
evident in those patients previously treated with chemotherapy. Other studies further showed a 
detrimental effect of OFS in self-reported health-related quality of life.125 However, no particular 
changes in global cognitive function, nor depression or anxiety scores were noted.131,132  
The use of OFS further opens the possibility of using AIs in premenopausal women. The 
incremental efficacy of OFS and AI (versus OFS-T) is not definitely established (M3 Supplementary 
Table A.2). While the ABCSG-12 trial did not document any DFS advantage of OFS-AI over OFS-T and 
even found a statistically significant detrimental impact of OFS-AI compared to OFS-T (of note, this 
trial also tested the role of adjuvant zoledronic acid), the analyses of SOFT and TEXT trials showed 
that patients treated with chemotherapy who remained premenopausal and those with <35 years 
(higher risk patients) are the ones obtaining the most benefit from AIs (absolute breast cancer-free 
interval reduction ranging from 5 to 15%).129,133,134 However, no OS differences were noted in the 
overall SOFT/TEXT cohort (HR 0.98, 95% CI 0.79–1.22). In terms of tolerability, both the toxicity 
profile and their evolution over time differ: patients taking tamoxifen plus OFS had more hot flashes 
and sweats that improve over time, while those on exemestane plus OFS had more vaginal dryness, 
greater loss of sexual interest, and difficulties becoming aroused that persist over time.135 No major 
differences in quality of life over time were captured with the instruments used. Of note, current 
guidelines consider both AI and tamoxifen reasonable alternatives when added to OFS, even though 
ASCO guidelines favor the use of AI in women <35 years.25,120 
OFS is also being increasingly used as an approach to reduce the likelihood of 
chemotherapy-induced ovarian insufficiency and thus as a complementary strategy to improve 
future fertility without impacting survival.136–138 Such use is reflected in current international 
guidelines.139–141 While we had access to the exact date of OFS initiation, in our cohort the date of 
(neo)adjuvant chemotherapy introduction was not thoroughly available beyond the knowledge of 
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its administration before or after surgery. This limited the possibility of describing the use of OFS as 
a fertility preservation strategy in our cohort of premenopausal women. 
Despite the large sample size and the methodological rigor, this study has limitations. It is 
a retrospective observational study, thus susceptible to residual confounding. ROR-S does not 
collect menopausal status, both at diagnosis and after primary treatment, that was estimated for 
local patterns. Also, ROR-S does not accurately collect co-morbidities, educational level, type of 
(neo)adjuvant chemotherapy, patients’ preferences or Ki67 that can be unbalanced between arms; 
nevertheless, we used different modelling strategies to address confounding with consistent 
findings. Therapy administration was measured by drug prescription, not actual drug 
administration, and a substantial proportion of patients did not have information available 
concerning treatment stop date. Also, median follow-up is short for a HR-positive population and 
there might exist a time bias associated with an increase in use of OFS over time. The follow-up is 
impacted by the inclusion of patients up to the date of censoring, but this was done to extract the 
most information possible from the analysis focusing on the patterns of use of OFS. In addition, the 
sensitivity analysis restricting to patients with 5 or more years of follow-up showed consistent 
results. Moreover, the follow-up is balanced between the two groups. While unexpected, the fact 
that the use of OFS is present since the beginning of the cohort, the fact that the increased uptake 
of OFS is predominantly achieved in the very later years of the cohort, and the fact that the overall 
absolute number of patients receiving OFS is lower than those not receiving this treatment explain 
the balanced follow-up and add to the robustness of the analysis. Finally, treatment effectiveness 
was measured as OS, not cancer-specific survival, and DFS was not available. While cancer-specific 
survival could add some extra robustness to our study, the relatively young age of this group of 
patients might increase the likelihood of the identification of mostly cancer-specific deaths. While 
ROR-S exhaustively collects OS through its electronic connection to the national death certificates 
database, as a population-based registry, recurrence events need to be proactively reported by 
contributing centers leading to a relevant proportion of patients with missing DFS status and thus 
rendering this outcome not useful for clinical research at this point in time. 
5.3.8 Conclusion 
Now that intensification of ET with OFS in pre-menopausal women with HR-positive breast 
cancer at high risk of relapse is becoming standard of care, this large cohort of premenopausal 
women receiving adjuvant ET shows real-world evidence that supports these guidelines. Since 
2014, a quarter of patients were treated with adjuvant OFS, of which more than 30% in combination 
with an AI. Use of adjuvant OFS showed an OS benefit. 
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5.4 Differential impact of endocrine therapy and chemotherapy on quality of life of 
breast cancer survivors: a prospective patient reported outcomes analysis. 
5.4.1 Introductory notes 
This project details several QoL metrics of breast cancer survivors 2 years after diagnosis. It 
further dissects the QoL implications according to the use of adjuvant endocrine therapy and/or 
chemotherapy and by menopausal status. This project was published in Annals of Oncology. Arlindo 
R. Ferreira led the study design, data analysis, results interpretation and manuscript writing. 
5.4.2 Authors 
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Delaloge1; S. Michiels1; F. Andre1; I. Vaz-Luis1,§. 
Authors affiliations: 1Gustave Roussy - Cancer Campus, Villejuif, France; 2Champalimaud 
Clinical Center, Champalimaud Foundation, Lisbon, Portugal; 3Centre François Baclesse Caen, Caen, 
France; 4Unicancer, Paris, France; 5Department of Medical Oncology, U.O.C. Clinica di Oncologia 
Medica, Ospedale Policlinico San Martino, Genova, Italy; 6Department of Internal Medicine and 
Medical Specialties (DiMI), School of Medicine, University of Genova, Genova, Italy; 7Centre 
Georges-François Leclerc, Dijon, France; 8Institut Curie, Paris, France; 9Institut Curie, Hôpital René 
Huguenin, Saint-Cloud, France; 10Paul Strauss Cancer Center and University of Strasbourg, 
Strasbourg, France; 11Department of Medical Oncology, Institut Claudius Regaud, Institut 
Universitaire du Cancer – Oncopole, Toulouse, France; 12C.R.L.C Val d'Aurelle, Montpellier, France; 
13Clinique Sainte Catherine Avignon, Avignon, France; 14Ministere de l'enseignement superieur et 
de la recherche, France; 15Ronald Reagan UCLA Medical Center, Los Angeles, CA, USA; 16Dana-Farber 
Cancer Institute, Boston, MA, USA; §Corresponding author. 
5.4.3 Abstract 
Background: In early breast cancer (BC) there has been a trend to escalate endocrine 
therapy (ET) and to de-escalate chemotherapy (CT). However, the impact of ET versus CT on the 
quality of life (QoL) of early BC patients is unknown. Here we characterize the independent 
contribution of ET and CT on patient-reported outcomes (PROs) at 2-years after diagnosis.  
Page 76 of 175 
 
Patients and methods: we prospectively collected PROs in 4262 eligible patients using the 
European Organization for Research and Treatment of Cancer QLQ-C30/BR23 questionnaires inside 
CANTO trial (NCT01993498). The primary outcome was the C30 summary score (C30-SumSc) at 2-
years after diagnosis.  
Results: From eligible patients, 37.2% were premenopausal and 62.8% postmenopausal; 
81.9% received ET and 52.8% CT. In the overall cohort, QoL worsened by 2-years after diagnosis in 
multiple functions and symptoms; exceptions included emotional function and future perspective, 
which improved over time. ET (pint=0.004), but not CT (pint=0.924), had a persistent negative impact 
on the C30-SumSc. In addition, ET negatively impacted role and social function, pain, insomnia, 
systemic therapy side effects, breast symptoms and further limited emotional function and future 
perspective recovery. Although CT had no impact on the C30-SumSc at 2-years it was associated 
with deteriorated physical and cognitive function, dyspnea, financial difficulties, body image and 
breast symptoms. We found a differential effect of treatment by menopausal status; in 
premenopausal patients, CT, despite only a non-significant trend for deteriorated C30-SumSc 
(pint=0.100), was more frequently associated with QoL domains deterioration than ET, whereas in 
postmenopausal patients, ET was more frequently associated with QoL deterioration, namely using 
the C30-SumSc (pint=0.004).  
Conclusion(s): QoL deterioration persisted at 2-years after diagnosis with different 
trajectories by treatment received. ET, but not CT, had a major detrimental impact on C30-SumSc, 
especially in postmenopausal women. These findings highlight the need to properly select patients 
for adjuvant ET escalation.  
Keywords: early breast cancer; quality of life; endocrine therapy; chemotherapy; patient-
reported outcome. 
5.4.4 Introduction 
Due to improvements in early detection and treatment achieved over the last decades, 80-
90% of women diagnosed with early-stage breast cancer (BC) in developed countries can expect 
long-term disease-free survival. With the growing number of women with history of BC, it is 
becoming increasingly important to address the potential long-term and late effects of treatments 
that survivors will face.56 
There have been remarkable changes in the pattern of treatment of early BC in the last few 
years. Notable is the recent trend to escalate ET in patients with hormone receptor (HR)-positive 
early BC by extending the duration of treatment and/or by treatment intensification with the 
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addition of ovarian function suppression (OFS) for premenopausal patients.25 Concurrently, there 
has been a trend to de-escalate chemotherapy (CT), driven by a desire to avoid short and long-term 
toxicities and the results of prospective trials that identified genomically low-risk patients who 
could be spared CT and treated with endocrine therapy (ET) alone.142  
Despite their proven efficacy in improving BC outcomes, both ET and CT have the potential 
to negatively impact survivors’ QoL.143–145 ET strategies such as tamoxifen, aromatase inhibitors (AI) 
and OFS have well described and persistent side effects that may facilitate deterioration of QoL, 
although most clinical trials data indicate that the impact of ET on QoL of BC patients is only 
modest.66 The deterioration in QoL might further negatively impact adherence and persistence to 
ET leading to early treatment discontinuation.146,147 CT also worsens QoL, and this effect is well 
demonstrated through active treatment and in the immediate post-CT phase. However, there are 
few data on the long-term independent effect of CT on QoL. In addition, the differential impact of 
ET versus CT on QoL has not been fully characterized, especially among cohorts treated with 
modern adjuvant regimens using validated and modern tools to measure patient reported 
outcomes (PROs).148 Such information could provide objective guidance for patients and physicians 
to weight the impact of each of these treatments on QoL and to define future research priorities in 
this evolving field.  
We therefore compared the impact of different classes of treatment (CT and ET) on 
European Organization for Research and Treatment of Cancer (EORTC)-defined QoL instruments 
using CANTO (NCT01993498), a multicenter, nationwide, prospective cohort study of 12,012 
women with stage I-III BC, of which 5,801 women available for research, that aims to quantify the 
toxicities of cancer treatment for up to 5 years after the end of primary treatment. We hypothesized 
that exposure to different classes of treatment, namely ET and/or CT, would have different impact 
on QoL 2-years after diagnosis. Moreover, we hypothesized that such impact would differ by 
menopausal status, given the different class of ET agents used (mostly tamoxifen in premenopausal 
and AIs in postmenopausal women) and the different sequelae of CT (with possible early loss of 
ovarian function in premenopausal women) by menopausal status. 
5.4.5 Patients and methods 
Study design and patient selection 
This was a prospective, longitudinal cohort study. We used data collected at diagnosis, end 
of primary treatment, which include completion of BC surgery, chemotherapy, or radiation therapy, 
whatever ended last (median time from diagnosis=10.4 months, interquartile range [IQR], 8.0-12.3) 
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and at 2-years after diagnosis (median time from diagnosis=22.6 months, IQR 20.1-24.8; patients 
receiving ET were at a median of 16.3 months, IQR 14.9-17.9, into ET). 
We included 4262 patients with stage I-III BC enrolled in CANTO cohort from March-2012 
to January-2015, corresponding to the first data lock of CANTO. M4 Supplementary Figure 1 details 
exclusion and inclusion criteria. All patients provided written informed consent.  
M4 Supplementary Figure 1 - Study consort diagram 
 
To assess the potential bias introduced by the exclusion of patients with missing evaluation 
2-years after diagnosis, the characteristics of such patients were compared to those of participating 
patients. Patients missing evaluation tended to be older, smokers, less educated, living alone, have 
lower income, present higher TNM stage or triple-negative BC, have undergone mastectomy and 
be more frequently depressed (M4 Supplementary Table 1). 
M4 Supplementary Table 1 – Demographic, clinical and pathological characteristics at baseline and 
treatment details of study participants, overall non-participants and non-participants due to 
missing PRO questioners. 
 
 Overall cohort 
Non-participants Missing PRO 
questioners 
Participants 
Number, % 1539 26.5 1472 25.4 4262 73.5 
Age, n (%) 
≤35 
>35 to ≤40 
>40 to ≤50 
>50 to ≤60 
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Income, n (%) 
<1500 

































Marital status, n (%) 
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Histology, n (%) 
Invasive carc., NST 
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AI – aromatase inhibitors; BCS – Breast conserving surgery; BMI – Body mass index; carc. – carcinoma; CT – 
Chemotherapy; HR – hormone receptors; HER2 – Human epidermal growth factor receptor 2; LHRH - luteinizing hormone-
releasing hormone antagonist or agonist; n – number; NST – no special type; PRO – patient reported outcomes. Missing 
values do not add to the percentage count of non-missing categories. Missing values are not included as a category in the 
statistical tests. All p-values refer to Pearson's chi-squared test. 
Variables assessment  
PROs Assessments 
PROs were assessed using the EORTC QoL Core 30 (EORTC QLQ-C30, version 4.0) and its BC 
specific module (QLQ-BR23).149 Higher scores reflect a better level of QoL and function for global 
health and functional scales, respectively, and greater severity for symptoms. The primary endpoint 
of the study was the QLQ-C30 summary score (C30-SumSc) and specific domains were secondary 
endpoints.149 Anxiety and depression were assessed using Hospital Anxiety and Depression Scale 
(HADS).  
Assessments of other variables  
Information on age, Charlson's comorbidity index, body mass index (BMI), smoking, marital 
status, education level, income, disease staging, center volume, type of surgery, axillary 
management, receipt of ET, CT, trastuzumab and radiotherapy was collected at diagnosis by 



















































Adjuvant endocrine therapy type, n (%) 
Tamoxifen ± LHRH 
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First, we described QoL over time and by treatment, examining the C30-SumSc and 
dichotomizing QoL scores by clinical severity. Severe impairment was defined as function 
impairment or symptom intensity meeting a predefined clinically meaningful level. Clinically 
meaningful levels were defined using as reference the mean score of the validation cohort of EORTC 
QLQ-C30/B23, specific to patients with stage I-II BC, plus a detrimental variation to the level of the 
lower boundary of medium clinically meaningful differences according to evidence-based 
guidelines for C30 domains150, or 10-points for B23 domains (a variation previously considered of 
clinical value)151. Functional scores below such thresholds defined “poor function”, while symptom 
scores above threshold values defined “severe symptoms”. 
Then, repeated measurements of QoL scores collected from diagnosis to the 2-year post-
diagnosis visit were analyzed as continuous outcomes using multivariate generalized estimating 
equations (GEE) with independent correlation structure. Model-derived least square mean values 
for QoL scores and respective mean least square (MLS) differences between diagnosis and the 2-
year post diagnosis visit by ET and/or CT (used as independent variables) were obtained. To test the 
hypothesis that the population-averaged domain scores differ over time by treatment with ET/CT, 
p-values for the interaction of ET/CT by time were computed (pint). Models included as covariates 
all variables previously described (“other variables” plus anxiety and depression), all of which were 
collected at diagnosis.  
An exploratory analysis was also conducted to determine the effect of treatment on QoL 
across four treatment groups: CT-only, ET-only, CT plus ET and no CT/ET. Similarly, MLS changes 
from diagnosis were estimated from GEE. 
All tests were two-sided with a 95% confidence interval (CI) and a p-value of <0.05 was 
considered significant. All analyses were conducted using Stata 15.1 (StataCorp, Texas, U.S.A.). 
5.4.6 Results 
Patient characteristics 
Of the 4262 women available for the analysis, 1587 (37.2%) were premenopausal and 2675 
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M4 Table 1 – Demographic, clinical and pathological characteristics at baseline and treatment 
details according to receipt of CT/ET. 
 Overall cohort 
All Chemotherapy Endocrine therapy 
Number, % 4262 (100) 2252 (52.8) 3490 (81.9) 
Age, median (IQR) 56 (48 - 65) 52 (44.5 - 61) 56 (48 - 65) 
Age, n (%) 
≤35 
>35 to ≤40 
>40 to ≤50 
>50 to ≤60 














































































































































Education, n (%) 
Primary school 
High school 
































Income, n (%) 
<1500 

































Marital status, n (%) 
Living alone 


























Histology, n (%) 
Invasive carc., NST 





































































































Breast conserving surgery; BMI – Body mass index; CT – Chemotherapy; HADS – Hospital Anxiety and Depression Scale; 
















IHC-defined subtype of breast 
































































































































































































Adjuvant endocrine therapy 
type, n (%) 
Tamoxifen ± LHRH 
AI ± LHRH 
LHRH 


























































































































Page 84 of 175 
 
M4 Supplementary table 2 – Demographic, clinical and pathological characteristics at baseline and treatment details 
according to menopausal status and receipt of CT/ET. 
 Premenopausal Postmenopausal 
All Chemo Endocrine 
therapy 
All Chemo Endocrine 
therapy 
Number, % 1587 (37.2) 1087 (68.4) 1317 (83.0) 2675 (62.8) 1165 (43.6) 2173 (81.2) 
Age, median (IQR) 46 (41 - 49) 44 (40 - 48) 46 (42 - 50) 63 (57 - 68) 61 (56 - 66) 63 (58 - 68) 
Age, n (%) 
≤35 
>35 to ≤40 
>40 to ≤50 
>50 to ≤60 
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Income, n (%) 
<1500 































































Marital status, n (%) 
Living alone 


















































Histology, n (%) 
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therapy type, n (%) 
Tamoxifen ± LHRH 
AI ± LHRH 
LHRH 
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HADS-defined 

































































Menses at 2 years after 




















































BCS – Breast conserving surgery; BMI – Body mass index; CT – Chemotherapy; HADS – Hospital Anxiety and Depression Scale; IQR – Interquartile 
range; n – number; Missing values do not add to the percentage count of non-missing categories. 
Page 88 of 175 
 
PRO assessments 
PROs over time 
 The overall QoL was negatively impacted 2-years after diagnosis in the general 
population (C30-SumSc, p<0.001). In addition, we observed a significant negative impact on role, 
cognitive and social functions, and also pain, dyspnea, fatigue, body image, systemic therapy 
side effects, constipation and breast and arm symptoms (all p<0.001) (M4 Figure 1, M4 
Supplementary Figure 2 and M4 Supplementary Table 3). Considering all domains, no substantial 
recovery was noticed from the end of primary treatment to the 2-year after diagnosis time point, 
except for emotional function, future perspective and appetite loss, which slightly improved 
during this period (all p<0.001). 
M4 Figure 1 - Mean least square change of EORTC QLQ C30 summary score from diagnosis (T1) 
to “end of primary treatment” (T2) and the “2-years after diagnosis visit” (T3) in patients treated 
and not treated with chemotherapy or endocrine therapy in the overall cohort (non-mutually 
exclusive groups) (1A), and in premenopausal (1B) and postmenopausal (1C) patients. Error bars 
refer to the 95% confidence interval of the estimate. Estimates and confidence intervals derived 
from multivariate generalized estimating equations models. 
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M4 Supplementary Figure 2 – Prevalence (%) of patients reporting poor functions or severe 
symptoms in the EORTC QLQ C30 and BR23 domains at “diagnosis” (T1), “end of primary 
treatment visit” (T2) and at “2-years after diagnosis visit” (T3). Results in the overall cohort (S2A), 
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M4 Supplementary table 3 – Patient reported outcomes scores at “diagnosis” (T1), “end of primary treatment visit” (T2) and at “2 years after diagnosis 
visit” (T3), overall and according to menopausal status. 
  T1 T2 T3 
Completion 
rate (%) 
mean (SD) Completion 
rate (%) 
mean (SD) Completion 
rate (%) 
mean (SD) 
All EORTC QLQ-C30, summary score 
Summary score 92.7 83.47 (12.29) 90.0 80.02 (14.44) 93.0 80.08 (14.21) 
EORTC QLQ-C30, functional scales 
Global health status 95.7 68.87 (18.70) 92.2 68.73 (18.13) 97.4 66.13 (17.94) 
Physical function 96.8 90.49 (13.63) 94.3 84.24 (15.27) 98.9 84.05 (15.80) 
Role function 96.7 86.86 (21.49) 94.2 80.55 (23.84) 98.4 82.50 (23.30) 
Emotional function 96.6 65.73 (24.16) 94.4 72.77 (23.84) 98.7 70.71 (24.49) 
EORTC QLQ-C30, symptoms scales 
Cognitive function 96.6 82.15 (21.31) 94.5 78.85 (23.27) 98.6 77.01 (24.31) 
Social functioning 95.3 91.07 (17.74) 93.9 83.61 (23.51) 98.4 85.77 (22.28) 
Fatigue 96.6 26.89 (23.70) 94.1 34.90 (25.16) 98.5 34.18 (24.32) 
Nausea/Vomiting 96.6 3.60 (10.87) 94.3 4.92 (12.70) 98.6 4.92 (13.58) 
Pain 96.8 15.57 (21.31) 94.5 27.27 (25.78) 98.4 28.61 (26.69) 
Dyspnea 96.1 11.59 (21.39) 93.4 19.45 (25.35) 97.7 19.63 (25.24) 
Insomnia 96.3 42.53 (33.31) 93.8 40.95 (34.04) 97.7 41.79 (34.43) 
Appetite 96.5 13.87 (23.49) 93.9 9.17 (20.20) 98.0 8.32 (19.66) 
Constipation 96.2 10.82 (22.41) 93.8 15.73 (26.04) 98.1 16.98 (27.40) 
Financial difficulties 94.0 6.02 (17.19) 93.1 11.42 (24.35) 98.1 7.44 (20.49) 
Diarrhea 95.8 8.15 (18.24) 93.6 9.09 (19.88) 97.0 8.57 (19.67) 
EORTC BR23, functional scales 
Sexual enjoyment 45.6 64.02 (26.92) 48.4 56.90 (26.81) 48.1 57.53 (27.75) 
Future perspectives 93.6 49.55 (31.32) 93.5 56.07 (31.69) 96.9 60.67 (31.38) 
Body image 93.3 88.73 (19.45) 93.6 74.20 (28.70) 97.3 76.85 (27.50) 
Sexual function 89.9 26.40 (26.32) 89.5 25.75 (24.96) 93.2 25.82 (25.18) 
EORTC BR23, symptoms scales 
Systemic therapy side effects 95.2 11.01 (11.41) 93.9 19.37 (15.96) 97.8 18.27 (14.38) 
Breast symptoms 84.0 12.86 (16.41) 93.9 25.36 (19.96) 97.5 19.26 (18.06) 
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Arm symptoms 92.7 12.97 (21.07) 94.0 25.97 (26.46) 97.4 23.20 (25.76) 
Hair loss 11.1 32.77 (34.24) 21.0 48.77 (39.22) 25.0 43.85 (36.50) 
Premenopausal EORTC QLQ-C30, summary score 
Summary score 93.9 82.27 (12.34) 92.0 78.92 (14.84) 96.2 79.57 (14.64) 
EORTC QLQ-C30, functional scales 
Global health status 96.0 68.70 (18.82) 92.5 67.94 (17.75) 98.0 67.13 (17.91) 
Physical function 96.9 93.66 (10.86) 93.9 85.98 (14.19) 99.1 87.19 (13.93) 
Role function 96.7 85.43 (22.05) 94.0 78.22 (24.48) 98.9 82.71 (22.89) 
Emotional function 96.5 62.18 (24.47) 94.1 70.06 (25.07) 99.1 68.73 (25.21) 
EORTC QLQ-C30, symptoms scales 
Cognitive function 96.5 80.31 (22.72) 94.1 76.49 (24.87) 99.0 74.12 (26.08) 
Social functioning 95.5 89.73 (18.56) 93.7 81.13 (25.13) 98.9 84.29 (22.90) 
Fatigue 96.7 30.93 (24.45) 94.0 38.48 (26.02) 98.9 37.19 (25.19) 
Nausea/Vomiting 96.9 4.83 (12.96) 94.0 5.13 (13.26) 99.1 5.30 (14.23) 
Pain 96.8 16.35 (20.83) 94.0 28.77 (26.28) 99.1 28.01 (26.14) 
Dyspnea 96.5 8.62 (18.89) 93.4 19.44 (25.34) 98.8 17.94 (24.69) 
Insomnia 96.6 44.81 (33.31) 93.6 44.44 (35.33) 98.5 42.93 (34.90) 
Appetite 96.6 18.40 (26.04) 93.8 9.25 (20.57) 98.6 8.12 (19.45) 
Constipation 96.2 8.95 (19.75) 93.9 15.23 (25.71) 98.6 16.85 (27.25) 
Financial difficulties 94.0 7.44 (18.73) 93.0 17.71 (29.45) 98.6 11.17 (24.65) 
Diarrhea 96.2 9.50 (19.63) 93.9 7.99 (19.34) 98.3 7.59 (18.54) 
EORTC BR23, functional scales 
Sexual enjoyment 63.5 66.10 (26.68) 66.0 59.69 (26.78) 67.8 60.75 (28.45) 
Future perspectives 94.8 45.17 (32.52) 93.3 51.11 (32.08) 97.5 57.21 (32.29) 
Body image 94.6 87.88 (19.85) 93.6 68.06 (30.51) 97.7 72.77 (29.54) 
Sexual function 92.8 35.26 (26.52) 91.6 35.17 (25.14) 95.7 36.26 (25.36) 
EORTC BR23, symptoms scales 
Systemic therapy side effects 95.6 9.78 (10.83) 93.8 19.65 (16.07) 98.2 18.59 (14.29) 
Breast symptoms 85.8 14.66 (17.39) 93.5 27.31 (20.43) 97.9 21.21 (19.07) 
Arm symptoms 93.2 13.30 (21.14) 93.6 28.91 (27.13) 98.0 24.80 (26.31) 
Hair loss 11.8 30.66 (34.20) 16.3 50.06 (41.23) 21.3 41.91 (38.20) 
Postmenopausal EORTC QLQ-C30, summary score 
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Summary score 92.0 84.19 (12.21) 88.9 80.69 (14.14) 91.1 80.40 (13.93) 
EORTC QLQ-C30, functional scales 
Global health status 95.5 68.96 (18.63) 92.1 69.20 (18.33) 97.0 65.53 (17.94) 
Physical function 96.7 88.61 (14.72) 94.6 83.21 (15.79) 98.8 82.18 (16.54) 
Role function 96.6 87.70 (21.11) 94.4 81.93 (23.35) 98.1 82.38 (23.54) 
Emotional function 96.7 67.84 (23.74) 94.6 74.37 (22.95) 98.5 71.89 (23.98) 
EORTC QLQ-C30, symptoms scales 
Cognitive function 96.6 83.24 (20.36) 94.7 80.25 (22.16) 98.4 78.74 (23.02) 
Social functioning 95.2 91.87 (17.19) 94.0 85.08 (22.38) 98.1 86.66 (21.86) 
Fatigue 96.5 24.49 (22.91) 94.2 32.78 (24.40) 98.2 32.37 (23.60) 
Nausea/Vomiting 96.5 2.86 (9.34) 94.5 4.80 (12.35) 98.4 4.69 (13.18) 
Pain 96.8 15.10 (21.58) 94.9 26.39 (25.44) 97.9 28.97 (27.02) 
Dyspnea 95.8 13.37 (22.56) 93.4 19.46 (25.36) 97.1 20.65 (25.52) 
Insomnia 96.1 41.17 (33.24) 93.9 38.89 (33.08) 97.2 41.11 (34.13) 
Appetite 96.4 11.18 (21.39) 94.0 9.12 (19.99) 97.7 8.44 (19.78) 
Constipation 96.1 11.93 (23.79) 93.7 16.02 (26.23) 97.8 17.06 (27.50) 
Financial difficulties 94.1 5.18 (16.15) 93.2 7.70 (19.84) 97.8 5.21 (17.16) 
Diarrhea 95.6 7.34 (17.30) 93.5 9.75 (20.17) 96.3 9.16 (20.30) 
EORTC BR23, functional scales 
Sexual enjoyment 35.0 61.78 (27.00) 37.9 54.01 (26.55) 36.4 53.97 (26.52) 
Future perspectives 92.9 52.20 (30.27) 93.6 59.01 (31.09) 96.5 62.74 (30.64) 
Body image 92.5 89.24 (19.19) 93.6 77.84 (26.93) 97.1 79.29 (25.90) 
Sexual function 88.1 20.87 (24.64) 88.3 19.95 (23.01) 91.7 19.36 (22.79) 
EORTC BR23, symptoms scales 
Systemic therapy side effects 95.0 11.74 (11.68) 94.0 19.21 (15.90) 97.6 18.07 (14.43) 
Breast symptoms 82.9 11.76 (15.67) 94.2 24.21 (19.60) 97.3 18.10 (17.33) 
Arm symptoms 92.4 12.77 (21.03) 94.2 24.23 (25.91) 97.0 22.23 (25.38) 
Hair loss 10.6 34.15 (34.25) 23.8 48.25 (38.39) 27.2 44.75 (35.68) 
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ET and/or CT impact on general QoL 
 Only ET was associated with deteriorated C30-SumSc 2-years after diagnosis (pint=0.004) 
that persisted over time (M4 Figure 1, M4 Table 2 [see page 95] and M4 Supplementary Table 4 
[see page 99]). In contrast, after a transient deterioration, there was no detrimental effect of CT 
on C30-SumSc at 2-years (pint=0.924). Young age, comorbidities, smoking, low income, and 
anxiety/depression were also associated with QoL deterioration at 2-years (M4 Supplementary 
Table 4 shows multivariate models for C30-SumSc, remaining models not shown).  
 We then assessed the impact of treatment on general QoL (C30-SumSc) according to 
menopausal status. In premenopausal patients, neither ET (pint=0.242) nor CT (pint=0.100) were 
associated with a significant decrease of C30-SumSc after multivariate adjusting. In 
postmenopausal women, ET (pint=0.004), but not CT (pint=0.394), was associated with a 
substantial decrease in general QoL (MLS change at 2-years of -4.07 vs. -1.39 for ET vs. no ET). 
Prevalence of poor functions and severe symptoms and mean changes in QoL scores 2-years 
after diagnosis for patients treated or not with CT and/or ET are shown for the overall cohort 
and according to menopausal status in M4 Table 2, M4 Figure 2 [see page 101] and M4 
Supplementary Figures 2-3 [see page 89 and 103]. 
QLQ-C30 
Patient-reported functional scales  
 In the overall cohort, at 2-years, statistically significant worse QoL was observed among 
patients treated with ET (vs. no ET) for role functioning (p for interaction between treatment 
group-time [pint]=0.005) and social functioning (pint=0.032); CT (vs. no CT) impacted negatively 
physical functioning (pint<0.001) and cognitive functioning (pint<0.001) (M4 Table 2, M4 Figure 
2a). In premenopausal patients, a statistically significant worse QoL was observed with CT (vs. 
no CT) for physical functioning (pint<0.001) and cognitive functioning (pint<0.001). ET did not 
impact any functional domain (M4 Table 2, M4 Figure 2b). In postmenopausal patients, 
statistically significant worse QoL was seen with ET for global health status (pint=0.006), role 
functioning (pint=0.001) and social functioning (pint=0.012). CT did not impact any functional 
domain (M4 Table 2, M4 Figure 2c).  
Patient-reported symptom scales  
 In the overall cohort, at 2-years, statistically significant worse QoL was observed with ET 
(vs. no ET) for pain (pint=0.001). Insomnia improved among those not treated with ET (vs. ET) 
(pint=0.014); CT (vs. no CT) impacted negatively dyspnea (pint<0.001) and financial difficulties 
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(pint=0.015). Appetite loss improved among those treated with CT (vs. no CT) (pint<0.001) (M4 
Table 2, M4 Figure 2a). In premenopausal patients, statistically significant worse QoL was 
observed with CT (vs. no CT) for dyspnea (pint=0.030), and financial difficulties (pint=0.045). 
Appetite loss improved among those treated with CT (vs. no CT) (pint<0.001). ET did not impact 
any symptom domain (M4 Table 2, M4 Figure 2b). In postmenopausal patients, statistically 
significant worse QoL was seen with ET for nausea (pint=0.001) and pain (pint=0.001) and CT (vs. 
no CT) impacted negatively dyspnea (pint=0.011). Appetite loss improved among those treated 
with CT (vs. no CT) (pint=0.009) (M4 Table 2, M4 Figure 2c).  
QLQ-BR23 
Patient-reported functional scales  
 In the overall cohort and by menopausal status, statistically significant worse QoL was 
observed with CT (vs. no CT) for body image (pint<0.001) at 2-years. ET did not impact any 
functional domain (M4 Table 2, M4 Supplementary Figure 3a-c).  
Patient-reported symptom scales  
 In the overall cohort, at 2-years, statistically significant worse QoL was observed with ET 
(vs. no ET) for systemic therapy side effects (pint<0.001) and breast symptoms (pint=0.024); CT 
(vs. no CT) impacted negatively breast symptoms (pint<0.001) (M4 Table 2, M4 Supplementary 
Figure 3a). In premenopausal and postmenopausal patients, statistically significant worse QoL 
was observed with CT (vs. no CT) for breast symptoms (pint<0.001 and 0.040, respectively) and 
ET impacted negatively systemic therapy side effects (pint=0.030 and 0.004, respectively)(M4 
Table 2, M4 Supplementary Figure 3b-c). Comparative analysis of sequential CT/ET, CT and ET-
only and no systemic treatment groups were consistent with the above findings (M4 
Supplementary Figure 4/5 [see page 105 and 107]). Independent of menopausal status, the 
sequential therapy with CT and ET have the highest impact on several QoL domains; however, 
global health status was mainly impacted by ET for the overall cohort and for postmenopausal 
women and by CT for premenopausal. Emotional function and future perspective recover was 
smaller among the groups treated with ET.
Page 96 of 175 
 
 
M4 Table 2 – Mean least square change of specific domain according to exposure to chemotherapy and/or to endocrine therapy. P-value highlights the p-value 
of the interaction test between receipt of chemotherapy or endocrine therapy and time. 
Symptom, dimension 
or scale 
Treatment Overall cohort Premenopausal Postmenopausal 
MLS 
change 
95% CI p-val. MLS 
change 
95% CI p-val. MLS 
change 
95% CI p-val. 
EORTC QLQ-C30, summary score 
Summary score No chemotherapy -3.094 -3.937 - -2.252 0.924 -1.184 -2.840 - 0.473 0.100 -3.825 -4.787 - -2.863 0.394 
Chemotherapy -3.038 -3.817 - -2.260 -2.863 -3.995 - -1.731 -3.199 -4.272 - -2.127 
No endocr. therapy -1.294 -2.634 - 0.045 0.004 -1.05 -3.385 - 1.285 0.242 -1.417 -3.032 - 0.198 0.004 
Endocrine therapy -3.458 -4.090 - -2.826 -2.572 -3.593 - -1.552 -4.066 -4.864 - -3.268 
EORTC QLQ-C30, functional scales 
Global health status   No chemotherapy -3.379 -4.558 - -2.199 0.054 -1.838 -4.123 - 0.447 0.697 -3.95 -5.320 - -2.580 0.118 
Chemotherapy -1.799 -2.895 - -0.703 -1.288 -2.851 - 0.274 -2.309 -3.842 - -0.776 
No endocr. therapy -1.215 -3.094 - 0.665 0.129 -2.971 -6.193 - 0.250 0.317 -0.31 -2.612 - 1.993 0.006 
Endocrine therapy -2.825 -3.713 - -1.937 -1.176 -2.583 - 0.232 -3.934 -5.073 - -2.795 
Physical functioning No chemotherapy -5.006 -5.926 - -4.087 <0.001 -3.707 -5.252 - -2.161 <0.001 -5.493 -6.632 - -4.353 0.055 
Chemotherapy -7.403 -8.260 - -6.547 -7.655 -8.719 - -6.591 -7.164 -8.439 - -5.889 
No endocr. therapy -5.402 -6.870 - -3.933 0.190 -6.754 -8.946 - -4.562 0.720 -4.696 -6.613 - -2.779 0.079 
Endocrine therapy -6.488 -7.182 - -5.795 -6.316 -7.275 - -5.356 -6.611 -7.559 - -5.663 
Role functioning No chemotherapy -4.76 -6.241 - -3.279 0.393 -0.271 -3.146 - 2.603 0.104 -6.43 -8.141 - -4.719 0.158 
Chemotherapy -3.878 -5.256 - -2.499 -3.164 -5.139 - -1.189 -4.578 -6.493 - -2.664 
No endocr. therapy -1.21 -3.570 - 1.150 0.005 -1.107 -5.164 - 2.951 0.551 -1.266 -4.141 - 1.610 0.001 
Endocrine therapy -4.975 -6.090 - -3.859 -2.453 -4.231 - -0.675 -6.669 -8.091 - -5.247 
Emotional functioning No chemotherapy 3.816 2.373 - 5.259 0.004 4.947 2.043 - 7.851 0.124 3.408 1.774 - 5.041 0.061 
Chemotherapy 6.727 5.381 - 8.072 7.711 5.716 - 9.707 5.757 3.926 - 7.588 
No endocr. therapy 6.592 4.283 - 8.901 0.253 7.525 3.411 - 11.639 0.716 6.11 3.355 - 8.866 0.188 
Endocrine therapy 5.102 4.014 - 6.191 6.691 4.896 - 8.487 4.044 2.685 - 5.404 
Cognitive functioning No chemotherapy -2.759 -4.256 - -1.262 <0.001 -1.378 -4.453 - 1.697 0.001 -3.258 -4.918 - -1.599 0.121 
Chemotherapy -6.503 -7.897 - -5.108 -7.789 -9.903 - -5.676 -5.232 -7.090 - -3.373 
No endocr. therapy -4.235 -6.631 - -1.840 0.633 -6.421 -10.785 - -2.058 0.736 -3.079 -5.877 - -0.282 0.410 
Endocrine therapy -4.88 -6.009 - -3.751 -5.601 -7.506 - -3.697 -4.39 -5.771 - -3.010 
No chemotherapy -4.959 -6.269 - -3.649 0.666 -4.35 -6.965 - -1.734 0.368 -5.183 -6.672 - -3.693 0.811 
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Social functioning Chemotherapy -5.353 -6.575 - -4.131 -5.809 -7.609 - -4.009 -4.91 -6.582 - -3.238 
No endocr. therapy -3.088 -5.189 - -0.987 0.032 -4.888 -8.603 - -1.172 0.795 -2.165 -4.685 - 0.355 0.012 
Endocrine therapy -5.629 -6.616 - -4.642 -5.426 -7.043 - -3.808 -5.761 -6.999 - -4.523 
EORTC QLQ-C30, symptoms scales 
Fatigue 
 
No chemotherapy 6.418 4.852 - 7.985 0.591 4.104 0.932 - 7.275 0.262 7.278 5.515 - 9.041 0.763 
Chemotherapy 7.005 5.546 - 8.464 6.308 4.128 - 8.489 7.684 5.711 - 9.658 
No endocr. therapy 5.913 3.411 - 8.414 0.477 5.063 0.579 - 9.546 0.797 6.352 3.381 - 9.323 0.416 
Endocrine therapy 6.915 5.735 - 8.095 5.704 3.742 - 7.665 7.728 6.262 - 9.194 
Nausea No chemotherapy 1.43 0.593 - 2.266 0.128 -0.665 -2.448 - 1.119 0.358 2.208 1.308 - 3.109 0.032 
Chemotherapy 0.542 -0.236 - 1.321 0.351 -0.876 - 1.578 0.73 -0.278 - 1.738 
No endocr. therapy -0.044 -1.379 - 1.291 0.105 1.206 -1.316 - 3.727 0.316 -0.695 -2.210 - 0.820 0.001 
Endocrine therapy 1.177 0.547 - 1.808 -0.201 -1.305 - 0.902 2.101 1.352 - 2.849 
Pain 
 
No chemotherapy 12.842 11.224 - 14.460 0.874 10.294 7.259 - 13.329 0.424 13.79 11.882 - 15.698 0.775 
Chemotherapy 13.02 11.514 - 14.527 11.796 9.710 - 13.881 14.208 12.071 - 16.344 
No endocr. therapy 9.078 6.500 - 11.656 0.001 8.732 4.448 - 13.016 0.197 9.259 6.051 - 12.466 0.001 
Endocrine therapy 13.799 12.581 - 15.018 11.809 9.933 - 13.686 15.128 13.543 - 16.714 
Dyspnea No chemotherapy 5.712 4.143 - 7.280 <0.001 6.23 3.337 - 9.123 0.03 5.516 3.644 - 7.389 0.011 
Chemotherapy 9.634 8.176 - 11.092 10.125 8.138 - 12.113 9.144 7.050 - 11.237 
No endocr. therapy 7.219 4.717 - 9.721 0.605 7.695 3.612 - 11.778 0.536 6.963 3.809 - 10.117 0.909 
Endocrine therapy 7.949 6.767 - 9.131 9.103 7.313 - 10.894 7.169 5.611 - 8.727 
Insomnia No chemotherapy -0.612 -2.872 - 1.647 0.355 -4.833 -9.165 - -0.502 0.185 0.951 -1.681 - 3.582 0.058 
Chemotherapy -2.067 -4.165 - 0.031 -1.281 -4.256 - 1.694 -2.856 -5.793 - 0.080 
No endocr. therapy -5.477 -9.068 - -1.886 0.014 -7.192 -13.309 - -1.074 0.095 -4.623 -9.031 - -0.215 0.054 
Endocrine therapy -0.478 -2.178 - 1.223 -1.506 -4.183 - 1.170 0.21 -1.978 - 2.398 
Appetite Loss No chemotherapy -4.044 -5.475 - -2.614 <0.001 -9.294 -12.200 - -6.388 0.175 -2.102 -3.696 - -0.509 0.009 
Chemotherapy -8.485 -9.817 - -7.153 -11.736 -13.734 - -9.738 -5.293 -7.078 - -3.508 
No endocr. therapy -7.356 -9.639 - -5.073 0.375 -11.378 -15.482 - -7.274 0.824 -5.248 -7.929 - -2.567 0.158 
Endocrine therapy -6.214 -7.294 - -5.134 -10.871 -12.669 - -9.073 -3.094 -4.421 - -1.767 
Constipation No chemotherapy 5.637 3.915 - 7.359 0.468 7.676 4.531 - 10.821 0.959 4.888 2.817 - 6.959 0.81 
Chemotherapy 6.508 4.904 - 8.111 7.776 5.618 - 9.935 5.269 2.949 - 7.589 
No endocr. therapy 4.299 1.543 - 7.055 0.156 3.694 -0.756 - 8.144 0.052 4.621 1.122 - 8.119 0.785 
Endocrine therapy 6.503 5.206 - 7.800 8.514 6.574 - 10.454 5.162 3.440 - 6.884 
Financial difficulties No chemotherapy 0.394 -0.843 - 1.631 0.015 1.382 -1.334 - 4.098 0.045 0.031 -1.251 - 1.313 0.833 
Chemotherapy 2.493 1.335 - 3.650 4.759 2.882 - 6.636 0.239 -1.203 - 1.680 
No endocr. therapy 1.123 -0.865 - 3.111 0.671 3.262 -0.611 - 7.135 0.823 0.009 -2.161 - 2.180 0.909 
Endocrine therapy 1.599 0.665 - 2.534 3.744 2.059 - 5.430 0.150 -0.917 - 1.217 
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Diarrhea No chemotherapy 0.951 -0.342 - 2.245 0.091 -1.619 -4.076 - 0.837 0.555 1.895 0.376 - 3.414 0.629 
Chemotherapy -0.57 -1.772 - 0.632 -2.517 -4.204 - -0.831 1.334 -0.364 - 3.032 
No endocr. therapy -1.136 -3.202 - 0.931 0.183 -2.972 -6.449 - 0.505 0.648 -0.187 -2.747 - 2.373 0.118 
Endocrine therapy  0.417 -0.557 - 1.390 -2.088 -3.606 - -0.571 2.091 0.829 - 3.352 
EORTC BR23, functional scales 
Sexual enjoyment¥ 
 
No chemotherapy -4.575 -7.354 - -1.796 0.124 -1.717 -6.113 - 2.679 0.055 -6.605 -10.138 - -3.072 0.527 
Chemotherapy -7.42 -9.756 - -5.084 -6.943 -9.961 - -3.924 -8.252 -11.935 - -4.569 
No endocr. therapy -5.994 -10.038 - -1.950 0.893 -3.855 -9.950 - 2.241 0.618 -7.956 -13.291 - -2.622 0.814 
Endocrine therapy -6.303 -8.298 - -4.308 -5.553 -8.282 - -2.823 -7.228 -10.132 - -4.324 
Future perspective No chemotherapy 11.476 9.513 - 13.439 0.625 12.645 8.775 - 16.514 0.945 11.024 8.771 - 13.276 0.657 
Chemotherapy 12.144 10.324 - 13.965 12.48 9.828 - 15.132 11.789 9.278 - 14.300 
No endocr. therapy 12.575 9.441 - 15.708 0.609 12.654 7.178 - 18.130 0.962 12.507 8.715 - 16.299 0.511 
Endocrine therapy 11.671 10.196 - 13.147 12.51 10.124 - 14.896 11.087 9.218 - 12.957 
Body image 
 
No chemotherapy -8.173 -9.712 - -6.635 <0.001 -9.087 -12.240 - -5.934 <0.001 -7.833 -9.545 - -6.122 <0.001 
Chemotherapy -15.243 -16.669 - -13.817 -17.813 -19.975 - -15.652 -12.705 -14.612 - -10.798 
No endocr. therapy -11.645 -14.108 - -9.183 0.771 -13.649 -18.126 - -9.173 0.511 -10.565 -13.451 - -7.678 0.673 
Endocrine therapy -12.049 -13.209 - -10.889 -15.285 -17.238 - -13.332 -9.872 -11.295 - -8.449 
Sexual functioning No chemotherapy 0.603 -1.068 - 2.273 0.253 3.277 -0.110 - 6.664 0.262 -0.419 -2.262 - 1.423 0.152 
Chemotherapy -0.725 -2.269 - 0.819 0.929 -1.389 - 3.248 -2.438 -4.495 - -0.381 
No endocr. therapy 0.886 -1.758 - 3.530 0.412 0.376 -4.377 - 5.129 0.558 1.152 -1.929 - 4.233 0.079 
Endocrine therapy -0.338 -1.594 - 0.917 1.93 -0.160 - 4.020 -1.929 -3.462 - -0.397 
EORTC BR23, symptoms scales 
Systemic therapy side 
effects 
No chemotherapy 6.57 5.710 - 7.430 0.157 8.195 6.571 - 9.818 0.474 5.973 4.962 - 6.984 0.977 
Chemotherapy 7.418 6.617 - 8.219 8.915 7.800 - 10.029 5.951 4.819 - 7.082 
No endocr. therapy 4.617 3.245 - 5.988 <0.001 6.356 4.063 - 8.650 0.03 3.713 2.013 - 5.412 0.004 
Endocrine therapy 7.561 6.913 - 8.209 9.128 8.126 - 10.130 6.513 5.673 - 7.353 
Breast symptoms No chemotherapy 8.109 6.923 - 9.295 <0.001 9.735 7.344 - 12.126 0.001 7.499 6.161 - 8.836 0.040 
Chemotherapy 5.128 4.027 - 6.229 4.844 3.208 - 6.480 5.399 3.902 - 6.896 
No endocr. therapy 4.533 2.642 - 6.425 0.024 4.038 0.681 - 7.396 0.131 4.822 2.563 - 7.082 0.092 
Endocrine therapy 6.947 6.054 - 7.840 6.862 5.384 - 8.340 6.99 5.878 - 8.101 
Arm symptoms No chemotherapy 9.144 7.552 - 10.737 0.065 8.742 5.638 - 11.846 0.069 9.302 7.465 - 11.139 0.550 
Chemotherapy 11.192 9.714 - 12.669 12.229 10.106 - 14.351 10.143 8.091 - 12.196 
No endocr. therapy 8.544 6.008 - 11.081 0.146 10.398 6.022 - 14.774 0.725 7.505 4.417 - 10.594 0.124 
Endocrine therapy 10.624 9.426 - 11.822 11.255 9.342 - 13.169 10.207 8.680 - 11.733 
Upset by hair loss* No chemotherapy 7.286 1.451 - 13.122 0.100 8.075 -3.305 - 19.455 0.208 6.822 0.145 - 13.499 0.250 
Chemotherapy 14.377 8.236 - 20.519 17.383 8.364 - 26.401 13.207 4.598 - 21.816 




No endocr. therapy 9.924 -0.275 - 20.123 0.878 7.839 -10.677 - 26.354 0.495 11.017 -1.114 - 23.148 0.747 
Endocrine therapy 10.801 6.139 - 15.462 14.817 7.142 - 22.492 8.796 2.919 - 14.672 
Asterisks denote that question was only to be answered (*) if patients stated to have been sexually active or (**) if patients stated they had experienced hair loss, resulting in fewer patients 
responding to these questions compared with other questions.   
Models include as covariates: age, Charlson’s comorbidity index, BMI, smoking, marital status, education level, income, disease staging center volume, type of surgery, axillary management, receipt 
of trastuzumab, receipt of radiotherapy, presence of anxiety and presence of depression, all of which collected at diagnosis.  
CI – confidence interval; Endocr. – endocrine; EORTC QLQ - European Organisation for Research and Treatment of Cancer quality of life questionnaire; MLS – Mean least square; p-val. – p-value. 
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M4 Supplementary table 4 – Generalized estimating equations of C30 summary score from diagnosis to 2 years after diagnosis: A) models including the 
interaction between use of adjuvant endocrine therapy and time, and B) models including the interaction between use of adjuvant chemotherapy and time. 
A 
 Overall cohort Premenopausal Postmenopausal 
Coefficient 95% CI p-value Coefficient 95% CI p-value Coefficient 95% CI p-value 
Use of adjuvant ET 0.375 -0.685 - 1.435 0.488 0.617 -1.221 - 2.455 0.511 0.434 -0.856 - 1.723 0.510 
Time -1.294 -2.634 - 0.045 0.058 -1.050 -3.385 - 1.285 0.378 -1.417 -3.032 - 0.198 0.085 
Interaction adjuvant 
ET*time -2.164 -3.644 - -0.683 0.004 -1.523 -4.071 - 1.025 0.242 -2.649 -4.450 - -0.847 0.004 
Use of adjuvant CT -0.086 -0.825 - 0.654 0.820 -1.416 -2.669 - -0.164 0.027 0.662 -0.256 - 1.580 0.157 
Age (categorical) 0.341 0.060 - 0.621 0.017 -0.131 -0.796 - 0.535 0.701 0.738 0.222 - 1.253 0.005 
Charlson ≥ 1 -1.886 -2.631 - -1.140 0.000 -0.125 -1.587 - 1.337 0.867 -2.499 -3.357 - -1.642 0.000 
BMI (categorical) -1.187 -1.563 - -0.812 0.000 -0.290 -0.927 - 0.347 0.373 -1.663 -2.125 - -1.200 0.000 
Current smoker -2.623 -3.424 - -1.822 0.000 -2.139 -3.325 - -0.953 0.000 -2.835 -3.933 - -1.736 0.000 
Living as a couple -0.383 -1.209 - 0.444 0.364 -1.040 -2.594 - 0.514 0.190 -0.016 -0.980 - 0.948 0.974 
Education (categorical) -0.250 -0.489 - -0.012 0.040 0.027 -0.396 - 0.450 0.900 -0.414 -0.702 - -0.127 0.005 
Income (categorical) 0.622 0.462 - 0.781 0.000 0.780 0.492 - 1.067 0.000 0.552 0.361 - 0.743 0.000 
Center volume (> 100 
patients) 0.224 -0.639 - 1.086 0.611 0.507 -0.899 - 1.912 0.480 -0.105 -1.197 - 0.987 0.851 
TNM Stage (categorical) -0.760 -1.362 - -0.159 0.013 -0.418 -1.338 - 0.501 0.372 -1.042 -1.839 - -0.245 0.010 
Mastectomy (vs. BCS) -0.344 -1.178 - 0.491 0.420 0.305 -0.949 - 1.559 0.633 -0.858 -1.982 - 0.267 0.135 
SLND or none (vs. ALND) 0.595 -0.196 - 1.386 0.140 0.735 -0.488 - 1.957 0.239 0.538 -0.501 - 1.577 0.310 
Use of adjuvant 
radiotherapy -1.178 -2.353 - -0.003 0.049 0.460 -1.452 - 2.373 0.637 -2.062 -3.556 - -0.568 0.007 
Use of adjuvant 
trastuzumab -0.567 -1.522 - 0.387 0.244 -0.509 -1.881 - 0.864 0.468 -0.737 -2.078 - 0.603 0.281 
Anxiety (categorical) -3.385 -3.751 - -3.018 0.000 -3.400 -3.998 - -2.803 0.000 -3.361 -3.823 - -2.899 0.000 
Depression (categorical) -6.635 -7.202 - -6.069 0.000 -6.015 -6.928 - -5.102 0.000 -7.001 -7.720 - -6.282 0.000 
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B 
 Overall cohort Premenopausal Postmenopausal 
Coefficient 95% CI p-value Coefficient 95% CI p-value Coefficient 95% CI p-value 
Use of adjuvant ET -0.113 -1.043 - 0.817 0.811 -0.580 -2.183 - 1.023 0.478 0.357 -0.799 - 1.512 0.545 
Time -3.094 -3.937 - -2.252 0.000 -1.184 -2.840 - 0.473 0.161 -3.825 -4.787 - -2.863 0.000 
Interaction adjuvant 
ET*time 0.056 -1.091 - 1.203 0.924 -1.679 -3.686 - 0.327 0.100 0.626 -0.815 - 2.067 0.394 
Use of adjuvant CT -0.703 -1.465 - 0.058 0.070 -0.148 -1.465 - 1.169 0.826 -0.876 -1.808 - 0.055 0.065 
Age (categorical) 0.339 0.058 - 0.620 0.018 -0.133 -0.798 - 0.533 0.696 0.733 0.217 - 1.249 0.005 
Charlson ≥ 1 -1.889 -2.634 - -1.143 0.000 -0.135 -1.597 - 1.326 0.856 -2.502 -3.360 - -1.644 0.000 
BMI (categorical) -1.187 -1.563 - -0.811 0.000 -0.287 -0.924 - 0.350 0.376 -1.661 -2.124 - -1.198 0.000 
Current smoker -2.624 -3.425 - -1.822 0.000 -2.130 -3.316 - -0.944 0.000 -2.838 -3.937 - -1.738 0.000 
Living as a couple -0.383 -1.210 - 0.444 0.364 -1.031 -2.584 - 0.523 0.194 -0.014 -0.979 - 0.952 0.978 
Education (categorical) -0.253 -0.492 - -0.015 0.038 0.028 -0.395 - 0.451 0.898 -0.420 -0.707 - -0.132 0.004 
Income (categorical) 0.621 0.461 - 0.781 0.000 0.778 0.490 - 1.065 0.000 0.551 0.360 - 0.742 0.000 
Center volume (> 100 
patients) 0.221 -0.642 - 1.083 0.616 0.510 -0.896 - 1.915 0.477 -0.110 -1.203 - 0.983 0.844 
TNM Stage (categorical) -0.755 -1.357 - -0.154 0.014 -0.419 -1.338 - 0.499 0.371 -1.031 -1.829 - -0.234 0.011 
Mastectomy (vs. BCS) -0.341 -1.177 - 0.494 0.423 0.309 -0.945 - 1.563 0.629 -0.854 -1.979 - 0.272 0.137 
SLND or none (vs. ALND) 0.600 -0.191 - 1.392 0.137 0.737 -0.485 - 1.959 0.237 0.550 -0.490 - 1.590 0.300 
Use of adjuvant 
radiotherapy -1.189 -2.364 - -0.013 0.047 0.457 -1.455 - 2.368 0.640 -2.081 -3.576 - -0.586 0.006 
Use of adjuvant 
trastuzumab -0.563 -1.519 - 0.392 0.248 -0.511 -1.884 - 0.861 0.465 -0.726 -2.068 - 0.616 0.289 
Anxiety (categorical) -3.384 -3.750 - -3.017 0.000 -3.404 -4.001 - -2.807 0.000 -3.357 -3.820 - -2.895 0.000 





Page 102 of 175 
 
M4 Figure 2 – Mean least square change of EORTC QLQ C30 PRO domains score from diagnosis to the “2-years after diagnosis visit” in patients treated and 
not treated with chemotherapy or endocrine therapy in the overall cohort (2A), and in premenopausal (2B) and postmenopausal (2C) patients. Error bars 
refer to the 95% confidence interval of the estimate. P-values refer to the interaction (pint) of the treatment with chemotherapy (CT) or endocrine therapy 
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M4 Supplementary Figure 3 – Mean least square change of EORTC QLQ BR23 PRO domains score from diagnosis to the “2-years after diagnosis visit” in 
patients treated and not treated with chemotherapy or endocrine therapy in the overall cohort (S3A), and in premenopausal (S3B) and postmenopausal 
(S3C) patients. Hair loss is not shown due to high dispersion of the data. Error bars refer to the 95% confidence interval of the estimate. P-values refer to the 
interaction (pint) of the treatment with chemotherapy (CT) or endocrine therapy (ET) and time. Only p-values <0.1 are shown. Estimates and confidence 
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M4 Supplementary Figure 4 – Mean least square change of EORTC QLQ C30 PRO domains score from diagnosis to the “2-years after diagnosis visit” in 
patients treated and not treated with chemotherapy and/or endocrine therapy in the overall cohort (S4A), and in premenopausal (S4B) and postmenopausal 
(S4C) patients. Error bars refer to the 95% confidence interval of the estimate. Estimates and confidence intervals derived from multivariate generalized 
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M4 Supplementary Figure 5 – Mean least square change of EORTC QLQ BR23 PRO domains score from diagnosis to the “2-years after diagnosis visit” in 
patients treated and not treated with chemotherapy and/or endocrine therapy in the overall cohort (S5A), and in premenopausal (S5B) and postmenopausal 
(S5C) patients. Hair loss is not shown due to high dispersion of the data. Error bars refer to the 95% confidence interval of the estimate. Estimates and 
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5.4.7 Discussion 
In this study, we investigated the variation in QoL from early BC diagnosis, thus before 
any intervention, to 2-years afterwards among 4262 patients enrolled in the prospective CANTO 
cohort, a large, real-world contemporary study of patients treated for BC across France. Using 
validated general and BC specific PROs, we found that patients report overall significantly 
deteriorated QoL 2-years after BC diagnosis that is impacted by both ET and CT independently. 
ET represented a considerable and persistent burden for some BC survivors’ QoL, affecting the 
C30-SumSc and a substantial number of domains, while CT effect seems to have a more transient 
negative impact on QoL. Nevertheless, differential patterns of change in QoL were observed 
according to adjuvant treatment class and after stratification by menopausal status at diagnosis.  
Corresponding with the improved BC survival, the need for patients and healthcare 
providers to understand the differential effect that distinct classes of adjuvant treatments may 
have on late QoL is emerging as a priority. Previous research suggested that most physical and 
psychosocial symptoms that commonly follow adjuvant BC treatment usually resolve in the first 
year after BC diagnosis and that most of BC survivors recover high functional levels of QoL152–154 
Nevertheless, it has been also reported that some patients may experience more persistent and 
distressing troubles that include longer-term physical, cognitive, and sexual 
disturbances.144,145,155,156 In this study, we found that a substantial number of BC survivors report 
poor QoL (and deteriorated from diagnosis) 2-years after diagnosis, including a decrease in the 
C30-SumSc, but also 27.8% of patients reporting poor global health status, 38.4% severe 
cognitive dysfunction, 51% severe pain, 45.5% severe dyspnea and 33.6% severe fatigue. 
Interestingly, when compared to diagnosis and thus before any intervention, our data 
seem to indicate that the receipt of distinct classes of adjuvant treatment was associated with 
differential patterns of QoL 2-years after. Prior studies have yielded inconsistent results in this 
regard. Some suggested that CT leads to cumulative, yet transient, QoL deterioration, which 
resolves shortly after treatment completion, whereas ET has a more prolonged negative effect 
on QoL, and other studies have suggested no major differences in QoL by treatment 
group.144,145,155–157 For example, a pooled analysis of International BC Study Group trials showed 
a measurable impact of CT on QoL during active treatment, which was, however, transitory.155 
Nevertheless, persistence of QoL deterioration was associated with treatment strategy over 
time, with patients treated with chemoendocrine treatment scoring lower than patients treated 
only with tamoxifen. A previous cross-sectional study evaluating the QoL of BC survivors on 
average 3-years after BC diagnosis suggested no overall major differences in QoL between 
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adjuvant treatments groups.145 This is consistent, with a recent analysis of the TAILORx trial that 
compared the impact of ET vs. ET+CT in the cognitive function, fatigue and endocrine 
symptoms.157 Overall, although the addition of CT to ET led to greater cognitive impairment, 
fatigue and endocrine symptoms in the first 3-6 months, this change diluted between groups at 
a follow-up up to 36 months. Our study, making a comprehensive evaluation of with the use of 
a QoL summary score and several Qol domains, expands this knowledge. Patients were assessed 
at 2-years after diagnosis and both CT and ET seemed to impact QoL, particularly the C30-SumSc, 
each however playing a distinct role in different domains. ET had a persistently negative and 
clinically meaningful impact in C30-SumSc and in multiple functions and symptoms, including 
role and social function and pain, insomnia and systemic therapy side effects. In contrast, ET 
seems to attenuate the recovery in domains that typically improve overtime such as emotional 
function and future perspectives. In contrast, the impact of CT seemed to be transient and 
restricted to physical and cognitive function, financial difficulties, body image and breast 
symptoms, with no impact in the C30-SumSc at 2-years post-diagnosis. Our approach to evaluate 
the contributions of ET and CT after stratification by menopausal status adds further to the 
literature. In premenopausal patients, receipt of CT although fading overtime overall, it was 
associated with significant deterioration of several QoL domains. In addition, while CT seems to 
be the only driver of cognitive impairment in premenopausal women, both ET and CT contribute 
additively to cognitive deterioration in postmenopausal women. In postmenopausal patients, 
deterioration of QoL was associated substantially with ET. Treatment and treatment 
implications can greatly differ by menopausal status partially explaining these differences. 
Eighty-nine percent of premenopausal women in our cohort who received ET were treated with 
tamoxifen compared to 88% of postmenopausal women who received AIs, therefore it is 
possible that the use of AI might have driven our findings on the postmenopausal cohort. This is 
in line with recent longitudinal cohort data of 186 BC patients that suggested significantly 
reduced physical QoL for patients treated with AIs 1-year after initiation of ET compared with 
tamoxifen, but it contrasts with clinical trial data that have traditionally suggested only small 
differences in QoL by type of ET. If this is correct, the recent trend towards escalation of ET, 
either by extending the total duration of treatment or, in premenopausal women by intensifying 
treatment with the use of OFS with tamoxifen or AIs, might therefore substantially add to the 
burden of ET on QoL. In premenopausal women the impact of CT in QoL might indeed reflect 
transient or permanent ovarian function failure, suggesting that uptake of OFS in these patients 
may have a major impact on their QoL.  
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For this study, we used a large national French cohort that is representative of the 
overall BC population (77.8% HR+/HER2- BC, 51.5% stage I, 86.0% of CT treated patients received 
anthracyclines-taxanes) and that offered a unique opportunity to have a detailed and up-to-date 
perspective of the impact of CT and ET in QoL of BC patients. Nevertheless, we acknowledge 
some limitations. The proportion of patients with missing QoL questionnaire at 2-years after 
diagnosis was over 25%. While not optimal, this can be expected given the real-world research. 
Specific populations, as older and less educated/lower income patients might be 
underrepresented in this study thus deserving a focused approach in future research. Also, this 
study included patients who were diagnosed between 2012 and 2015, and treatment patterns 
have evolved since. The proportion of patients currently on adjuvant OFS plus AI or tamoxifen is 
higher than what was noted in the present study, which might underestimate the toxicity of ET 
in premenopausal women. Likewise, the most frequent adjuvant anthracycline-taxane 
combination regimen in CANTO was FEC-T (5-fluorouracil-epirubicin-cyclophosphamide 
followed by a taxane), while in current practice EC/AC-T (epirubicin/doxorubicin-
cyclophosphamide followed by a taxane) is predominant. A minority of patients was treated 
with anthracyclines-sparing regimens which is, in some practices, an emerging regimen to treat 
early breast cancer. In addition, we did not explore the QoL impact by endocrine or CT regimen, 
since it is out of the scope of this paper. Moreover, there is not just one QoL metric, but many 
outcomes that have to be assessed to capture the overall impact of treatment on QoL, 
nevertheless we integrated a QoL summary score as primary outcome. Furthermore, we used 
EORTC QLQ BR23 module instead of the BR45 which was unavailable at CANTO study inception 
and is now in phase IV testing. Given that the QLQ BR45 might better capture specific BC 
treatment toxicities (e.g. joint pain and muscle ache), our results may be a conservative picture 
of the ET impact. In addition, due to the observational design and although we performed a 
comprehensive adjustment of our models, we cannot exclude unmeasured confounding, 
including factors such as treatment adherence. Lastly, no formal adjustment for multiplicity has 
been performed given the observational nature of the study. 
In conclusion, QoL was deteriorated at 2-years after BC diagnosis in multiple functions 
and symptoms. QoL deterioration was associated with ET in postmenopausal women, and 
receipt of CT seemed to have a larger impact in premenopausal women. This differential effect 
of treatment classes by menopausal status on QoL should be considered when discussing 
optimal adjuvant therapy options and survivorship care as they may have implications for 
adherence and long-term health and psychosocial outcomes. While systemic treatment is a 
major driver in QoL, we recognize that the optimal support is a continuum that must consider, 
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among others, the psychological disruption of cancer diagnosis and the sequelae of local 
interventions. Our data challenge the common idea that ET is an innocent player in the QoL 
arena and highlight that appropriate selection of women for ET treatment escalation should be 
a research priority. 
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5.5 Serum detection of non-adherence to adjuvant tamoxifen and breast cancer 
recurrence risk. 
5.5.1 Introductory notes 
This project quantifies adherence 1 year after adjuvant tamoxifen prescription by two 
methods to access adherence, specifically a self-reported questionnaire or by serum 
assessment. It further quantifies the impact of non-adherence on cancer outcomes. This project 
is under submission. Arlindo R. Ferreira participated in the study design, led data analysis, and 
further participated in results interpretation and manuscript writing. 
5.5.2 Authors 
Barbara Pistilli1, Angelo Paci1,2, Arlindo R. Ferreira1,3,4, Antonio Di Meglio1,3, Vianney 
Poinsignon1, Aurelie Bardet1,5, Gwenn Menvielle6, Agnes Dumas5,7,8, Sandrine Pinto6, Sarah 
Dauchy1, Leonor Fasse1,9, Paul H. Cottu10, Florence Lerebours10, Charles Coutant11, Anne Lesur12, 
Olivier Tredan13, Patrick Soulie14, Laurence Vanlemmens15, Christelle Jouannaud16, Christelle 
Levy17, Sibille Everhard18, Patrick Arveux5,11,  Anne Laure Martin18, Alexandra Dima19, Nancy U. 
Lin20, Ann H. Partridge20, Suzette Delaloge1, Stefan Michiels1,5, Fabrice André1,3, Ines Vaz-Luis1 
Authors affiliations: 1Institut Gustave Roussy, Villejuif, FR; 2Université Paris-Sud, Faculté 
de Pharmacie, Chatenay-Malabry, FR; 3INSERM-Unit 981, Villejuif, FR; 4Champalimaud Clinical 
Center, Champalimaud Foundation, Lisboa, PT; 5INSERM-Unit 1018, Villejuif, FR; 6Institut Pierre 
Louis d’Epidemiologie et de Santé Publique, Paris, FR; 7UMR-Unit 1123, Paris, FR; 8Université 
Paris Diderot UFR de Médecine, Paris, FR; 9Université Paris Decartes, Paris, FR; 10Institut Curie, 
Paris, FR; 11Georges-Francois Leclerc Centre, Dijon, FR; 12Institut de Cancerologie de Lorraine, 
Nancy, FR; 13Centre Léon Bérard, Lyon, FR; 14Institut de Cancerologie de L’Ouest, Saint Herblain, 
FR; 15Centre Oscar Lambret, Lille, FR; 16Institut Jean Godinot, Reims, FR; 17Centre Francois 
Baclesse Centre Lutte Contre le Cancer, Caen, FR; 18UNICANCER, Paris, FR; 19Université Claude 
Bernard, Villeurbanne, FR; 20Dana Farber Cancer Institute, Boston, MA, USA. 
5.5.3 Abstract 
Purpose: Non-adherence to long-term treatments is often under recognized by 
physicians, and a gold standard for its assessment does not exist. In breast cancer, non-
adherence to medication constitutes a major obstacle for optimal outcomes. We sought 
to evaluate the rate of biochemical non-adherence to adjuvant tamoxifen one year after 
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treatment prescription using drug serum assessment and to examine its effects on short-
term distant disease-free-survival (DDFS).   
Patients and Methods: We studied 1177 premenopausal women enrolled on a 
large prospective national clinical study (CANTO/NCT01993498). Definition of 
biochemical non-adherence was based on a tamoxifen serum level <60 ng/ml. Patients 
were also requested to self-report adherence to tamoxifen during concomitant follow-
up visits. Survival analyses were conducted using propensity score inverse probability 
treatment weighting and Cox proportional hazards models.  
Results: Serum assessment of tamoxifen identified 16.0% of patients (n=188) 
below the set adherence threshold. Patient-reported rate of non-adherence was lower 
(12.3%). Of 188 biochemical non-adherent patients, 104 (55%) stated they had been 
regularly taking tamoxifen. After a median follow-up time of 24.2 months since 
tamoxifen serum assessment, biochemical non-adherent patients had significantly 
shorter DDFS (adjusted hazard ratio of distant recurrence or death 2.31 [1.05-5.06]; 
p=0.036) and an absolute 5.9% increase in the risk of DDFS at 3 years.  
Conclusions: Therapeutic drug monitoring may be a useful method to promptly 
identify patients who do not take adjuvant tamoxifen as prescribed and are at risk of 
poorer outcomes. Targeted interventions facilitating patients’ adherence are needed 
and have the potential to improve short-term breast cancer outcomes. 
Trial registration: NCT01993498. 
5.5.4 Introduction    
Previous studies suggested that 30-50% of patients with chronic conditions in developed 
countries are non-adherent to prescribed medications.158,159 Annually in the US, non-adherence 
to chronic medications is responsible for increased mortality, hospitalizations and health-care 
costs.158,160 Non-adherence also impacts patient-physician relationships, possibly leading to 
breakdowns in trust and communication.159,161 In addition, since health care systems are 
evolving into models where health care providers’ payments are tied to outcomes, non-
adherence can also impact health care providers reimbursement.162 Therefore, optimizing 
adherence may lead to dramatic improvements in health outcomes, patient satisfaction and 
costs. 
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To be able to design effective programs supporting adherence it is first essential to 
better recognize when actual medication use differs from the prescribed regimen.  There is no 
gold standard to identify non-adherence, with the prevalent use of indirect methods, commonly 
based on pharmacy prescription refills, patient-administered questionnaires, which although 
informative do not capture the actual medication intake. Particularly, it has been shown that 
patient self-report tend to overestimate adherence rates from two- to four-fold and pharmacy 
claims do not perfectly reflect the medication intake, especially if low out-of-pocket costs.163 
Direct methods, as measurement of the level of the drug or its metabolites in the blood or urine 
are less well studied and are not currently used in clinical practice.158,161,164,165 Furthermore, non-
adherence is a complex phenomenon with a multitude of factors associated, including patient, 
health care provider and disease-specific features making it hard to identify and intervene on 
causes of non-adherence.158,160  
Eighty percent of breast cancer patients have hormone receptor-positive (HR+) disease 
and more than 90% of these patients present with stage I-III disease rendering them eligible for 
curative treatment.10 For patients with HR+ breast cancer receiving adjuvant endocrine therapy, 
previous studies suggested that non-adherence is a prevalent issue.166–168 Because 5-years of 
adjuvant endocrine therapy reduces recurrence rate by 50% throughout the first 10 years and 
mortality by a third throughout the first 15 years10 and extending the duration of endocrine 
therapy beyond five years can also impact risk of recurrence by up to 40%, non-adherence 
constitutes a major obstacle for optimal disease and survival outcomes.10,67 In premenopausal 
patients with HR+ breast cancer, especially those younger than 40, non-adherence to adjuvant 
endocrine therapy seems to be a major issue, and evidence suggested poorer survival outcomes 
in this population compared to older ones, partly due to higher non-adherence rates.169 
CANcer TOxicities (CANTO) study (NCT01993498) has collected prospectively detailed 
tumor, treatment, toxicities, health-related patient reported outcomes (HRPROs) and biological 
data, on a cohort of 12,012 women with newly diagnosed early breast cancer. In this study we 
evaluated the hypothesis that therapeutic drug monitoring may promptly identify patients who 
are non-adherent to breast cancer adjuvant endocrine therapy and at risk of a worse outcome.  
To do this, we examined non-adherence by tamoxifen serum assessment among premenopausal 
patients of the CANTO cohort, in the first year after the start of adjuvant endocrine treatment 
and its impact on short-term breast cancer survival outcomes.  
5.5.5 Patients and Methods 
Study design and patient selection 
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Data Source 
The CANTO cohort enrolled patients across the entire national French territory from 
2012 to 2018. Eligibility criteria include patients 18 years of age or older, with a primary diagnosis 
of invasive stage cT0-cT3, cN0-3 breast cancer and no previous treatments for current breast 
cancer. Patients are assessed at diagnosis and shortly after primary treatment (primary surgery, 
chemotherapy or radiotherapy, whichever comes last), near to endocrine therapy prescription, 
if indicated, and then at Year 1, 3, and 5 after the initial post-primary treatment evaluation. Data 
collection at each time point includes clinical, treatment (including medication adherence 
assessed by trained clinical research nurse [CRN]), toxicity data, HRPROs and serum samples.80 
The protocol is available with the full text of this article. 
Study oversight  
CANTO is coordinated by UNICANCER (National French Cancer Centers Cooperative 
Group). The study was approved by the national regulatory authorities and ethics committee 
(ID-RCB: 2011-A01095-36; 11-039). All patients enrolled in the study provided written informed 
consent including consent for the biological data collection.  
Variables assessment  
Assessment of non-adherence  
Non-adherence at Year 1 post-tamoxifen prescription was defined as non-persistence 
(early discontinuation) and/or suboptimal medication implementation (interruptions, skipped 
doses), in accordance with EMERGE guidelines at least one year after tamoxifen prescription.170 
We focused on women who potentially initiated tamoxifen and we excluded those who were 
prescribed tamoxifen but did not agree to initiate the treatment, as captured by CANTO clinical 
report form (CRF): “Endocrine therapy: yes/no”; “if no, state reason: patient’s refusal?; 
contraindication? Non-indication?”.  
Non-adherence to tamoxifen at Year 1 post-tamoxifen prescription was determined 
using an objective and direct method, tamoxifen serum assessment (biochemical non-
adherence) (primary outcome) and a subjective and indirect method, patient’s self-declaration 
(secondary outcome).  
Definition of primary outcome (biochemical non-adherence) 
Blood samples were immediately stored at -80° C after collection. Tamoxifen serum level 
was determined by liquid chromatography-tandem mass spectrometry on 200-400 µL of serum 
Page 118 of 175 
 
in the multiple reaction monitoring mode of a 6460 triple quadrupole mass spectrometer 
(Agilent Technologies, Waldbronn, Germany).171 
We used a predefined threshold of 60 ng/ml, for defining biochemical non-adherence 
to tamoxifen on the basis of pharmacological studies.172–174 Supplementary appendices M5 S1.1 
and M5 S1.2 detail tamoxifen metabolism and pharmacokinetic and cut-off definition for 
biochemical non-adherence. 
Definition of secondary outcome 
Patient’s self-declarations on adherence to tamoxifen were collected by trained CRNs at 
the same time point of blood collection for tamoxifen serum-assessment by semi-structured 
interviews. M5 Supplementary Appendix S1.2 details the definition of patient’s self-declaration. 
Assessment of Survival Outcomes 
For survival analyses, we focused primarily in distant disease-free survival (DDFS), given 
that the loco-regional recurrences are frequently amenable to definitive treatment thus limiting 
results interpretation in a cohort with a relatively short follow-up and limited number of 
recurrences. DDFS was defined as time from tamoxifen serum assessment to date of distant 
recurrence or death by any cause.175 Secondarily, we examined breast cancer free interval 
(BCFI), which was defined time from tamoxifen serum assessment to date of contralateral breast 
cancer, local, regional or distant recurrence or death by breast cancer.175 Since our focus was to 
assess the impact of non-adherence at Year 1 after tamoxifen prescription, a landmark analysis 
was performed and per consort diagram all patients with a distant disease event before this time 
point were upfront excluded from this study. 
Study covariates  
All study covariates were categorized as per M5 Table 1, including baseline socio-
demographic, clinical, and behavioral factors, treatment toxicities and HRPROs shortly after 
treatment prescription. 
Statistical analysis 
Concordance between serum assessment and patient’s self-report was tested by chi-
square test and estimated using Cramer-V coefficient. Multivariate logistic regression modeled 
the association of relevant covariates with non-adherence at Year 1 post-tamoxifen prescription. 
Several methods examined the independent impact of biochemical non-adherence and patient 
reported non-adherence on DDFS.  Time-to-event outcomes were estimated and plotted using 
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the Kaplan-Meier method. To deal with confounding, as a primary analyses we used propensity 
score (PS) inverse probability treatment weighting (IPTW) in a Cox model.176 To assess 
robustness of results a multivariable Cox proportional hazards (CPH) model was also performed 
as a sensitivity analysis. Variables included both in the PS IPTW and CPH mode were known 
breast cancer prognostic factors and included: age at diagnosis, TNM staging, type of surgery, 
receipt of (neo) adjuvant chemotherapy and center size. In a second sensitivity analysis, to 
incorporate known social, psychological and behavioral confounders PS IPTW was also weighted 
by marital status, education, body mass index, smoking habits, anxiety, depression and 
symptomatology at treatment initiation.  PS diagnostics were performed using user-written 
package pstest for Stata (by E. Leuven and B Sianesi). Variance estimation was optimized by 
using a bootstrapped PS and, to deal with instability that can ensue from large weights, a 
stabilized IPTW was implemented.176,177 Since the Year 1 visit did not occur exactly at the same 
time from diagnosis for all patients, description of time between scheduled visits in adherent 
and non-adherent patients was also performed. All time-to-event analyses met proportional 
hazards assumption as assessed by the Schoenfeld residuals. Given the low DDFS event rate, 
median follow-up was the median of the observed follow-up times using all patients. There were 
low rates of missing variables, which were considered missing at random among adherent and 
non-adherent patients (M5 Table 1), given balanced distribution among groups.  Therefore, no 
multiple imputation was performed. Secondary analyses focused on BCFI were performed. All 
tests were 2-sided and p-values of ≤ 0.05 were considered statistically significant. No formal 
adjustment for multiplicity has been performed given the observational nature of the study. The 
analyses were performed using Stata 15.1 (StataCorp LP). 
5.5.6 Results 
Study Cohort    
From the 5,801 women enrolled in CANTO with available data, we first excluded those 
who were post-menopausal at cancer diagnosis (n=3725), those with HRe-negative breast 
cancer or not receiving endocrine therapy (n=413) and those prescribed aromatase inhibitors 
before Year 1 visit (n=183). We then selected all women who were premenopausal at diagnosis 
and were prescribed and agreed to take adjuvant tamoxifen (n=1480). Finally, we selected 
women among whom tamoxifen serum assessment was performed at Year 1 post-tamoxifen 
prescription (n=1177) (M5 Figure 1). M5 Supplementary Table S1 describes characteristics of 
non-participant patients who were excluded due to absence of blood assessment (n=303/1480, 
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20.5%). Nonparticipant patients had lower likelihood to belong to a high-volume recruitment 
center; no other major differences emerged between groups. 
M5 Figure 1 – Consort diagram of study participants. AI – aromatase inhibitor; ET – endocrine 
therapy; LHRH – luteinizing hormone releasing hormone; TAM – tamoxifen. 
 
Among the analytic cohort, median time from tamoxifen prescription to measurement 
of non-adherence was 16.2 months (interquartile range [IQR] 15.1 - 17.8). Median age was 45 
years (IQR 41 – 49). Patients’ characteristics at baseline and treatment details are reported in 
M5 Table 1. 






Number % Number % Number % 
Total number  1177  100 989 84.0 188 16.0 
Tamoxifen serum concentration 
Median (IQR) 
Min. – Max. 
 
110 (80 – 144) 
6 – 298 
 
119 (96 – 152) 
60 – 298 
 
6 (6 – 38) 
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Missing 72 6.1 61 6.2 11 5.9 
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AJCC – American Joint Committee on Cancer; BCS- Breast Conservative Surgery; CTCAE - Common 
Terminology Criteria for Adverse Events; EORTC QLQ - European Organisation for Research and Treatment 
of Cancer Quality of Life Questionnaires; HADS - Hospital Anxiety and Depression Scale, IHC – 
immunohistochemistry; IQR – interquartile range; NST – No Special Type; pts – patients.  
 
Non-adherence at Year 1 post-tamoxifen prescription  
Tamoxifen serum concentrations at Year 1 post-tamoxifen prescription ranged between 
<6 and 298 ng/ml, with a median of 110 ng/ml (M5 Table 1, M5 Figure S1 and M5 Table S2). 
Overall, 188 (16%) patients were below the set biochemical adherence threshold to tamoxifen 
at Year 1; 145 patients (12.3%) self-declared to be non-adherent: 89 (7.6%) reported tamoxifen 
discontinuation and 56 (4.7%) temporary interruptions. Among the 145 patients declaring to be 
non-adherent, only few (n=67) were able to provide a personal or medical reason for non-
adherence. Among these, toxicity was mentioned by 57 patients. Of 188 biochemical non-
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adherent patients, 104 (55.3%) stated they had been regularly taking tamoxifen over the last 
year. Conversely, 61 patients revealed a non-adherent behavior despite being adherent by 
serum assessment, of whom the majority (82%) reported transitory tamoxifen interruptions. 
Although biochemical and self-declaration non-adherence were significantly associated 
(p<.0001) only moderate concordance between the two methods was found (concordance: 86% 
[95% CI 84 to 88%]; Cramer V = 0.429) (M5 Table 2).  















Biochemical non-adherence was associated with multiple factors. Patients not living 
with a partner as a couple (vs. with a partner) (adjusted odds ratio [aOR]=1.72 [1.02-2.89]), those 
with more comorbidities (Charlson’s comorbidity score ≥1 vs. 0) (aOR=1.85 [1.09-3.15]) and 
patients who did not receive treatment with (neo) adjuvant chemotherapy (vs. those who 
received chemotherapy) (aOR=1.74 [1.04-2.91]) had higher odds of biochemical non-adherence. 
In addition, symptoms after tamoxifen prescription (median time from prescription to 
assessment = 3.9 [3.0-5.1] months), including musculoskeletal symptoms (aOR=1.58 [1.06-2.37]) 
and severe fatigue (aOR=1.65 [1.07-2.5]) increased the risk of biochemical non-adherence (M5 




Serum assessment  










 Adherent, n (%) 928 (93.8) 104 (55.3) 1032 (87.7) 
Non-adherent, n (%) 61 (6.2)* 84 (44.6) 145 (12.3) 
Total  989 (84.0) 188 (16.0) 1177 
Concordance: 86% (95% CI 84 to 88%)  
Chi-square p-value <.0001  
Cramer V = 0.4293 
*61 patients were adherent by serum assessment but 
declared to be non-adherent: a) 50 due to treatment 
interruptions, b) 8 due to switch to AI for toxicity, c) 3 
due to treatment discontinuation 
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M5 Figure 2 – Multivariate estimates of variables associated with serum-defined adherence. 
BMI – Body mass index; CT – Chemotherapy. Severe Fatigue and insomnia defined as the 
respective subscale EORTC-C30 score> 40.178 Anxiety and Depression defined using Hospital 
Anxiety and Depression Scale.179 
 
Impact of non-adherence at Year 1 post-tamoxifen prescription on survival outcomes  
After a median follow-up of 24.2 months from tamoxifen prescription (IQR 22.8-27.0), 
38 events were registered (M5 Table S3 details distribution of events). The median DDFS follow-
up is balanced between adherence/non-adherence groups defined by serum assessment 
(median 24.3 [IQR 22.8 – 27.5] vs. 24.1 [IQR 21.3 – 25.8] for non-adherence).   
In the PS IPTW, the proportion of patients alive at three years was 95.4% in the adherent cohort 
and 89.5% in the non-adherent cohort (M5 Figure 3-A). In the multivariate IPTW model, non-
adherent patients had a 131% increase in the risk of death or disease recurrence (Hazard ratio 
[HR] = 2.31 [1.05-5.06]) with a 5.9% absolute difference in the risk of a DDFS event at three years. 
The number needed to avoid non-adherence to impact 1 DDFS event at three years was 17.  
Diagnoses of the models performance are fully presented in M5 Supplementary Appendix S2. 
Sensitivity and secondary analyses demonstrated consistent results (M5 Figure 3-B and M5 
Figure S3). M5 Table S4-S7 present full univariable and multivariable models. No difference in 
DDFS or BCFI outcomes was found between self-reported adherence and non-adherence (M5 
Figure S4). 
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M5 Figure 3 – DDFS (distant recurrences and death) according to serum-defined adherence 
status in the propensity score weighted cohort (IPTW; A) and in the non-IPTW cohort (B). Time 
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5.5.7 Discussion 
Non-adherence to adjuvant endocrine therapy for early breast cancer is often under-
recognized partly due to the unavailability of a gold standard method for its detection and 
challenges in incorporating assessments of adherence into routine clinical practice.  
Our study emphasizes that the real-life prevalence of non-adherence to medications is 
still not well-quantified:  health-care providers tend to overestimate to what extent patients 
take their prescribed long-term oral treatments, whereas patients tend to underreport 
treatment discontinuations or interruptions.180 Studies that tried to quantify the prevalence of 
non-adherence have yielded heterogeneous results; mostly reporting on indirect estimations 
obtained using patient self-report and prescription refills.158,159,165 In breast cancer, previous 
studies, based on indirect methods, suggested that non-adherence to adjuvant endocrine 
therapy over 5 years ranges from 25% to more than 40-50%, with this proportion rising over 
time.166–168,181 Only one study measured adherence to endocrine therapy by using an objective 
method based on drug serum assessment, although it did not provide correlations with breast 
cancer outcomes.165 In our study serum assessment was able to identify a worryingly high 
proportion of patients, one in six, who were non-adherent to therapy at only one year after 
treatment prescription. Patient self-reports underestimated rates of non-adherence. Notably, 
55% of patients who were non-adherent by serum assessment would not overtly acknowledge 
non-adherence. 
Furthermore, non-adherence by serum assessment measured as early as Year 1 after 
treatment prescription emerged as marker of poorer outcomes regardless of other main 
prognostic factors, suggesting that risk of recurrence increases as soon as the patients start to 
be non-adherent. Although it is very unusual to see a significant impact on outcomes with such 
short-term follow-up among patients with HR+ breast cancer, prior researches are consistent 
with our findings. Controversial results were reported across different studies, suggesting the 
possibility that inadequate exposure to tamoxifen due to non-adherence may lead to a 
suboptimal concentration of its active metabolites.174,182 Prior retrospective analyses based on 
pharmacy claims data also suggested a negative impact of non-adherence on breast cancer 
outcomes, but used an arbitrary cut-off of 80% medication possession ratio to define adequate 
adherence.183–185 However, pharmacy claims typically cannot be obtained in real-time on an 
individual patient-level, and thus cannot be used to tailor treatment in the clinic.158,166,167 
This study provides important insights on the complexity of non-adherence and on the 
multitude of its contributors.  We found that sicker, non-partnered patients and those with 
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higher symptomatology burden, including more severe fatigue and musculoskeletal symptoms, 
had a higher likelihood of being non-adherent to therapy.  Most of these associations have also 
been observed in other chronic diseases such as HIV, cardiac diseases and diabetes and are 
explained by several differences in social and clinical characteristics across patients. In addition 
to these previously known barriers, patients not having received adjuvant chemotherapy also 
were more likely not to be adherent to tamoxifen in our analysis. We hypothesize that patients 
who did not receive adjuvant chemotherapy are less aware of the health risks related to their 
disease and misconceive the beneficial impact of adjuvant endocrine therapy on breast cancer 
outcomes.   
CANTO offered an unparalleled opportunity to test the performance of therapeutic drug 
monitoring in adjuvant treatment of breast cancer. Nevertheless, we acknowledge some 
limitations. First, we used non-previously validated thresholds of tamoxifen concentration to 
define biochemical non-adherence. However, we employed a conservative approach based on 
previous pharmacological studies171–174 focused on the 3-month steady-state tamoxifen 
concentration, which all our patients should have achieved. In addition, we acknowledge that 
we did not assess the most active tamoxifen metabolites, but as mentioned the data on the 
impact of these metabolites on the outcome are still inconclusive. Second, the self-reported 
assessment of adherence and respective reasons were not based on validated scales, but still 
reflects what is currently done in clinical practice. Although CRNs systematically asked and 
collected the reasons for treatment interruption or discontinuation, a small number of patients 
disclosed this information limiting our ability to capture the complexity of factors affecting 
medication-taking behavior. Third, due to the low number of events and the lack of validation 
cohort, we cannot draw definitive conclusions on the generalizability of the negative impact of 
non-adherence on breast cancer outcomes. Nevertheless, our results are clinically plausible and 
the wide inclusion and exclusion criteria in CANTO call into the external validity of results. 
Fourth, we are aware that it is hard to isolate the true impact of non-adherence to tamoxifen on 
outcomes, because it is part of a multitude of health-related behaviors impacting prognosis.186 
Indeed, due to the observational design, we cannot exclude unmeasured confounding impacting 
our survival analyses. Nevertheless, we employed a PS weighting to relevant known prognostic 
factors aiming to a comprehensive adjustment in our analyses.176,177 Fifth, we cannot exclude 
the impact of awareness of being observed on adherence (Hawthorne effect). Nevertheless, in 
our study the long-term observation, assessment of multiple clinical and biological data and 
evaluation of adherence using indirect and direct methods may minimize this effect.187 Finally, 
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our results may not be generalizable to other populations as we restricted our analysis to the 
French pre-menopausal population with breast cancer.  
This study adds to the understanding of the multifaceted and complex issue of ’non-
adherence’ to chronic medications, suggesting that therapeutic drug monitoring may serve as 
an important tool to identify non-adherence. Our results suggest that the introduction in clinical 
practice of an inexpensive blood test enables to identify non-adherent patients who are at risk 
of a distant relapse event very early in their adjuvant treatment trajectory. We could potentially 
avoid one distant relapse event if we helped 17 patients to take medications as prescribed.  The 
impact of interventions to optimize adherence on a population level thus could be very large. 
Targeted interventions managing adherence to adjuvant endocrine therapy are needed and 
have the potential to improve breast cancer outcomes.  
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5.5.9 Supplementary material 
M5 SUPPLEMENTARY APPENDIX S1 
M5 S1.1 Tamoxifen metabolism and pharmacokinetics considerations 
Tamoxifen has a steady-state concentration that is reached in ≈ 4 weeks and an 
elimination half-life of 7 days.188 The long half-life of tamoxifen makes it detectable for up to 6 
weeks after treatment discontinuation.189–191 Serum concentration of tamoxifen is constant over 
its steady-state phase, and therefore tamoxifen concentration evaluation is not required to be 
performed at specific time points from tamoxifen intake.192 In addition, tamoxifen has a different 
molecular mass from tamoxifen metabolites, thus its co-elution with other metabolites is not 
possible;193 furthermore, standard chromatographic separation allows avoiding co-elution of 
tamoxifen with any other compounds. 
Tamoxifen serum concentration does not vary by CYP2D6 polymorphisms unlike its main 
metabolite, endoxifen.193–195 Drug-drug interactions with CYP2D6 inhibitors (e.g. paroxetine or 
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fluoxetine) do not influence tamoxifen levels. There are very few drugs, such as rifampicin, 
aminogluthetimide, curcumin and piperine, which may decrease tamoxifen serum levels.196–198 
CANTO collects extensive data on concomitant medications. In our study, none of women with 
tamoxifen serum levels <60 ng/ml was exposed to any of the drugs mentioned above that may 
interfere with tamoxifen serum levels. Finally, although some studies showed that tamoxifen 
serum levels may increase with increasing weight, in our cohort we did not find a significant 
correlation between tamoxifen serum levels and patients’ weight.172,199 
 
M5 S1.2 Definition of biochemical non-adherence 
The cut-off to define non-adherence was pre-specified on the basis of previous 
pharmacological data that reported an average three-month steady-state tamoxifen 
concentration around 120 ng/ml, ranging from 70 to 180 ng/ml, in patients receiving 20 mg of 
tamoxifen per day.172–174 Since all our patients were prescribed 20 mg of tamoxifen for more 
than three months (median time from tamoxifen prescription to measurement of non-
adherence was 16.2 months, IQR 15.1 - 17.8), we used a putative threshold of 60 ng/ml for 
defining biochemical non-adherence to tamoxifen. Moreover, a prior study evaluating 
pharmacokinetics and pharmacogenetics of tamoxifen in a large cohort of premenopausal 
patients receiving adjuvant tamoxifen used ≤150 nM (corresponding to ≤60 ng/ml) as cut-off for 
identifying poorly adherent patients.174 
We also investigated a possible linear relationship between tamoxifen serum 
concentration and survival outcomes. To do this, we applied several methods. First, we modeled 
tamoxifen concentration using spline functions. We fitted the spline modeling function including 
3 knots and 4 degrees of freedom (natural splines as per Harrell et al, 2001). Although the 
graphical representation of hazard ratio value according to tamoxifen concentration may 
suggest a linear relationship between tamoxifen concentration and survival outcomes, the wide 
confidence intervals around these estimates do not allow us to confirm that such a relationship 
exists. In addition, we modeled the association between tamoxifen serum levels as a continuous 
variable and its association with cancer outcomes, assuming a linear relation between the two 
variables, which was not statistically significant. Thus, even if a linear relationship cannot be 
excluded, the available data do not allow to definitely conclude on this question. Full results are 
provided in the supplementary material. 
In summary, the current data do not allow to exclude or confirm a linear relationship 
between tamoxifen serum concentration and survival outcomes. In contrast, the pre-defined 
cut-off of 60 ng/ml provides a clinically actionable threshold of non-adherence, identifying those 
at risk of poorer outcomes.   
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M5 S1.1 A - Multivariate Cox proportional hazards model for distant disease-free survival (A) 
and breast cancer free interval (B) using as explanatory variable a restricted cubic spline of 







                                                                                  
1.n_pts_volume_2     .9900578    1.01787    -0.01   0.992     .1319919    7.426324
   2.n_chemo_tp1     .4008416   .3355396    -1.09   0.275     .0777038    2.067774
    Mastectomie      1.352698   .5341309     0.77   0.444     .6238677    2.932981
       n_surgery  
                  
      STADE III      9.398298   6.014756     3.50   0.000     2.680984    32.94611
       STADE II      1.655869    1.06062     0.79   0.431     .4718601    5.810839
     n_stade_tnm  
                  
            age1     .9305044   .0223773    -3.00   0.003     .8876632    .9754132
  tam_level_rcs2     1.008232   .0053608     1.54   0.123       .99778    1.018794
  tam_level_rcs1     .9922906   .0060834    -1.26   0.207     .9804388    1.004286
                                                                                  
              _t   Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval]
                                                                                  
Log likelihood  =   -196.39029                  Prob > chi2      =      0.0000
                                                LR chi2(8)       =       59.71
Time at risk    =  28161.16963
No. of failures =           34
No. of subjects =        1,056                  Number of obs    =       1,056
Cox regression -- Breslow method for ties
                                                                               
1.n_pts_vol~2     1.289398    1.31199     0.25   0.803     .1754978    9.473326
2.n_chemo_tp1     .9133665   .4674599    -0.18   0.859     .3349663    2.490514
 Mastectomie      1.004011   .3191401     0.01   0.990     .5384817       1.872
    n_surgery  
               
   STADE III      9.833952   5.069485     4.43   0.000     3.580359    27.01031
    STADE II      2.239248   1.076472     1.68   0.094     .8727799    5.745126
  n_stade_tnm  
               
         age1     .9343054   .0193198    -3.29   0.001     .8971964    .9729493
tam_level_r~2     .8471397   .0997095    -1.41   0.159     .6726164    1.066946
tam_level_r~1     1.328378   .2694972     1.40   0.162     .8925499    1.977019
                                                                               
           _t   Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval]
                                                                               
Log likelihood  =   -294.66801                  Prob > chi2      =      0.0000
                                                LR chi2(8)       =       56.17
Time at risk    =  28149.50615
No. of failures =           49
No. of subjects =        1,056                  Number of obs    =       1,056
Cox regression -- Breslow method for ties
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M5 S1.2 A - Hazard ratio derived from multivariate Cox proportional hazards model for distant 
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M5 S1.1 B - Multivariate Cox proportional hazards model for distant disease-free survival using 
as explanatory variable continuous levels of serum tamoxifen (A) Multivariate Cox proportional 
hazards model for breast cancer free interval using as explanatory variable continuous levels of 







                                                                               
1.n_pts_vol~2     1.051837   1.079841     0.05   0.961     .1406321    7.867058
2.n_chemo_tp1     .4002277   .3332548    -1.10   0.271     .0782606     2.04678
 Mastectomie      1.308295    .518693     0.68   0.498     .6014981    2.845622
    n_surgery  
               
   STADE III      9.804075   6.264828     3.57   0.000     2.802121    34.30255
    STADE II      1.720393    1.09744     0.85   0.395     .4927711     6.00634
  n_stade_tnm  
               
         age1     .9314806   .0225922    -2.93   0.003     .8882367    .9768299
tamoxifene_~_     1.000716   .0032964     0.22   0.828     .9942757    1.007197
                                                                               
           _t   Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval]
                                                                               
Log likelihood  =   -197.48189                  Prob > chi2      =      0.0000
                                                LR chi2(7)       =       57.52
Time at risk    =  28161.16963
No. of failures =           34
No. of subjects =        1,056                  Number of obs    =       1,056
Cox regression -- Breslow method for ties
                                                                               
1.n_pts_vol~2     1.318079   1.340945     0.27   0.786     .1794624    9.680761
2.n_chemo_tp1     .9043867    .460753    -0.20   0.844      .333194    2.454772
 Mastectomie      .9942492   .3176898    -0.02   0.986      .531512    1.859848
    n_surgery  
               
   STADE III      9.867039     5.0877     4.44   0.000     3.591579    27.10743
    STADE II      2.238047    1.07326     1.68   0.093     .8743266    5.728813
  n_stade_tnm  
               
         age1     .9344741   .0193068    -3.28   0.001     .8973894    .9730913
tamoxifene_~_     .9973065   .0027304    -0.99   0.325     .9919695    1.002672
                                                                               
           _t   Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval]
                                                                               
Log likelihood  =   -295.39307                  Prob > chi2      =      0.0000
                                                LR chi2(7)       =       54.72
Time at risk    =  28149.50615
No. of failures =           49
No. of subjects =        1,056                  Number of obs    =       1,056
Cox regression -- Breslow method for ties
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M5 S1.3 Self-declaration of non-adherence  
Patient’s self-declarations on adherence to tamoxifen were collected by ad hoc clinical 
research nurses using semi-structured interviews including the following questions (translated 
from the French here): a. did you take your endocrine therapy regularly? ; b. did you ever stop to 
taking it ?; c. If yes, for how many days? When? Why? The main variable of interest was patient’s 
reported adherence and non-adherence as a binary variable. Patient’s statements were 
collected as per study CRFs, as follows: a. ongoing hormone therapy yes/no; b. treatment 
interruption: yes/no; duration of treatment interruption (days); c. treatment discontinuation 
date; reasons of treatment discontinuation: toxicity/patient’s refusal/physician’s choice/end of 
treatment/other. A patient would be considered as having self-declared non-adherence if any 
of the following was reported:  no ongoing hormone therapy or treatment interruption yes or 
any duration of treatment interruption reported or treatment discontinuation date preceding 
the Year 1 post-tamoxifen prescription assessment or patient’s refusal/toxicity indicated as 
treatment discontinuation reasons. 
A patient would be considered as adherent by self-declaration if all of the followings 
were reported: ongoing hormone therapy yes and treatment interruption no and duration of 
treatment interruption not reported and treatment discontinuation date not indicated or 
following Year 1 post-tamoxifen assessment and reasons for treatment discontinuation not 
indicated or physician’s choice/end of treatment/other. 
In addition, type of self-declared non-Adherence was also defined including a. tamoxifen 
suboptimal implementation (any voluntary or involuntary missed doses or treatment pauses 
followed by restarts) and b. tamoxifen early discontinuation (tamoxifen cessation or switch to 
aromatase-inhibitors because of tamoxifen-related side effects or patient’s decision). 
 
M5 S1.4 Impact of concomitant medications on serum-assessed and self-declared non-adherence 
Tamoxifen serum concentration does not vary by CYP2D6 polymorphisms unlike its main 
metabolite, endoxifen.193–195 Drug-drug interactions with CYP2D6 inhibitors (e.g. paroxetine or 
fluoxetine) do not influence tamoxifen levels. Particularly in our study, we did not find any 
statistical significant correlation between exposition to Selective Serotonin Reuptake Inhibitors 
(SSRIs)/Serotonin–norepinephrine reuptake inhibitors (SNRIs) and serum-assessed non-
adherence (p = 0.3401). Among the 167 patients who declared to be taking SSRIs/SNRIs at the 
same time as tamoxifen, serum concentrations of tamoxifen at Year 1 had a median of 102 ng/ml 
(interquartile range:  72-132 ng/ml). In contrast, for the patients not taking SSRIs/SNRIs, serum 
concentrations of tamoxifen at Year 1 had a median of 113 ng/ml (interquartile range: 82-147 
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ng/ml). Despite minimal differences between groups, the median values in both groups were 
above the pre-specified biochemical non adherent cut-off used in this study (60 ng/ml).  There 
are very few drugs, such as rifampicin, aminogluthetimide, curcumin and piperine, which may 
decrease tamoxifen serum levels.196–198 CANTO collects extensive data on concomitant 
medications. In our study, none of women with tamoxifen serum levels <60 ng/ml was exposed 
to any of the drugs mentioned above that may interfere with tamoxifen serum levels.  Of note 
four patients with tamoxifen serum levels ≥60 ng/ml were exposed to curcumin (range of 
tamoxifen serum dose among these patients: 74 – 217 ng/ml).   
M5 SUPPLEMENTARY APPENDIX S2  
M5 S2.1 Propensity score IPTW diagnostics 
Propensity score IPTW diagnostics for serum-defined adherence (A) and self-reported adherence 
(B) 
M5 S2.1 A - PS distribution, overall (A) and in adherent and non-adherent patients (B) 
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M5 S2.1 B - Descriptive statistics on balance between adherent and non-adherent patients for 
variables included in the propensity score: A) in graphical format and B) in table format. 
“Unmatched” refers to non-adjusted cohort and “matched” to IPTW cohort. 
A       B 
  
 
M5 S2.1 C - PS distribution, overall (A) and in adherent and non-adherent patients (B) 




* if B>25%, R outside [0.5; 2]
                                                                                   
 Matched     0.002      2.21    0.819      5.6       6.4      11.7    1.13      0
 Unmatched   0.003      3.13    0.679      6.7       7.6      13.9    1.14      0
                                                                                   
 Sample      Ps R2   LR chi2   p>chi2   MeanBias   MedBias      B      R     %Var
                                                                                   
* if variance ratio outside [0.75; 1.33] for U and [0.75; 1.33] for M
                                                                                        
                                                                              
                       M    .97872   .97869      0.0    15.8     0.00  0.997       .
n_pts_volume_2         U    .97872   .97877     -0.0            -0.00  0.997       .
                                                                              
                       M    1.3138   1.3299     -3.4    18.8    -0.43  0.666    0.98
n_surgery              U    1.3138   1.3337     -4.2            -0.53  0.596    0.97
                                                                              
                       M    1.5904   1.6454    -11.4    16.4    -1.44  0.151    1.06
n_chemo_tp             U    1.5904   1.6562    -13.6            -1.73  0.084    1.08
                                                                              
                       M    1.6383   1.6856     -7.0    15.6    -0.87  0.383    0.93
n_stade_tnm            U    1.6383   1.6943     -8.3            -1.03  0.304    0.91
                                                                              
                       M    44.979   44.595      6.4    15.9     0.82  0.411    1.17
age1                   U    44.979   44.523      7.6             0.98  0.330    1.17
                                                                                        
Variable          Matched   Treated Control    %bias  |bias|      t    p>|t|    V(C)
                Unmatched         Mean               %reduct       t-test       V(T)/
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M5 S2.1 D - Descriptive statistics on balance between adherent and non-adherent patients for 
variables included in the propensity score: A) in graphical format and B) in table format. 
“Unmatched” refers to non-adjusted cohort and “matched” to IPTW cohort. 
A       B 
  
 
Model fitness diagnostics 
M5 S2.2 A - Model fitness for distant disease-free survival when considering multivariable 
models with clinical variables (A), clinical variables plus adherence (B). Frame (C) further details 





                                                                                
n_pts_volume_2     1.306706   .4558496     0.77   0.443     .6595272    2.588946
     n_surgery     1.303793   .5165844     0.67   0.503     .5997196     2.83445
    n_chemo_tp     2.529734   2.106609     1.11   0.265     .4945907     12.9391
                
    STADE III      9.893208   6.326458     3.58   0.000     2.824979    34.64648
     STADE II      1.718308   1.097648     0.85   0.397     .4913112    6.009596
   n_stade_tnm  
                
          age1     .9342952    .022378    -2.84   0.005     .8914487    .9792011
                                                                                
            _t   Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval]
                                                                                
Log likelihood  =    -197.2149                  Prob > chi2      =      0.0000
                                                LR chi2(6)       =       58.06
Time at risk    =  28161.16963
No. of failures =           34
No. of subjects =        1,056                  Number of obs    =       1,056
* if B>25%, R outside [0.5; 2]
                                                                                   
 Matched     0.011      9.23    0.100     11.2      13.2      27.3*   0.91      0
 Unmatched   0.014     11.98    0.035     12.8      15.0      31.0*   0.91      0
                                                                                   
 Sample      Ps R2   LR chi2   p>chi2   MeanBias   MedBias      B      R     %Var
                                                                                   
* if variance ratio outside [0.72; 1.39] for U and [0.72; 1.39] for M
                                                                                        
                                                                              
                       M    .98621    .9787      5.6    11.6     0.60  0.550       .
n_pts_volume_2         U    .98621   .97771      6.4             0.66  0.507       .
                                                                              
                       M    1.2483     1.33    -18.0    12.9    -1.97  0.049    0.85
n_surgery              U    1.2483   1.3421    -20.6            -2.25  0.025    0.83
                                                                              
                       M    1.5655   1.6454    -16.4    12.7    -1.87  0.062    1.08
n_chemo_tp             U    1.5655    1.657    -18.8            -2.16  0.031    1.10
                                                                              
                       M    1.6667   1.6855     -2.8    11.6    -0.31  0.758    0.98
n_stade_tnm            U    1.6667    1.688     -3.1            -0.35  0.727    0.98
                                                                              
                       M    45.372   44.596     13.2    12.4     1.50  0.135    1.04
age1                   U    45.372   44.486     15.0             1.70  0.089    1.03
                                                                                        
Variable          Matched   Treated Control    %bias  |bias|      t    p>|t|    V(C)
                Unmatched         Mean               %reduct       t-test       V(T)/
                                                                                        







M5 S2.2 B - Model fitness for breast cancer free interval when considering multivariable models 
with clinical variables (A), clinical variables plus adherence (B). Frame (C) further details 





                                                                                    
    n_pts_volume_2      1.25469   .4413376     0.65   0.519     .6296889    2.500039
         n_surgery     1.356864   .5342893     0.78   0.438     .6271345    2.935703
        n_chemo_tp     2.627443   2.197425     1.16   0.248     .5100857    13.53392
                    
        STADE III      9.863814   6.307697     3.58   0.000     2.816565    34.54379
         STADE II      1.677311   1.075913     0.81   0.420        .4771    5.896821
       n_stade_tnm  
                    
              age1     .9381248   .0221169    -2.71   0.007     .8957628    .9824902
n_tamoxifen_adhe~m     2.294149   .9420511     2.02   0.043     1.025866    5.130412
                                                                                    
                _t   Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval]
                                                                                    
Log likelihood  =   -195.45482                  Prob > chi2      =      0.0000
                                                LR chi2(7)       =       61.58
Time at risk    =  28161.16963
No. of failures =           34
No. of subjects =        1,056                  Number of obs    =       1,056
(Assumption: A nested in B)                           Prob > chi2 =    0.0606
Likelihood-ratio test                                 LR chi2(1)  =      3.52
                                                                               
1.n_pts_vol~2     1.344159   1.368046     0.29   0.771     .1828615    9.880501
2.n_chemo_tp1     .9217388   .4681993    -0.16   0.873     .3405949    2.494466
 Mastectomie      .9836253   .3158226    -0.05   0.959     .5242347    1.845583
    n_surgery  
               
   STADE III      9.845698   5.079033     4.43   0.000     3.582143    27.06139
    STADE II      2.244595   1.074074     1.69   0.091     .8786677    5.733914
  n_stade_tnm  
               
         age1     .9321385   .0192868    -3.40   0.001     .8950932     .970717
                                                                               
           _t   Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval]
                                                                               
Log likelihood  =   -295.87847                  Prob > chi2      =      0.0000
                                                LR chi2(6)       =       53.74
Time at risk    =  28149.50615
No. of failures =           49
No. of subjects =        1,056                  Number of obs    =       1,056







M5 SUPPLEMENTARY FIGURES   
M5 Figure S1 – Distribution of tamoxifen concentration in the overall cohort (A) and according 




                                                                               
1.n_pts_vol~2     1.202608   1.224043     0.18   0.856     .1635879    8.840911
2.n_chemo_tp1     .8930007   .4566803    -0.22   0.825     .3277537    2.433078
 Mastectomie      1.011401   .3224111     0.04   0.972     .5414768     1.88915
    n_surgery  
               
   STADE III      9.902269   5.121913     4.43   0.000     3.592971    27.29076
    STADE II      2.208698    1.06318     1.65   0.100     .8598087     5.67376
  n_stade_tnm  
               
         age1     .9346217   .0188453    -3.35   0.001      .898406    .9722973
n_tamoxifen~m      2.36386   .7929667     2.56   0.010     1.224849    4.562059
                                                                               
           _t   Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval]
                                                                               
Log likelihood  =   -293.05813                  Prob > chi2      =      0.0000
                                                LR chi2(7)       =       59.39
Time at risk    =  28149.50615
No. of failures =           49
No. of subjects =        1,056                  Number of obs    =       1,056
(Assumption: A nested in B)                           Prob > chi2 =    0.0175
Likelihood-ratio test                                 LR chi2(1)  =      5.64





M5 Figure S2 – Multivariate estimates of variables associated with self-reported adherence. BMI 
– Body mass index; CT – Chemotherapy. Severe Fatigue and insomnia defined as the respective 
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M5 Figure S3 – Sensitivity analysis of DDFS (distant recurrences and death) according to serum-
defined adherence status using an extended list of variables in the propensity score weighting 
cohort (IPTW). Time 0 defines time of the post-tamoxifen prescription visit and date of serum 
assessment of tamoxifen. 
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M5 Figure S4– DDFS (distant recurrences and death) according to self-reported adherence 
status in the propensity score weighted cohort (IPTW; A) and in the non-IPTW cohort (B). Time 
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M5 SUPPLEMENTARY TABLES 
M5 Table S1 – Demographic, social, clinical and pathological characteristics at baseline and 
treatment details within participants and premenopausal non-participants (patients without 




Number % Number % 
Total number  1177 79.5 303 20.5 NA 
Age 
≤35 
>35 to ≤40 
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M5 Table S2 – Description of tamoxifen serum concentration according to method to assess 
adherence. *lower tamoxifen quantification limit 
Serum concentration of 
tamoxifen (ng/ml) 
Serum defined Self-reported defined 
Adherent Non-adherent Adherent Non-adherent 
Median (IQR) 
Min. – Max. 
119 (96 – 152) 
60 – 298 
6 (6 – 38) 
6 – 60 
115 (88 - 148) 
6 – 298 
10 (6 - 104) 
6 - 272 
< 60, n (%) 
< 6*, n (%) 
6-60, n (%)  
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M5 Table S3 – Descriptive evaluation of survival data (with censor date on 31-05-2018) 
 Overall cohort IPTW weighted cohort 
 Adherent Non-adherent Adherent Non-adherent 
Serum-defined adherence 
Observations, n (%) 896 (84.8) 161 (15.2)   

























Year of enrollment 
Median (IQR) 
Min. – Max. 
 
2013 (2013 - 2014) 
2012 - 2015 
 
2013 (2013 - 2014) 
2012 - 2014 
  
DDFS follow-up, from Year 1 visit 
Median (IQR) 
95% CI 
Min. – Max. 
 
24.3 (22.8 – 27.5) 
24.1 – 24.4 
0.2 – 52.9 
 
24.1 (21.4 – 25.8) 
23.9 – 24.4 
1.1 – 53.1 
  
DDFS follow-up, from baseline 
Median (IQR) 
95% CI 
Min. – Max. 
 
47.6 (44.0 – 51.7) 
47.3 – 48.0 
16.8 – 72.5 
 
46.1 (41.0 – 49.0) 
45.1 – 47.1 
15.7 – 73.4 
  
DDFS, median (IQR) NR (NR - NR) NR (NR - NR) NR (NR - NR) NR (NR - NR) 
DDFS point estimates, % (95% CI) 
1 year post Year 1 visit 
2 years post Year 1 visit 
3 years post Year 1 visit 
4 years post Year 1 visit 
5 years post Year 1 visit 
 
98.8 (97.8 – 99.3) 
97.6 (96.3 – 98.4) 
95.3 (92.4 – 97.1) 
95.3 (92.4 – 97.1) 
NR 
 
98.7 (95.1 – 99.7) 
95.2 (90.2 – 97.7) 
92.1 (81.3 – 96.7) 














BCFI, median (IQR) NR (NR - NR) NR (NR - NR) NR (NR - NR) NR (NR - NR) 
BCFI point estimates, % (95% CI) 
1 year post Year 1 visit 
2 years post Year 1 visit 
3 years post Year 1 visit 
4 years post Year 1 visit 
5 years post Year 1 visit 
 
98.7 (97.6 – 99.2) 
96.7 (95.3 – 97.7) 
93.2 (89.9 – 95.5) 
92.7 (89.1 – 95.0) 
NR 
 
97.5 (93.4 – 99.1) 
93.3 (87.8 – 96.3) 
87.3 (75.2 – 93.8) 















Observations, n (%) 931 (88.1) 126 (11.9)   

























Year of enrollment 
Median (IQR) 
Min. – Max. 
 
2013 (2013 - 2014) 
2012 - 2015 
 
2013 (2013 - 2014) 
2012 - 2014 
  
DDFS follow-up, from Year 1 visit 
Median (IQR) 
95% CI 
Min. – Max. 
 
24.2 (22.7 – 26.9) 
24.1 – 24.4 
0.2 – 52.9 
 
24.4 (23.0 – 28.1) 
24.0 – 24.9 
1.1 – 53.1 
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DDFS, median (IQR) NR (NR - NR) NR (NR - NR) NR (NR - NR) NR (NR - NR) 
DDFS point estimates, % (95% CI) 
1 year post Year 1 visit 
2 years post Year 1 visit 
3 years post Year 1 visit 
4 years post Year 1 visit 
5 years post Year 1 visit 
 
98.7 (97.7 – 99.3) 
97.1 (95.7 – 98.0) 
94.8 (91.9 – 96.6) 
94.8 (91.9 – 96.6) 
NR 
 
99.2 (94.4 – 99.9) 
98.4 (93.6 – 99.6) 
95.4 (83.1 – 98.8) 














BCFI, median (IQR) NR (NR - NR) NR (NR - NR) NR (NR - NR) NR (NR - NR) 
BCFI point estimates, % (95% CI) 
1 year post Year 1 visit 
2 years post Year 1 visit 
3 years post Year 1 visit 
4 years post Year 1 visit 
5 years post Year 1 visit 
 
98.5 (97.5 – 99.1) 
96.2 (94.7 – 97.3) 
92.2 (88.7 – 94.6) 
91.6 (87.9 – 94.2) 
NR 
 
98.4 (93.8 – 99.6) 
96.7 (91.5 – 98.8) 
93.8 (83.0 – 97.8) 














1Numbers add to more than 100% because patients can have more than one type of recurrence. 
CI – confidence interval; DDFS – distant disease-free survival; IPTW – inverse-probability treatment 
weighting; IQR – interquartile range; NR – not reached. 
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M5 Table S4 – Univariate and multivariate association with DDFS (Cox proportional hazards model). Variable selection for multivariate analysis was based on 
prior information of variables associated with cancer survival outcomes. Number of variables used in the multivariate model was limited by the number of 
DDFS events. 
 Univariate association Multivariate association, serum-
defined adherence 
Multivariate association, self-reported 
adherence 
HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value 
Age at diagnosis, for every 
1-year increase 
0.91 (0.87 – 0.95) <0.001 0.94 (0.89 – 0.97) 0.005 0.93 (0.88 – 0.98) 0.003 
Age at diagnosis 
≤35 
>35 to ≤40 




0.19 (0.05 – 0.70) 
0.25 (0.11 – 0.55) 



















    






0.92 (0.12 – 6.92) 
(reference) 
1.45 (0.62 – 3.39) 










Invasive carcinoma, NST 





0.46 (0.11 – 1.94) 
2.28 (0.54 – 9.59) 
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2.90 (0.91 – 9.28) 







1.68 (0.48 – 5.89) 







1.73 (0.50 – 6.03) 





















































    





























    



























1.88 (0.85 – 4.15) 0.120 2.34 (1.05 – 5.23) 0.038   
Tamoxifen adherence, self-
reported 
0.71 (0.21 – 2.33) 0.575   0.69 (0.20 – 2.32) 0.547 
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M5 Table S5 – Multivariate association with DDFS (Cox proportional hazards model, PS weighted cohort). Variable selection for multivariate analysis was 
based on prior information of variables associated with cancer survival outcomes. Number of variables used in the multivariate model was limited by the 
number of DDFS events. 
 Multivariate association, serum-
defined adherence 
Multivariate association, self-reported 
adherence 
HR (95% CI) p-value HR (95% CI) p-value 
Age at diagnosis, for every 
1-year increase 
0.94 (0.90 – 0.98) 0.003 0.93 (0.89 – 0.98) 0.006 






1.67 (0.44 – 6.41) 







1.80 (0.47 – 6.92) 





















































2.31 (1.06 – 5.06) 0.036   
Tamoxifen adherence, self-
reported 
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M5 Table S6 – Univariate and multivariate association with breast cancer free interval (Cox proportional hazards model). Variable selection for multivariate 
analysis was based on prior information of variables associated with cancer survival outcomes. Number of variables used in the multivariate model was 
limited by the number of DFS excluding second primaries events. 
 Univariate association Multivariate association, serum-
defined adherence 
Multivariate association, self-reported 
adherence 
HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value 
Age at diagnosis, for every 
1-year increase 
0.92 (0.88 – 0.96) <0.001 0.93 (0.90 – 0.97) 0.001 0.93 (0.89 – 0.97) 0.001 
Age at diagnosis 
≤35 
>35 to ≤40 




0.29 (0.11 – 0.76) 
0.25 (0.13 – 0.50) 



















    






1.75 (0.53 – 5.79) 
(reference) 
1.16 (0.56 – 2.42) 






    
Histology 
Invasive carcinoma, NST 





0.31 (0.08 – 1.30) 
1.61 (0.39 – 6.69) 













1.97 (0.58 – 6.69) 
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2.70 (1.17 – 6.22) 







2.21 (0.86 – 5.67) 







2.25 (0.88 – 5.74) 




















































    



























    



























2.02 (1.05 – 3.89) 0.034 2.36 (1.22 – 4.56) 0.010   
Tamoxifen adherence, self-
reported 
0.83 (0.33 – 2.10) 0.696   0.82 (0.32 – 2.10) 0.686 
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M5 Table S7 – Multivariate association with breast cancer free interval (Cox proportional hazards model, PS weighted cohort). Variable selection for 
multivariate analysis was based on prior information of variables associated with cancer survival outcomes. Number of variables used in the multivariate 
model was limited by the number of DFS excluding second primaries events. 
 Multivariate association, serum-
defined adherence 
Multivariate association, self-reported 
adherence 
HR (95% CI) p-value HR (95% CI) p-value 
Age at diagnosis, for every 
1-year increase 
0.94 (0.90 – 0.97) 0.001 0.93 (0.89 – 0.97) 0.001 






2.17 (0.79 – 5.96) 







2.19 (0.81 – 5.97) 
















0.99 (0.53 – 1.87) 
 
0.985 

































2.38 (1.27 – 4.47) 0.007   
Tamoxifen adherence, self-
reported 
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6. Discussion and conclusions 
Throughout the body of work of this thesis and using data derived from multiple sources, 
we found that adjuvant endocrine therapy in the form of AI for postmenopausal women and 
OFS for pre-menopausal women were successfully introduced in clinical practice and improved 
the overall survival of patients with hormone-receptor positive early breast cancer. We also 
showed that adjuvant systemic treatments for breast cancer modulate QoL, with endocrine 
therapy being a relevant driver of deteriorated overall QoL and of specific QoL sub-domains, 
especially in postmenopausal women. Finally, we uncover that as shortly as 1 year after 
endocrine therapy initiation, 1 in 6 women are not taking adjuvant tamoxifen. Taking our work 
as an all, we provide new pieces of information to support an informed conversation between 
patients and physicians, as well as we uncover QoL dimensions that are specifically harmed by 
adjuvant systemic treatment and that can benefit from tailored interventions to improve QoL, 
adherence to treatment and ultimately cancer outcomes. 
 
6.1 Real-world evidence shows the uptake in clinical practice and supports the 
effectiveness of AI and ovarian function suppression for the adjuvant treatment of breast 
cancer 
Over the last 2 decades, the landscape of adjuvant endocrine treatment of hormone-
receptor positive breast cancer evolved from tamoxifen to a wider set of options. For 
postmenopausal women, starting in 2005, international guidelines included AI as an alternative 
to tamoxifen, either replacing tamoxifen or to be used in sequence.85 For premenopausal 
women, starting in 2015, international guidelines recommended the use of ovarian suppression 
for patients at higher risk of recurrence.84 These two examples were an opportunity to analyze 
both the uptake of new evidence into clinical practice and the adherence to international 
guidelines in Portuguese centers. In two of our studies, we summarized the introduction of AI 
and OFS into clinical practice in a group medium and large size hospitals in Lisbon region, 
Portugal.200,201 In the first study of postmenopausal women, we recorded a fast uptake of 
adjuvant AI with approximately 40% of patients receiving this treatment in 2006 of which in 
approximately 60% of the cases as a switch strategy (tamoxifen followed by an AI or an AI 
followed by tamoxifen).200 This pattern remained mostly stable through the period of analysis 
ranging from 2006 and 2008. However, at the center level, we recorded a more dynamic pattern, 
with centers quickly introducing AIs, e.g. center A that in 2006 was using AI in more than 60% of 
patients and in 2008 in close to 80%, and centers slowly introducing this treatment, e.g. center 
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D that in 2006 and 2007 only prescribed tamoxifen, but in 2008 prescribed AIs to more than 65% 
of patients thus becoming in that year the second center with the highest proportion of patients 
receiving AIs. While patient preferences and disease characteristics might partially explain these 
differences, center and physician factors might also contribute to these differences. In line with 
this observation, center of care was independently associated with the use of AIs in a 
multivariate model. In the second study of premenopausal women, we identified the use of 
adjuvant OFS at least since 2006 and an acceleration in the uptake of this drug after 2014 (from 
every 1 in 7 to every 1 in 4 patients).201 This was an interesting finding, given the lack of 
consistent evidence to support the use of OFS before 2014, but to a certain extent aligned with 
the equipoise on the topic that prompted the pursuit of the seminal clinical trials in the field, as 
the SOFT, TEXT and ASTTRA trials. We could not dissect the use of OFS by center in this study. 
Taken together, while overall practice patterns seem to be aligned with the available evidence 
and international recommendations, we identified different center-specific patterns that are at 
least in part explained by local preferences. In addition, there is, at times, some clinical practices 
that occur despite the unavailability of definitive evidence to support its use, as highlighted by 
the use of adjuvant OFS in premenopausal women before 2014. Translation to practice of 
evidence derived from clinical trials and from clinical guidelines is known to be frequently sub-
optimal.91 While in some cases there might exist barriers to the introduction of new practices, 
there are others in which treatments are used in the absence of robust evidence supporting its 
use. As clinicians we need to be vigilant and seek a balanced use of treatment options and thus 
avoid under and overtreatment as well as the use of unproven interventions. The identification 
of cultural and administrative barriers to optimal care (both towards under and overtreatment) 
and the design of strategies to overcome such barriers should be an institutional priority in each 
center. Moreover, academic centers should monitor treatment heterogeneities and use them 
as opportunities to run definitive clinical trials when such differences are driven by treatment 
efficacy equipoise. 
Beyond the introduction of new treatment practices, the most appropriate duration of 
treatment is also a contemporaneous theme in the adjuvant endocrine therapy arena.202 
Although extended adjuvant tamoxifen for up to 10 years (compared to 5 years) has shown to 
improve long-term overall survival, AI for up to approximately 7 or 10 years has not yet shown 
such robust improvement in outcomes.67 Most studies evaluating adjuvant OFS administered 
this treatment for 2 years, but more recent studies administered OFS for 5 years (partially due 
to the objective of testing the efficacy of AIs in premenopausal women).52,121 Our analyses 
showed that most patients received adjuvant tamoxifen and AIs for 5 years and adjuvant OFS 
Page 154 of 175 
 
for 2 years. These practices reflect the available evidence at the time of treatment prescription. 
Updated analysis of the real-world treatment patters might help dissect the use and 
effectiveness of extended adjuvant endocrine treatment.  
In the highlighted studies, both adjuvant AIs (when compared to tamoxifen) and OFS 
(when compared to no OFS) improved cancer outcomes as measured by overall survival. In both 
cases, to our knowledge, this is the first real-world evidence supporting the use of AI (vs. 
tamoxifen) and OFS (vs. no OFS) in routine clinical practice. In addition, while previous studies 
point to an interaction between histologic type and efficacy of AI/tamoxifen, in specific with a 
relative resistance of invasive lobular carcinomas to tamoxifen and thus a preferred sensitivity 
to AIs103, we did not identify this signal when looking to specific subtypes of lobular breast 
carcinomas, as pure and mixed lobular carcinomas.203 While a growing body of evidence is 
identifying relevant biologic differences between lobular and breast carcinomas of no special 
type, it may be that what separates the lobular family of tumors either was not enough to 
produce a difference in efficacy that our study was able to discern (power limitation) or may 
alternatively support a lack of efficacy difference inside the lobular family of tumors. In both 
studies we found a small absolute impact of AIs (over tamoxifen) and OFS (over no OFS) in the 
overall cohort: at 5 years, 5.4% for the comparison between AI-tamoxifen and 2.1% for the 
comparison OFS-no OFS. This absolute difference is however in line with the magnitude of effect 
detected in clinical trials and in other advances in the endocrine therapy arena. At the same 
time, this piece of evidence is reassuring of the positive impact of both AIs (for postmenopausal 
women) and OFS (for premenopausal women) in terms of saving lives of patients. 
Nevertheless, tamoxifen, AI and ovarian function suppression are associated with 
specific tolerability and safety issues. On the one hand tamoxifen increases the risk for 
thromboembolic events and endometrial cancer (the later in postmenopausal women), while 
on the other hand AIs increase the risk for osteoporosis and bone fractures, but also  arthralgias 
and other musculoskeletal disorders.58 In the case of OFS, it is associated with more frequent 
hot flashes, loss of sexual interest and sleep disturbance, but also vaginal dryness.66 Considering 
the profile of adverse events and the overall absolute small improvements in disease recurrence 
and overall survival, current guidelines recommend the use of AIs in postmenopausal women 
with higher risk of recurrence, as with positive lymph nodes, higher histologic grade or high ki67 
and after discussing the tolerability issues of each drug with patients.14 Another strategy is to 
expose patients to AIs during a period of the overall treatment plan following a switch approach. 
In fact, a remarkable conclusion from the EBCTCG metanalysis comparing tamoxifen to AIs (in 
monotherapy or sequence) is that the overall survival impact of an AI-only strategy vs. a 
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tamoxifen – AI switch strategy is very similar (RR 0.96, 95% CI 0.86 – 1.07; 7 years rate of death 
from any cause 14.5 vs. 13.6% for switch vs. AI-only treatment).39 Likewise, guidelines also 
recommend the use of OFS not in all but in a subset of premenopausal women, in specific those 
≤35 years old and those who classically would warrant treatment with chemotherapy (node 
positive and/or high grade) that remained premenopausal.14 To a certain extent this approach 
challenges the observation that both adjuvant AIs and OFS are effective (relative benefit) in 
patients with hormone receptor-positive tumors irrespective of e.g. histologic grade, stage or 
HER2 status (in SOFT trial a significant interaction favoring OFS + tamoxifen vs. tamoxifen in 
terms of DFS was found, but there were very small numbers of HER2 positive tumors and such 
an interaction was not found for the OFS + AI vs. tamoxifen).52,204 However, in both cases the 
exercise is to select patients at higher absolute risk of recurrence for treatment with AIs (in 
monotherapy or in sequence) or OFS and thus obtain the larger absolute gains. In our analyses 
we found that physicians are indeed selecting some subgroups of patients for AIs, as defined by 
higher disease stage, higher tumor histologic grade or tumor HER2 positivity. Similarly, 
physicians are selecting for OFS patients with higher tumor histologic grade, HER2 positivity and 
treatment with (neo)adjuvant chemotherapy. This is reasonable in the continuum of the risk of 
recurrence, as the larger absolute reductions in the risk of recurrence and death will be in felt in 
those patients with larger absolute risks at baseline. To accommodate the absolute risk of 
detrimental cancer outcomes, as well as known QoL differences between treatments and 
patients’ preferences is thus a reasonable route with a considerable room for tailored 
approaches incorporating in postmenopausal women tamoxifen, AI or their sequence for 5 or 
for extended periods of up to 10 years, and in premenopausal women tamoxifen or OFS with 
either tamoxifen or AI, also for periods ranging from 5 to up to 10 years of total adjuvant 
endocrine therapy. 
Despite the consistent improvement of outcomes derived from adjuvant endocrine 
treatment, the risk of recurrence in patients with hormone receptor-positive tumors persists, 
with more than 50% of recurrences occurring after 5 years of diagnosis and some of them 
occurring even 20 years after diagnosis.41 In the metastatic setting new avenues were opened 
with the use of CDK4/6 inhibitors and by targeting the PIK3CA/AKT/mTOR pathway. Future 
improvements in the realm of adjuvant treatment of hormone-receptor positive breast cancers 
might occur by moving these agents to the adjuvant setting. Based on these observations, 
several studies are already testing the role of e.g. CDK4/6 inhibitors and PI3K inhibitors in the 
early disease setting.205,206 Yet, the challenge of avoiding late relapses is still not being addressed 
with these innovations, as most of these interventions are focusing on the intensification of 
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treatment in the first year of adjuvant endocrine therapy. The investment in changing health 
behaviors, as exercise and alcohol consumption, and risk factors, as excess weight, could be 
independent sources of incremental gains coming from non-pharmacological interventions.207–
210 In addition, the evolving field of genomic signatures is showing promising new tools that with 
further validation might be helpful in identifying those patients that might be eligible for 
extended adjuvant endocrine therapy, as is the example of the gene signature breast cancer 
index.211,212 
6.2 Adjuvant endocrine therapy is a relevant driver of QoL deterioration two years after 
diagnosis, a fact that should be considered when planning the optimal care and research 
priorities in the field of adjuvant systemic treatments for breast cancer 
Over the last decades, the optimization of local and systemic treatments allowed for 
most patients with breast cancer to expect long-term survivals. A part of these gains derived 
from incremental improvements of adjuvant systemic treatments, as endocrine therapy in 
patients with hormone receptor-positive tumors, HER2-directed therapy in patients with HER2-
positive tumors and chemotherapy.5 It is widely known that cancer treatments concomitantly 
increase the risk for a range of adverse events and have thus the risk to deteriorate patients 
QoL. As a strategy to balance both efficacy and tolerability, we have observed in recent years a 
trend to deescalate the use of chemotherapy while increasing the use of endocrine therapy. This 
strategy was mostly driven by the aim to reduce short and long-term toxicities of chemotherapy 
and further guided by the identification of genomically-defined groups of patients that could be 
spared chemotherapy. However, there is only scarce high-quality data on the long-term QoL 
impact of chemotherapy and the differential impact of chemotherapy and endocrine therapy, 
especially using well validated metrics and comparing contemporaneous regimens, thus we took 
advantage of CANTO study to extensively study QoL 2 years after diagnosis of breast cancer.213  
Overall, 2 years after diagnosis and compared to before no treatment initiation, QoL was 
impacted in several domains and in a composite score accommodating several functions and 
symptoms. Although it is well recognized that local treatments (as surgery and radiotherapy) 
and adjuvant systemic treatments impact patients’ wellbeing, for the systemic part of 
treatments the longitudinal impact was ill defined152–154,214,215, and only more recently did we 
have access to longitudinal descriptions of long-term consequences of systemic treatments, 
namely cognitive, physical and in sexual function.144,145,155,156 Our data extends this knowledge 
by showing that, at diagnosis and thus before any treatment, many patients already report 
symptoms and function impairment and that there is a larger scope of functions and symptoms 
that are deteriorated with multimodal cancer treatments. In specific, most functions deteriorate 
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over time with e.g. poor global health status going from affecting 22.7% at diagnosis to affect 
27.8% 2 years after, poor role function from 9.7 to 17.1%, poor physical function from 9.2 to 
12.6%, poor cognitive function from 22.9 to 38.4%, poor social function from 16.0 to 24.9%, poor 
sexual enjoyment from 29.5 to 38.4% and poor body image from 15.2 to 32.7%. Likewise, most 
symptoms deteriorate over time with e.g. severe pain going from affecting 26.5% at diagnosis 
to affect 51.0% 2 years after, severe dyspnea from 27.2 to 45.2%, severe constipation from 23.3 
to 34.3%, severe systemic therapy side effects from 10.0 to 24.2%, severe breast symptoms from 
13.6 to 23.0%, severe arm symptoms from 19.7 to 37.4% and severe upset by hair loss from 59.2 
to 72.2 (among those reporting hair loss). Although as age progresses certain functions and 
symptoms are expected to deteriorate, the collection of outcomes after an interval of 2 years 
and the substantial changes point to the overall relevant burden of cancer treatments in patients 
QoL. Interestingly, poor emotional function and poor future perspective (but also severe 
appetite loss) improve over time showing a positive psychological impact of treatment on 
patients’ wellbeing.  
Despite the evidence showing that treatment impacts patients’ wellbeing, how different 
classes of systemic treatment impact QoL is not definitively established. A recent substudy of 
the TAILORx trial focusing on the relative contribution of endocrine therapy vs. endocrine 
therapy plus chemotherapy in 3 specific dimensions of QoL (cognitive function, fatigue and 
endocrine symptoms) up to 36 months after treatment initiation added a piece of evidence to 
this question.157 In this study, the chemo-endocrine therapy arm was associated with a short-
term (3-6 months) significant greater cognitive impairment, fatigue and endocrine symptoms 
(during the adjuvant chemotherapy period of time). After this period, despite an absolute lower 
QoL in patients in the chemo-endocrine therapy arm such differences are not significant. In our 
study QoL differed over time by class of systemic therapy. Looking at the C30 summary score 
(composite score of several functions and symptoms) and compared to those not receiving 
chemotherapy, patients receiving chemotherapy have their QoL correct over time. In contrast, 
the impact of endocrine therapy was a relevant driver of overall persistent QoL deterioration 2 
years after diagnosis. Of note, both endocrine therapy and chemotherapy influenced specific 
functions and symptoms differently. Endocrine therapy negatively influenced role and social 
functions, but also pain, insomnia, systemic therapy side effects and breast symptoms. 
Moreover, it attenuated the recovery of emotional function and future perspectives, two 
domains that showed to correct over time in the overall cohort and capturing psychological 
dimensions of the patients’ wellbeing. Chemotherapy negatively impacted physical and 
cognitive function, but also financial difficulties, body image and breast symptoms. With the 
introduction of extended adjuvant endocrine therapy for up to 10 years, survivorship clinics 
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should look to these patients as a group at considerable risk for QoL deterioration and 
downstream risks, as treatment non-adherence. 
Moreover, our results further reveal that the effect of endocrine therapy is especially 
detrimental in postmenopausal women. Of note, in our study of adjuvant tamoxifen compared 
to adjuvant AI in postmenopausal women, when looking at patients receiving a switch strategy 
(tamoxifen – AI or AI – tamoxifen), of the 5% of patients that started with an AI (95% of patients 
started with tamoxifen) it was striking to observe that the median time on an AI was of 1.3 years 
and that 25% of these patients took an AI for less than 2 months.200 This is not a typical switch 
strategy and may inform about tolerability challenges that some patients face with AI. 
Conversely, in those patients starting with tamoxifen median time on first agent was of 2.7 years. 
With the recent intensification of adjuvant treatments in premenopausal women using OFS (in 
our study in around 25% after 2014201) and the growing use of AIs (in our study in around 30% 
of those receiving OFS201) we need to be vigilant on the QoL implications of such options. 
In our work we identified detrimental QoL signals that merit consideration when 
discussing and planning optimal survivorship care, adjuvant treatment options and when 
designing studies of escalation of endocrine therapy. These data are especially relevant in the 
setting of improving patients’ survival after the diagnosis of breast cancer and longer treatment 
duration, particularly those based on endocrine therapy that, despite improving oncologic 
outcomes, also impose persistent changes in QoL. The interplay between different classes of 
treatment is however complex and future research should deepen the knowledge on the QoL 
impact of the multimodal treatments of breast cancer, namely the interaction between 
locoregional and systemic treatments. With the aim of improving patients’ wellbeing and cancer 
outcomes, tolerability issues are cornerstone, as these are a recognized barrier to treatment 
adherence and ultimately to the overall principle of helping to live longer and better 
lives.186,216,217  
 
6.3 One year after diagnosis 1 in 6 premenopausal women are not adherent to adjuvant 
tamoxifen with disease recurrence implications 
A well-known obstacle to the improvement of cancer outcomes in the setting of oral 
adjuvant treatments is the adherence and persistence to treatment.71 However, the true 
magnitude of the problem is unclear given the intrinsic challenges of studying the field as there 
is no gold standard method to quantify treatment non-adherence.72 In this setting we took 
advantage of the CANTO study to develop a substudy quantifying the prevalence of treatment 
non-adherence to adjuvant tamoxifen using 1) a self-evaluation questionnaire and 2) by directly 
quantifying tamoxifen levels in the blood (serum assessment). A surprising proportion of 16% of 
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patients (1 in 6) was non-adherent 1 year after treatment prescription when measuring 
tamoxifen serum levels. Another relevant observation was that, when using a questionnaire, the 
proportion of patients declaring to be non-adherent was 12.3%, an estimate 23.1% lower than 
that using the serum assessment method and missing 104 patients that stated to be adherent 
but were classified as non-adherent using the serum assessment. While associated, only a 
moderate association between the two methods was found (concordance: 86% [95% CI 84 to 
88%]; Cramer V = 0.429). This finding is especially relevant, because when looking to cancer 
outcomes, while the cohort with serum-defined non-adherence had a higher risk for distant 
recurrence those with self-reported non-adherence had not (non-significant trend). This informs 
about the classification power of the serum assessment method to identify a group of patients 
not only taking tamoxifen in a sub-optimal way, but most importantly at higher risk of recurrence 
and thus in need of tailored interventions to optimize treatment adherence. Moreover, given 
the dichotomous nature of the serum assessment results, it is clinical actionable even when 
quantified as early as 1 year after initiation of adjuvant tamoxifen. Indeed, for every 17 patients 
undergoing interventions able to restore optimal adherence we could avoid one distant 
recurrence. 
In our work we looked for the demographic, social and disease features associated with 
non-adherence to facilitate the identification of a group at higher risk for non-adherence. In this 
setting, patients not living as a couple, more symptomatic (as with severe fatigue and 
musculoskeletal symptoms), with other comorbidities and not treated with adjuvant 
chemotherapy were more likely to be non-adherent to therapy. We have already discussed how 
these features might impact adherence, but social support, poor tolerability, other 
comedications and the perceived risk of recurrence might be in the causal pathway to non-
adherence in these cases.  While helping to select patients for specific tailored supportive 
interventions, in places where serum drug quantification is not readily available, these features 
might further support the development of a clinical score that triages patients at higher clinical 
risk of non-adherence to serum assessment.  
In our study of postmenopausal women receiving adjuvant tamoxifen or AI, while 
median duration of treatment in monotherapy was close to a total of 5 years, the lower 
boundary of the IQR was as low as of 38 months (3.2 years).200 This observation highlights, from 
the prescription side, that in this cohort 25% of the patients completed less than 3.2 years of 
adjuvant treatment. While the reasons for this observation were not possible to retrieve given 
the design of this study it is also a concerning finding. Interestingly, there were no substantial 
differences in the lower boundary of the IQR of the time on adjuvant endocrine treatment 
between tamoxifen and AIs (3.2 years and 3.5 years for tamoxifen and AI, respectively). A similar 
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observation can be seen for patients opting for a switch strategy (tamoxifen – AI or AI – 
tamoxifen). In our study of premenopausal women receiving or not adjuvant OFS the median 
time on OFS was 2.1 years with the lower boundary of the IQR of the time on OFS of 1.7 years.201 
The optimal duration of OFS is not definitely established and evolved over time, with recent 
guidelines recommending 5 years of treatment.14 That said, several clinical trials used a shorter 
duration of 2 years of adjuvant OFS which might explain the findings of our study. Assuming an 
intended duration of treatment of about 2 years, our results show that also with OFS some 
patients struggled to complete the intended duration of treatment. 
 
6.4 Future steps 
Throughout the development and implementation of this body of work the PhD 
candidate developed technical expertise in handling real-world data and dealing with various 
typologies of outcomes research projects. With these tools and the body of work generated, 
several paths of future research and collaboration were opened. 
With a focus on the comparative effectiveness of medical interventions, a natural 
collaboration would come from the continued interaction with RON, and possibly with Infarmed, 
to contribute towards an ever improving mechanism to monitor the real-world effectiveness of 
new cancer treatments. With the growing portfolio of treatments available for cancer patients 
and the persistent gap between patients recruited for clinical trials and those composing the 
large bulk of patients followed in routine clinical practice, there is a huge need for real-world 
evidence to support health technologies assessment.  
With a focus on the impact of breast cancer treatments on QoL, we aim at further 
dissecting the impact of systemic and local treatments on the QoL of breast cancer patients. 
Such next steps would come from the granular look towards different types of endocrine 
therapy and chemotherapy, the study of the interaction between local and systemic treatments, 
but also from the addition of longer follow-up to the current analyses. Moreover, with an 
additional focus on tolerability to medical interventions, we aim at characterizing the 
downstream actions of health professionals after the occurrence of adverse events and to use 
this information to build interventions aiming at improving the management of adverse events. 
Finally, we aim at identifying opportunities to translate advanced analytics, as artificial 
intelligence, to the field of survivorship to, e.g., develop tools to predict the occurrence of 
adverse events that will ultimately improve patients QoL and cancer outcomes.  
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6.5 Conclusions 
Endocrine therapy is a powerful tool that helped generations of patients with hormone 
receptor positive breast tumors to improve their cancer outcomes. Each of the innovations in 
the field led to incremental gains. In our work we found that such innovations were translated 
to clinical practice and that results observed in clinical trials were also recorded in the real-world, 
importantly in terms of overall survival. In this setting we need to be vigilant and make local and 
national efforts to move treatment innovation to clinical practice so that our patients can benefit 
from the latest achievements in cancer care. The improvements in efficacy obtained through 
adjuvant endocrine therapy seem to be however counterbalanced by a relevant deterioration 
in patients’ QoL that may harm treatment adherence and ultimately cancer outcomes. In the 
era of endocrine therapy escalation, a relevant research effort should be allocated to balance 
efficacy and QoL considering the continuum of recurrence risk. Moreover, identifying and 
overcoming barriers to optimal survivorship care might facilitate the management of tolerability 
troubles and thus help to maximize adherence/persistence to treatment. While endocrine 
therapy improves survival, the QoL impact is palpable. Focusing our efforts as health 
professionals in understanding this interaction and optimizing its balance is the challenge that 
lays ahead of us.  
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